AU731187B2 - Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists - Google Patents
Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists Download PDFInfo
- Publication number
- AU731187B2 AU731187B2 AU31354/97A AU3135497A AU731187B2 AU 731187 B2 AU731187 B2 AU 731187B2 AU 31354/97 A AU31354/97 A AU 31354/97A AU 3135497 A AU3135497 A AU 3135497A AU 731187 B2 AU731187 B2 AU 731187B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- groups
- formula
- compound
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Indole Compounds (AREA)
Description
WO 97/44329 PCT/US97/08577 1
SPECIFICATION
DIARYLALKYL CYCLIC DIAMINE DERTVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS Technical field This invention relates to novel diarylalkyl cyclic diamine derivatives.
This invention also relates to chemokine receptor antagonists that may be effective as a therapeutic agent and/or preventive agent for diseases such as atherosclerosis, rheumatoid arthritis, psoriasis, asthma, ulcerative colitis, glomerulonephritis, multiple sclerosis, pulmonary fibrosis, and myocarditis, in which tissue infiltration of blood monocytes and lymphocytes plays a major role in the initiation, progression or maintenance of the disease.
Background Technology Chemokines are a group of inflammatory/immunomodulatory polypeptide factors produced by lymphatic tissues and by activated macrophages and leukocytes at inflammatory sites; they have a molecular weight of 6-15 kD, contain four cysteine residues, are basic and have heparin binding activity. The chemokines can be classified into two subfamilies, the CXC chemokines and CC chemokines, by the common location of the four cysteine residues and by the differences in the chromosomal locations of the genes encoding them. For example IL-8 (abbreviation for interleukin-8 is a CXC chemokine, while the CC chemokines include MIP-la/P (abbreviation for macrophage inflammatory protein-la/0), MCP-1 (abbreviation for monocyte chemotactic protein-1), and RANTES (abbreviation for regulated on activation, normal T-cell expressed and secreted cytokine). There also exists a chemokine called lymphotactin, which does not fall into either chemokine subfamily. These chemokines promote cell migration, increase the expression of cellular adhesion molecules such as integrins, and promote cellular adhesion, and are thought to be the protein factors intimately involved in the adhesion and infiltration of leukocytes into the pathogenic sites in such as inflammatory tissues (for references, see for example, Michiel, D., Biotechnology, 1993, 11, 739; Oppenheim, et al., Annual Review of Immunology, 1991, 9, 617-648; Schall, Cytokine, 1991, 3, 165-183; Springer, Cell, 1994, 76, 301-314; Furie, American Journal of Pathology, 1995, WO 97/44329 PCT/US97/08577 2 146, 1287-1301; Kelner, et al., Science, 1994, 266, 1395-1399).
For example, MIP-la induces cell migration and causes a transient increase in intracellular calcium ion concentration levels, an increase in the expression of integrins, adhesion molecules, and degranulation of monocytes and lymphocytes, and inhibits bone marrow stem cell proliferation (See for example, Wolpe, S.D., et al., Journal of Experimental Medicine, 1988, 167, 570-581; Wolpe, et al., Faseb Journal, 1989, 3, 2565-2573; Taub, et al., Science, 1993, 260, 355-358; Schall, et al., Journal of Experimental Medicine, 1993, 177, 1821-1825; Neote, et al., Cell, 1993, 72. 415-425; Vaddi, et al., The Journal of Immunology, 1994, 153, 4721-4732).
With respect to the activity of MIP-la in vivo and its role in the pathogenesis of disease, it has been reported that it is a pyrogen in rabbits (see for example Davatelis, et al., Science, 1989, 243, 1066-1068); that MIP-la injection into mouse foot pads results in an inflammatory reaction such as infiltration by neutrophils and mononuclear cells (see for example Alam, R., et al., The Journal of Immunology, 1994, 152, 1298-1303); that MIP-la neutralizing antibody has an inhibitory effect or a therapeutic effect in animal models of granuloma, multiple sclerosis and idiopathic pulmonary fibrosis (see for example Lukacs, et al., Journal of Experimental Medicine, 1993, 177, 1551-1559; Kaprus, et al., The Journal of Immunology, 1995, 155, 5003-5010; Smith, et al., The Journal of Immunology, 1994, 153, 4704-4712); and that coxsackie virus induced myocarditis is inhibited in mice with a disrupted MIP-la gene (see for example Cook, D.N. et al.. Science, 1995, 269, 1583-1585). These studies indicate that MIP-la is deeply involved in the local attraction of various subtypes of leukocytes and the initiation, progression and maintenance of resulting inflammatory response.
MCP-1 (also known as MCAF (abbreviation for macrophage chemotactic and activating factor) or JE) is a chemokine produced by macrophages, smooth muscle cells, fibroblasts, and vascular endothelial cells and causes cell migration and cell adhesion of monocytes, memory T cells, and natural killer cells, as well as mediating histamine release by basophils (For reference, see for example, Rollins, etal., Proc. Natl.Acad. Sci.USA, 1988, 85, 3738-3742; Matsushima, et al., Journal of Experimental Medicine, 1989, 169, 1485-1490; Yoshimura, T. et al., Febs Letters, 1989, 244, 487-493; Rollins, B.J. et al., Blood, 1991, 78, 1112-1116; Carr, et al., Proc. Natl. Acad. Sci. USA, 1994, 91, WO 97/44329 PCT/US97/08577 3 3652-3656; Jiang, et al., American Journal of Physiology, 1994, 267, C1112-C1118; Allavena, et al., European Journal of Immunology, 1994, 24, 3233-3236; Alam, et al., The Journal of Clinical Investigation, 1992, 89, 723-728).
In addition, high expression of MCP-1 has been reported in diseases where accumulation of monocyte/macrophage and/or T cells is thought to be important in the initiation or progression of diseases, such as atherosclerosis, restenosis due to endothelial injury following angioplasty, rheumatoid arthritis, glomerulonephritis, pulmonary fibrosis, asthma and psoriasis (for reference, see for example, Firestein, G.S. et al., Arthritis and Rheumatism, 1990, 33, 768-773; Nikolic-Peterson, et al., Kidney International, 1994, enlarged ed., 45, S79-S82; Thomas, et al., American Reviewof Respiratory Disease, 1987, 135, 747-760; Ross, Nature, 1993, 362, 801-809; Cooper, K.D., et al., The Journal of Investigative Dermatology, 1994, 102, 128-137; Sousa, et al., American Journal of Respiratory Cell AndMolecular Biology, 1994).
Furthermore, anti-MCP-1 antibody has been reported to inhibit delayed type hypersensitivity and hepatitis (for reference, see for example Rand, et al., American Journal of Pathology, 1996, 148. 855-864; Wada, et al., Faseb Journal, 1996, 10, 1418-1425).
These data indicate that chemokines such as MIP-la and MCP-1 attract monocytes and lymphocytes to disease sites and mediate their activation and thus are thought to be intimately involved in the initiation, progression and maintenance of diseases deeply involving monocytes and lymphocytes, such as atherosclerosis, rheumatoid arthritis, psoriasis, asthma, ulcerative colitis, glomerulonephritis, multiple sclerosis, pulmonary fibrosis and myocarditis.
Therefore, drugs which inhibit the action of chemokines on target cells may be effective as a therapeutic and/or preventive drug in diseases such as atherosclerosis, rheumatoid arthritis, psoriasis, asthma, ulcerative colitis, glomerulonephritis, multiple sclerosis, pulmonary fibrosis, and myocarditis.
Genes encoding receptors of specific chemokines have been cloned, and it is now known that these receptors are G protein-coupled seven-transmembrane receptors present on various leukocyte populations (for reference, see for example, Holmes, et al., Science 1991. 253, 1278-1280; Murphy et al., Science, 253, 1280-1283; Neote, K. et al., Cell, 1993, 72, 415-425; Charo, et al., Proc. Natl. Acad. Sci. USA, 1994, 91, 2752-2756; Yamagami, S., WO 97/44329 PCT/US97/08577 4 et al., Biochem. Biophys. Res. Commun., 1994, 202, 1156-1162; Combadier, C., et al., The Journal of Biological Chemistry, 1995, 270, 16491-16494, Power, et al., J. Biol. Chem., 1995, 270, 19495-19500; Samson, et al., Biochemistry, 1996, 35, 3362-3367; Murphy, P.M.,Annual Review of Immunology, 1994, 12, 592-633). Therefore, compounds which inhibit the binding of chemokines such as MIP-la and/or MCP-1 to these receptors, that is, chemokine receptor antagonists, may be useful as drugs which inhibit the action of chemokines such as MIP-la and/or MCP-1 on the target cells, but there are no drugs known to have such effects.
Cyclic diamine derivatives containing diarylalkyl groups are known to have muscarine receptor antagonistic activity (JP09-020758, Kokai) and may be useful as a drug in the treatment of substance abuse disorders (W09320821), may potentiate the effect of anti-cancer drugs by the inhibition of P-glycoproteins (JP03-101662, Kokai; EP363212), has calcium antagonistic activity DE3831993, W09013539, JP63-280081, Kokai; EP289227, JP62-167762, Kokai; DE3600390), have activity on the central nervous system and inhibits hypermotility (W08807528), have antiaggression, antipsychotic, antidepressant and, analgesic effect (JP57-500828, Kokai), has coronary vasodilating activity (JP51-098281, Kokai), has anti-lipidemia effect and promotes vascular blood flow (JP49-093379, Kokai; EP42366), have coronary vasodilating activity and anti-reserpine activity (Aritomi, et al., Yakugaku Zasshi, 1971, 91, 972-979); have anti-serotonin and anti-histamine activity (JP45-031193, Kokoku); and have central nervous system depressant activity (Vadodaria, D.J., et al., J. Med. Chem., 1969, 12, 860-865). However, these compounds differ from the novel compounds of the present invention and these compounds have not been known to interfere with binding of chemokines to the target cells.
Disclosure of the Invention Therefore, it is an object of the present invention to discover small molecule drugs which inhibit the binding of chemokines such as MIP-la and/or MCP-1 to their receptors on the target cells.
It is another object of the present invention to establish a method to inhibit the binding to the receptors on the target cells and/or effects on target cells of chemokines such as MIP-1 a and/or MCP-1.
WO 97/44329 PCT/US97/08577 It is an additional object of the present invention to propose a method for the treatment of diseases for which the binding of chemokines such as MIP-la and/or MCP-1 to the receptor on the target cell is one of the causes.
As a result of their intensive studies, the present inventors discovered that a cyclic diamine derivative having a diarylalkyl group or its pharmacologically acceptable acid adduct has an excellent activity to inhibit the binding of chemokines such as MIP-la and/or MCP-1 and the like to the receptor of a target cell, which has led to the completion of this invention.
That is, the present invention provides a cyclic diamine derivative or its pharmacologically acceptable acid adduct (Invention represented by the formula below:
R
2 3
(CH
2 )j-N N-R 4
[I]
(CH2) [wherein R' and R 2 are identical to or different from each other representing a phenyl group or an aromatic heterocyclic group having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, and/or nitrogen atoms, in which the phenyl or aromatic heterocyclic group may be substituted by any number of halogen atoms, hydroxy groups, C 1 lower alkyl groups, C-C 6 lower alkoxy groups, phenyl groups.
benzyl groups, phenoxy groups, methylenedioxy groups, Ci-C 6 hydroxyalkyl groups, carboxy groups, C 2 alkoxycarbonyl groups, C 2
-C
7 alkanoylamino groups, dioxolanyl grpoups, or by group represented by the formula: -NRSR 6 or else may be condensed with a benzene ring to form a condensed ring, furthermore above substituents for the phenyl or aromatic heterocyclic group and the condenced ring condenced with a benzene ring are optionally substituted by any substituents independently selected from halogen atoms, hydroxy groups, or Cl-C 6 lower alkoxy groups, and R 5 and R 6 may be identical to or different from each other representing hydrogen atoms, C 1
-C
6 lower alkyl groups, or C 2
-C
6 lower alkenyl groups;
R
3 represents a hydrogen atom, hydroxy group, cyano group, Ci-C, lower alkoxy group or C 2 lower alkanoyloxy group; j represents an integer of 0-3; k represents 2 or 3; WO 97/44329 PCTIUS97/08577 6
R
4 is a group represented by: 1) Formula: -A 1
-R
7 (in the formula, R 7 represents a phenyl group which may be substituted by any number of the same or different {halogen atoms, hydroxy groups, amino groups, lower alkyl groups, Ci-C, lower alkoxy groups, cyano groups, nitro groups, trifluoromethyl groups, C 2
-C
7 alkoxycarbonyl groups, C 2 alkanoyl groups, C,-C, alkylsulfonyl groups, trifluoromethylsulfonyl groups, phenylsulfonyl groups {which may be substituted with a hydroxy group), 1-pyrrolylsulfonyl groups, Ci-C, hydroxyalkyl sulfonyl groups, Ci-C 6 alkanoylamino groups, or a group represented by the formula: -CONR 8
R
9 in which R 8 and R 9 identical to or different from each other, represent hydrogen atoms or C 1 lower alkyl groups; A' is a group represented by the formula: -(CH2)m- or a group represented by formula:
(CH
2 2 in which G represents G 1 or G 2
G
1 represents -SO 2 -CONH-, -NHCO-, -NHCONH-, or -NH-SO 2
G
2 represents -(C=NH)NH-SO 2 -CO-NH-NH-CO-. -CO-NH-NH-CO-NR' 0
-CO-NH-CH
2
-CO-NH-NH-SO
2 or -CO-
N(CH
2
-CO-OCH
3
R'
1 represents a hydrogen atom or a phenyl group; m is an integer of 0-3; p is an integer of 1-3; q represents 0 or 1); 2) Formula: -A 2
-R"
(wherein A 2 represents -CO- or R" represents: a) A phenyl group which may be substituted by any number of the same or different {halogen atoms, lower alkyl groups. lower alkoxy groups, groups represented by formula -CH 2
-NR"
2 R" or groups represented by the formula: 0 -N N- R 14 b) An aromatic monocyclic heterocyclic group having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, and/or nitrogen atoms, and optionally substituted with any of the same or different number of {halogen atoms, C,-
C
6 lower alkyl groups, C lower alkoxy groups} or c) A group represented by the formula: -CH 2 -NR1 5
R
6 WO 97/44329 PCT/US97/08577 7 where R2, R 14 and R 15 identical or different groups, represent hydrogen atoms or Ci-Cs lower alkyl groups and R" 6 represents {a phenyl group or a phenylalkyl group), which may be substituted by any number of the same or different halogen atoms, lower alkyl group, or C 1-C, lower alkoxy group); 3) Formula: -(CH2),-R 17 (in the formula, R" is a group which may be substituted at any possible sites by any number of the same or different {halogen atoms, hydroxy groups, Ci-C, lower alkyl groups, or C,-C 6 lower alkoxy group representing a hydrogen atom, cyano group, C,-C 7 alkoxycarbonyl group, Cj-C 6 hydroxyalkyl group, Ci-C, lower alkynyl group, C 3
-C
6 cycloalkyl group, C 3
-C
7 alkenoyl group, a group represented by the formula: -(CHOH)CH 2 OR', a group represented by the formula: -CO-NH-NH-CO-OR", a group represented by the formula 0 h2 a group represented by the formula:
H
NO
NH
a group represented by the formula: 0 N a group represented by the formula: 0 a group represented by the formula WO 97/44329 PCT/US97/08577 0
CH
3
A
N
N^
0
N\
CH
3 a group represented by the formula:
N^
H
a group represented by the formula:
H
3 C COH 3 0 0 a group represented by the formula: 0 0 a group represented by the formula: 0 -(CHOH) -CH-N 0 a group represented by the formula: 0 0 or a group represented by the formula:
HO
0
H
^K.X
in which n represents an integer of 1-4; R 18 is C,-C 6 lower alkyl group, C 2
-C
6 lower alkenyl group, or C 2
-C
6 lower alkynyl group and R' 9 represents a C,-C 6 lower WO 97/44329 PCTIUS97/08577 9 alkyl group); 4) Formula: -(CH2)r-A 3
-R
2 (wherein r represents an integer of 0-3; A 3 represents a single bond, -CO-, -CO-NH-NH-CO-. -CO-NH-NH-CO-NH-. -CO-NH-CH 2 -CO-NH-NH-SO-, -(CHOH)-CH 2 or -(CHOH)-CH 2
OCH
2
R
20 represents an aromatic heterocyclic group containing 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, and/or nitrogen atoms in which the aromatic heterocyclic group may be substituted by any number of the same or different {halogen atoms, lower alkyl groups, Ci-C 6 lower alkoxy groups, or pyrrolyl groups} or may be condensed with a benzene ring to form a condensed ring); or Formula: -CH,-CO-NR 2 1
R
22 (wherein R 21 represents a hydrogen atom or Ci-C, lower alkyl group; R 22 represents a hydrogen atom, Ci-C, lower alkyl group, a group represented by the formula:
R
24
-CH-CHOH
(CH 2 )s-R 23 or a group represented by the formula: 0
I
-CH -C-R 26 (CH 2 )t-R 2 or R 21 and R 22 may be taken together with the nitrogen to form a 4 to 7-membered saturated heterocycles, which may contain an oxygen atom, sulfur atom, or another nitrogen atom; where s represents 0 or 1; t represents an integer of 0-2; R 23 represents a hydrogen atom, hydroxy group, phenyl group, C,-C 6 lower alkyl group.
or C 1 lower alkoxy group; R 24 represents a hydrogen atom or phenyl group which may be substituted by hydroxy group; R 25 represents a hydrogen atom. phenyl group {which may be substituted by hydroxy group}. C 2
-C
7 alkoxycarbonyl group, C,- C, lower alkyl group, Ci-C 6 alkylthio group, or 3-indolyl group; and R 26 represents a hydroxy group, amino group, C 1
-C
6 lower alkoxy group, or phenylalkyloxy group); Excepting that if R 3 is a hydrogen atom, then, j is not 0, substituent for R 7 is not hydroxy, CI-C 6 lower alkyl or Ci-C 6 lower alkoxy; G 1 is not or its substituents, if R" is a phenyl group, are not C 1
-C
6 lower alkyl group;
R"
7 is not a hydrogen atom, C2-C, alkoxycarbonyl group, or Ci-C 6 hydroxyalkyl group; WO 97/44329 PCT/US97/08577 r is not 0 and A 3 is not a single bond or -CO-.
Furthermore, if R 3 represents a hydrogen atom and k represents 2, R 7 is not unsubstituted; m is not 0 and R" is not a substituted or unsubstituted phenyl group.
If R 3 is a cyano group, R 7 is not unsubstituted, and the substituent groups for R 7 are not halogen atom, Cz-C, lower alkyl group or CI-C 6 lower alkoxy group.] The present invention provides a method of inhibiting the binding of chemokines to the receptor of a target cell and/or a method to inhibit its action onto a target cell using a pharmacological formulation containing as an active ingredient, a cyclic diamine derivative or its pharmacologically acceptable acid adduct (Invention 2) represented by the formula [II] below:
R
2 3 R-3 Ri (CH, 2
N-R
4 (CH 2 )k [wherein R' and R 2 are identical to or different from each other representing a phenyl group or an aromatic heterocyclic group having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, and/or nitrogen atoms, in which the phenyl or aromatic heterocyclic group may be substituted by any number of halogen atoms, hydroxy groups, Ci-C 8 lower alkyl groups, Ci-C, lower alkoxy groups, phenyl groups, benzyl groups, phenoxy groups, methylenedioxy groups, C 1
-C
6 hydroxyalkyl groups, carboxy groups, C 2 alkoxycarbonyl groups, C 2
-C
7 alkanoylamino groups, dioxolanyl grpoups, or by group represented by the formula: -NRSR 6 or else may be condensed with a benzene ring to form a condensed ring, furthermore above substituents for the phenyl or aromatic heterocyclic group and the condenced ring condenced with a benzene ring are optionally substituted by any ssubstituents independently selected from halogen atoms, hydroxy groups, or CI-C 6 lower alkoxy groups, and R 5 and R 6 may be identical to or different from each other representing hydrogen atoms, C 1
-C
6 lower alkyl groups, or C 2
-C
6 lower alkenyl groups;
R
3 represents a hydrogen atom, hydroxy group, cyano group. CI-C 6 lower alkoxy group or C 2
-C
7 lower alkanoyloxy group; WO 97/44329 PCTIUS97/08577 11 j represents an integer of 0-3; k represents 2 or 3;
R
4 is a group represented by: 1) Formula: -A'-R 7 (in the formula, R 7 represents a phenyl group which may be substituted by any number of the same or different {halogen atoms, hydroxy groups, amino groups, Cz-C 6 lower alkyl groups, lower alkoxy groups, cyano groups, nitro groups, trifluoromethyl groups, C 2 alkoxycarbonyl groups, C 2
-C
7 alkanoyl groups, C,-C 6 alkylsulfonyl groups, trifluoromethylsulfonyl groups, phenylsulfonyl groups {which may be substituted with a hydroxy group}, 1-pyrrolylsulfonyl groups, Cz-C, hydroxyalkyl sulfonyl groups, C,-C 6 alkanoylamino groups, or a group represented by the formula: -CONR'R 9 in which R 8 and identical to or different from each other, represent hydrogen atoms or Cl-C, lower alkyl groups; A' is a group represented by the formula: or a group represented by formula: 2 in which G represents G' or G2; G 1 represents -CONH-, -NHCO-, -NHCONH-, or -NH-SO 2
G
2 represents -(C=NH)NH-SO,-, -CO-NH-NH-CO-, -CO-NH-NH-CO-N R' -CO-NH-CH,-CO-, -CO-NH-NH-SO 2 or -CO- N(CH2-CO-OCH3)-NH-CO-; R' 1 represents a hydrogen atom or a phenyl group; m is an integer of 0-3; p is an integer of 1-3; q represents 0 or 1); 2) Formula: -A2-R" (wherein A 2 represents -CO- or -SO 2 R" represents: a) A phenyl group which may be substituted by any number of the same or different {halogen atoms, lower alkyl groups. Cz-C, lower alkoxy groups, groups represented by formula -CH 2 -NR 2
R'
3 or groups represented by the formula: 0 -N N-R 14 b) An aromatic monocyclic heterocyclic group having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, and/or nitrogen atoms, and optionally substituted with any of the same or different number of {halogen atoms, C,-
C
6 lower alkyl groups, C 1-C 6 lower alkoxy groups} or C) A group represented by the formula: -CH 2
-NR"R"
6 where R1 2 R 3 R" and identical or different groups, represent hydrogen atoms or lower alkyl groups and R" represents (a phenyl group or a phenylalkyl group), which may be substituted by any number of the same or different halogen atoms, lower alkyl group, or C 1 lower alkoxy group); 3) Formula: in the formula,
R
17 is a group which may be substituted at any possible sites by any number of the same or different groups such as halogen atoms, hydroxy groups,
CI-C
6 lower alkyl groups, or CI-C 6 lower alkoxy groups; or R' representing a hydrogen atom. cyano group,
C
2 C alkoxycarbonyl group, hydroxyalkyl group.
CI-C, lower alkynyl group, cycloalkyl group. alkenoyl group, a group represented by the formula: -(CHOH)CHORZ, a group represented by the formula: -CO-NH-NH-CO-ORL a group represented by the formula
O
O
a group represented by the formula:
H
N 0
NH
a group represented by the formula: O N' a group represented by the formula: a group represented by the formula WO 97/44329 PCT/US97/08577 13 0
OH
3 N N
ON
OH
3 a group represented by the formula:
H
a group represented by the formula:
CH
3
H
3 C CH3 O O 0 a group represented by the formula: 0
N
0 0 0 a group represented by the formula: 0 or a group represented by the formula:
HO
H
in which n represents an integer of 1-4; R 18 is C 1
-C
6 lower alkyl group, C 2
-C
6 lower alkenyl group, or C 2 lower alkynyl group and R' 9 represents a Ci-C 6 lower WO 97/44329 PCT/US97/08577 14 alkyl group); 4) Formula: -(CH 2 )r-A 3
-R
20 (wherein r represents an integer of 0-3; A 3 represents a single bond, -CO-, -CO-NH-NH-CO-, -CO-NH-NH-CO-NH-, -CO-NH-CH,-CO-, -CO-NH-NH-SO 2
-(CHOH)-CH
2 or -(CHOH)-CH 2 OCH,-; R 20 represents an aromatic heterocyclic group containing 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, and/or nitrogen atoms in which the aromatic heterocyclic group may be substituted by any number of the same or different {halogen atoms, Ci-C, lower alkyl groups, Ci-C, lower alkoxy groups, or pyrrolyl groups) or may be condensed with a benzene ring to form a condensed ring); Formula: -CH 2
-CO-NR
1
R
22 (wherein R 21 represents a hydrogen atom or C,-C 6 lower alkyl group; R 22 represents a hydrogen atom, Ci-C, lower alkyl group, a group represented by the formula: t 24 -CH -CHOH
I
(CH 2 )s-R 23 ;or a group represented by the formula: 0 -CH -C-R 26 (CH 2 )t-R 2 or R 21 and R 22 may be taken together with the nitrogen to form a 4 to 7-membered saturated heterocycles, which may contain an oxygen atom, sulfur atom, or another nitrogen atom; where s represents 0 or 1; t represents an integer of 0-2; R 2 3 represents a hydrogen atom, hydroxy group, phenyl group, Cz-C 6 lower alkyl group, or Ci-C, lower alkoxy group; R 24 represents a hydrogen atom or phenyl group which may be substituted by hydroxy group; R 25 represents a hydrogen atom. phenyl group {which may be substituted by hydroxy group}, C 2
-C
7 alkoxycarbonyl group, C,- C, lower alkyl group, Cz-C 6 alkylthio group, or 3-indolyl group; and R 26 represents a hydroxy group, amino group, C 1
-C
6 lower alkoxy group, or phenylalkyloxy group); -9 6) A hydrogen atom, C 1
-C
6 alkanoyl group, or Cz-C. alkoxycarbonyl group.] Here, the compounds represented by the above formula [II] have activities to inhibit the binding of chemokines such as MIP-la and/or MCP-1 and the like WO 97/44329 PCT/US97/08577 to the receptor of a target cell and activities to inhibit physiological activities of cells caused by chemokines such as MIP-la and/or MCP-1 and the like.
Preferred Embodiments of the Invention On Invention 1 In the above formula R 1 and R 2 are identical to or different from each other representing a phenyl group or an aromatic heterocyclic group having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, and/or nitrogen atoms, in which the phenyl or aromatic heterocyclic group may be substituted by any number of halogen atoms, hydroxy groups, Ci-C, lower alkyl groups, Ci-C, lower alkoxy groups, phenyl groups, benzyl groups, phenoxy groups, methylenedioxy groups, hydroxyalkyl groups, carboxy groups, C 2
-C
7 alkoxycarbonyl groups,
C
1 alkanoylamino groups, dioxolanyl grpoups, or by group represented by the formula: -NR 5
R
6 or else may be condensed with a benzene ring to form a condensed ring. Unsubstituted aromatic heterocyclic groups having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, and/or nitrogen atoms are specifically, for example, thienyl, furyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazinyl, triazolyl, oxadiazolyl, thiadiazolyl group and the like, preferably including thienyl, furyl, pyrrolyl, and pyridyl groups.
The halogen atom as substituents for a phenyl group or an aromatic heterocyclic group in R 1 and R 2 include fluorine atoms, chlorine atoms, bromine atoms, iodine atoms, suitably including fluorine atoms and chlorine atoms. The Ci-C, lower alkyl groups mean C 1
-C
8 straight-chain or branched alkyl groups such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, isopropyl. isobutyl, sec-butyl, tert-butyl, isopentyl. neopentyl, tert-pentyl.
isohexyl, 2-methylpentyl, 1-ethylbutyl, and the like, suitably specifically including, methyl, ethyl, and isopropyl groups. The Ci-C, lower alkoxy groups mean groups consisting of C 1 part of the aforementioned Ci-C, lower alkyl groups and oxy groups, specifically, for example, methoxy group and ethoxy group. The Cl-C, hydroxyalkyl groups are groups in which part of the aforementioned
C
1 lower alkyl groups are substituted at their any positions by a hydroxy group, preferably and specifically for example, hydroxymethyl group, 2-hydroxyethyl WO 97/44329 PCT/US97/08577 16 group, and the like. The C 2 alkoxycarbonyl groups mean the aforementioned
C,-C
6 lower alkoxy groups and carbonyl groups, preferably specifically for example, a methoxycarbonyl group and ethoxycarbonyl group. The C 2 lower alkanoylamino groups mean C 2
-C
7 lower straight-chain or branched alkanoylamino groups such as acetylamino, propanoylamino, butanoylamino, pentanoylamino, hexanoylamino, heptanoylamino, isobutyrylamino, 3-methylbutanoylamino, 2methylbutanoylamino, pivaloylamino, 4-methylpentanoylamino, 3,3dimethylbutanoylamino, 5-methylhexanoylamino group, and the like, where the preferred and specific example includes an acetylamino group. Condensed rings obtained by condensation with a benzene ring mean a ring obtained by the condensation with a benzene ring of a phenyl group or an aromatic monocyclic heterocyclic ring having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, and/or nitrogen atoms, at any possible sites, suitably and specifically for example, naphthyl, indolyl. benzofuranyl, benzothienyl, quinolyl group, indolyl group, benzimidazolyl group.
R
5 and R 6 represent each independently hydrogen atoms, CI-C, lower alkyl groups, or C 2
-C
6 lower alkenyl groups. The CI-C 6 lower alkyl groups are the same as defined for the aforementioned C,-C 6 part of the Ci-C 8 lower alkyl groups as substituents for a phenyl group or an aromatic heterocyclic group in R' and R 2 where the same examples can be given for the preferred specific examples. The
C
2
-C
6 lower alkenyl groups are for example, C 2
-C
6 straight-chain or branched alkenyl groups such as vinyl, allyl, 2-butenyl, 3-butenyl, 4-pentenyl, 4-methyl-3-pentenyl, and the like, where preferred specific examples include allyl, 2-butenyl, and 3-butenyl group.
Furthermore above substituents for the phenyl or aromatic heterocyclic group and the condenced ring condenced with a benzene ring in R 1 and R 2 are optionally substituted by any ssubstituents independently selected from halogen atoms, hydroxy groups, or lower alkoxy groups. The halogen atoms and C 1
-C
6 lower alkoxy groups are the same as defined for the aforementioned substituents for a phenyl group or an aromatic heterocyclic group in R 1 and R 2 and the same examples can be listed as preferred specific examples
R
3 in the above formula represents a hydrogen atom, hydroxy group, cyano group, C,-C 6 lower alkoxy group, or C 2 lower alkanoyloxy group. The C 1
-C,
lower alkoxy groups are the same as defined for the Ci-C 6 lower alkoxy groups WO 97/44329 PCTIUS97/08577 17 in the aforementioned substituents for a phenyl group or an aromatic heterocyclic group in R 1 and R 2 where the same examples can be given for their preferred specific examples. The C 2
-C
7 lower alkanoyloxy groups mean C 2
-C
7 lower straight-chain or branched alkanoyloxy groups such as acetyloxy, propanoyloxy, butanoyloxy, pentanoyloxy, hexanoyloxy, heptanoyloxy, isobutyryloxy, 3methylbutanoyloxy, 2-methylbutanoyloxy, pivaloyloxy, 4-methylpentanoyloxy, 3,3-dimethylbutanoyloxy, 5-methylhexanoyloxy group, and the like, where the preferred and specific example includes an acetyloxy group. Preferred specific examples for R 3 include a hydrogen atom and hydroxy group.
In the above formula j represents an integer of 0-3. If R 3 represents a hydrogen atom, j is not 0. It is particularly preferred for j to be 2.
k in the above formula I represents 2 or 3; it is particularly preferred to use a homopiperazine derivative in which k is 3.
R
4 in the above formula represents a group represented by: 1) Formula: -Al-R 7 2) Formula: 3) Formula: -(CH 2 7 4) Formula: -(CH 2 )r-A-R 20 or Formula: -(CH,)-CO-NR 2 1
R
22 Here -CO- represents a carbonyl group. It is particularly preferred for R 4 to be represented by formula -A 1 or formula -(CH 2 )r-A 3
-R
20
R
7 represents a phenyl group which may be substituted by any number of the same or different (halogen atoms, hydroxy groups, amino groups, lower alkyl groups, lower alkoxy groups, cyano groups, nitro groups, trifluoromethyl groups, C 2 alkoxycarbonyl groups, C 2 alkanoyl groups, C,-C, alkylsulfonyl groups, trifluoromethylsulfonyl groups, phenylsulfonyl groups {which may be substituted with a hydroxy group), 1-pyrrolylsulfonyl groups, C,-C, hydroxyalkyl sulfonyl groups, Ci-C 6 alkanoylamino groups, or a group represented by the formula: -CONR'R 9 However, if R 3 represents a hydrogen atom, the substituent for a phenyl in R 7 is not a hydroxy, C 1
-C
6 lower alkyl, or C 1
-C
6 lower alkoxy; if R 3 is a hydrogen atom and k=2, R 7 is not an unsubstituted phenyl group; WO 97/44329 PCTIUS97/08577 18 if R 3 represents a cyano group, R 7 is not unsubstituted and the substituent for a phenyl in R 7 is not a halogen atom, Ci-C, lower alkyl, or C 1 lower alkoxy group.
The halogen atoms, Ci-C 6 lower alkyl groups, Ci-C 6 lower alkoxy groups,
C
2 alkoxycarbonyl groups, and C 2
-C
7 alkanoylamino groups as substituents for a phenyl in R 7 are the same as defined for the aforementioned substituents for a phenyl group or an aromatic heterocyclic group in R 1 and R 2 and the same examples can be listed as preferred specific examples. The C 2 lower alkanoyl groups mean C,-C 7 lower straight-chain or branched alkanoyl groups such as acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, heptanoyl, isobutyryl, 3methylbutanoyl, 2-methylbutanoyl, pivaloyl, 4-methylpentanoyl, 3,3dimethylbutanoyl, 5-methylhexanoyl group, and the like, where the preferred and specific example includes an acetyl group. The Ci-C 6 alkylsulfonyl groups mean those consisting of the aforementioned Ci-C 6 part of the lower alkyl groups and sulfonyl groups, preferably and specifically, for example, a methylsulfonyl group. The phenylsulfonyl groups may be substituted with a hydroxy group at any position. The C,-C 6 hydroxyalkylsulfonyl groups mean those consisting of the aforementioned C 1
-C
6 hydroxyalkyl groups and sulfonyl groups, preferably and specifically, for example, a (2-hydroxyethyl) sulfonyl group. R'and R 9 the same or different groups, represent hydrogen atoms or lower alkyl groups. The lower alkyl groups as R 8 and R 9 are the same as defined for the aforementioned
CI-C
6 part of the lower alkyl groups as substituents for a phenyl group or an aromatic heterocyclic group in R 1 and R 2 and the same examples are listed for their preferred specific examples.
A is a group represented by the formula: -(CH 2 m or a group represented by formula: -(CH 2 )p-G-(CH 2 in which G represents G or G2; G 1 represents -CONH-, -NHCO-. -NHCONH-, or -NH-SO 2
G
2 represents (C=NH)NH-S0 2 -CO-NH-NH-CO-, -CO-NH-NH-CO-NR' 0 -CO-NH-CH,-CO-, -CO-NH-NH-
SO
2 or -CO-N(CH,-CO-OCH 3
R
10 represents a hydrogen atom or a phenyl group; m is an integer of 0-3; p is an integer of 1-3; q represents 0 or 1); however, if R 3 is a hydrogen atom, G' is not or if R 3 represents a hydrogen atom and if k=2, m is not 0. In the above formula, -CO- means a carbonyl group and -SO2- means a sulfonyl group. Preferred A 1 groups are specifically, for example, those represented by the formula -(CH 2 with m being preferably 1.
Preferred A' groups are also specifically, for example, -(CH 2 )p-CO-NH-NH-CO- WO 97/44329 PCT/US97/08577 19
(CH
2
-(CH
2 )p-CO-NH-NH-CO-NH-(CH 2) -(CH 2 )p-CO-NH-CH,-CO-(CH 2 with p being preferably 1.
A
2 represents -CO- (carbonyl group) or -SO2- (sulfonyl group).
R" represents: a) A phenyl group which may be substituted by any number of the same or different (halogen atoms, Cz-C, lower alkyl groups, Cz-C 6 lower alkoxy groups, groups represented by formula -CH 2
-NR
2
R"
3 or groups represented by the formula: 0 -N
N-R
14 b) An aromatic monocyclic heterocyclic group having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, and/or nitrogen atoms, and optionally substituted with any of the same or different number of {halogen atoms, C,-
C
6 lower alkyl groups, C -C 6 lower alkoxy groups} or c) A group represented by the formula: -CH 2
-NR
5
R
16 However if R 3 represents a hydrogen atom, the substituent group for a phenyl group in R" is not a Ci-C, lower alkoxy group; if R 3 represents a hydrogen atom and k is 2, R" is not a substituted or unsubstituted phenyl group. The halogen atoms, Ci-C 6 lower alkyl groups, or C 1
-C
6 lower alkoxy groups as substituents for the groups in R" are the same as defined for the aforementioned substituents for a phenyl group or an aromatic heterocyclic group in R x and R 2 and the same examples can be given as preferred specific examples.
Specific examples for R" in which the aromatic monocyclic heterocyclic group is unsubstituted can be the same specific examples for the aromatic heterocyclic groups with no substituents in R 1 and R 2 Preferred examples specifically include a pyridyl group.
R
12
R
13
R
14 and R' 5 represent each independently hydrogen atoms or C1-C, lower alkyl groups. The Ci-C, lower alkyl groups are of the same definition for the aforementioned Ci-C 6 part of the Cz-C, lower alkyl groups as substituents WO 97/44329 PCT/US97/08577 for a phenyl group or an aromatic heterocyclic group in R' and R 2 where the same examples can be listed as preferred specific examples.
R1 6 represents a {phenyl group or phenylalkyl group) which may be substituted by any number of the same or different {halogen atoms, Ci-C, lower alkyl groups, or lower alkoxy group). The halogen atom, lower alkyl group or Ci-C 6 lower alkoxy group as substituents are the same as defined for the aforementioned substituents for a phenyl group or an aromatic heterocyclic group in R' and R 2 where the same examples can be given as preferred specific examples. The phenylalkyl group means a group consisting of a phenyl group and a C,-C 6 alkylene group, preferably and specifically for example, a benzyl group.
R"
7 is a group which may be substituted at any possible sites by any number of the same or different {halogen atoms, hydroxy groups, CI-C, lower alkyl groups, or lower alkoxy groups), representing a hydrogen atom, cyano group, C 2
-C
7 alkoxycarbonyl group, C,-C 6 hydroxyalkyl group,
C,-C
6 lower alkynyl group, C 3
-C
6 cycloalkyl group, C 2
-C
7 alkenoyl group, a group represented by the formula: -(CHOH)CH 2 OR'O, a group represented by the formula:
-CO-NH-NH-CO-OR"
9 a group represented by the formula 0 0 a group represented by the formula:
H
O
W
NH
0 a group represented by the formula: O N a group represented by the formula: WO 97/44329 PCT/US97/08577 0 a group represented by the formula 2 CH3 n N
CH
3 a group represented by the formula: O H
H
a group represented by the
H
3 C formula:
CH
3
-CH
3 a group represented by the formula: 0
-N
ruprprsntdbyte omua a group represented by the formula: 0 -(CHOH) -CH2-N 0 a group represented by the formula: I I S or a group represented by the formula: WO 97/44329 PCT/US97/08577 22
HO
0
H
If, however, R 3 represents a hydrogen atom, R 17 is not a hydrogen atom,
C
2
-C
7 alkoxycarbonyl group, or Ci-C, hydroxyalkyl group. R" may be bonded at any possible site to an alkylene group -(CH 2 The C 2 alkoxycarbonyl and Ci-C 6 hydroxyalkyl groups are the same as defined for the aforementioned substituents for a phenyl group or an aromatic heterocyclic group in R 1 and R 2 where the same examples may be given as preferred specific examples. The CI-C 6 lower alkynyl group means a C 2 straight-chain or branched alkynyl groups such as ethynyl, 1-propynyl, 2-propynyl, 2-butynyl, 3-butynyl, 4-pentynyl, 5-hexynyl, 1methyl-4-pentynyl group, and the like, preferably and specifically, for example, ethynyl group and 1-propynyl group. The C 3
-C
6 cycloalkyl groups mean cyclic alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl groups and the like. The C 3 lower alkenoyl group means a C 3
-C
7 straight-chain or branched alkenoyl groups such as propenoyl. 2-metylpropenoyl, 2-buenoyl, 3-butenoyl, 2-methyl-3-butenoyl, 3-methyl-2-butenoyl. 2-pentenoyl, 4-pentenoyl, 2methyl-2-pentenoyl, 2,2-dimethyl-4-pentenoyl, 2-hexenoyl, 3-hexenoyl, 6heptenoyl, and the like, preferably and specifically, for example propenoyl and 2-metylpropenoyl group.
The halogen atom, C,-C 6 lower alkyl group or C1-C6 lower alkoxy groups as substituents for R" 7 are the same as defined for the aforementioned substituents for a phenyl group or an aromatic heterocyclic group in R' and R2, and the same examples can be given as preferred specific examples.
R'
8 represents a C1-C6 lower alkyl group, C2-C6 lower alkenyl group, or
C
2
-C
6 lower alkynyl group. The Ci-C6 lower alkyl groups are the same as defined for the aforementioned part of the lower alkyl groups as substituents for a phenyl group or an aromatic heterocyclic group in R 1 and R 2 where the same examples can be given as preferred specific examples. The C2-C6 lower alkenyl S 30 groups are the same as the C2-C6 lower alkenyl groups in the aforementioned R and R 6 where the preferred examples are specifically allyl, 2-butenyl, and 3-butenyl group. The C2-C, lower alkynyl groups are the same as the lower alkynyl groups in the aforementioned R 17 where the preferred examples are specifically 2-propynyl group and 3-butynyl group.
WO 97/44329 PCT/US97/08577 23
R
9 represents a Ci-C 6 lower alkyl group. Here, the C 1
-C
6 lower alkyl group is the same as defined for the aforementioned CI-C 6 part of the lower alkyl groups as substituents for a phenyl group or an aromatic heterocyclic group in R' and R 2 where the same examples can be given as preferred specific examples.
n is an integer of 1-4. It is particularly preferred for the n to be 1 or 2.
A
3 represents a single bond, -CO-NH-NH-CO-, -CO-NH-NH-CO-NH-,
-CO-NH-CH
2 -CO-NH-NH-SO,-, -(CHOH)-CH 2 or -(CHOH)-CH 2
OCH
2 However, if
R
3 represents a hydrogen atom, A 3 is not a single bond. Here, -CO- means a carbonyl group and -SO 2 means a sulfonyl group. A 3 is preferably a single bond or
CO-NH-NH-CO-.
R
20 represents an aromatic heterocyclic group containing 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, and/or nitrogen atoms in which the aromatic heterocyclic group may be substituted by any number of the same or different (halogen atoms, C 1
-C
6 lower alkyl groups, CI-C 6 lower alkoxy groups, or pyrrolyl groups) or may be condensed with a benzene ring to form a condensed ring. As to specific examples in which the aromatic monocyclic heterocyclic group R 20 has no substitution, the same specific example can be given as in the cases with no substituents on the aromatic heterocyclic rings in R 1 and R 2 preferred examples are spec ifically a pyridyl group and is oxazolyl group.
The halogen atom, lower alkyl group, or Ci-C 6 lower alkoxy group as substituents for the aromatic heterocyclic group in R 20 are the same as defined for the aforementioned substituents for a phenyl group or an aromatic heterocyclic group in R 1 and R 2 where the same examples can be given as suitable specific examples. The condensed ring obtained by condensation with a benzene ring in R 20 is the same as defined for the condenced ring in R and R 2 where the same examples can be given as suitable specific examples.
r is an integer of 0-3. However, if R 3 represents a hydrogen atom, r is not 0. In particular, it is preferred for r to be 1.
R
21 represents a hydrogen atom or C 1 lower alkyl group, R 22 represents WO 97/44329 PCTIUS97/08577 24 a hydrogen atom, lower alkyl group, a group represented by the formula: 24 -CH -CHOH (CH 2 23 ;or a group represented by the formula: 0
II
-CH -C-R 26 (CH 2 )t-R 2 or may be taken together with the nitrogen to form a 4 to 7-membered saturated heterocycles, which may contain an oxygen atom, sulfur atom, or another nitrogen atom. The lower alkyl groups in R 2 1 and R 22 are the same as defined for the aforementioned part of the lower alkyl groups as substituents for a phenyl group or an aromatic heterocyclic group in R x and R 2 where the same examples can be given for the preferred specific examples. Saturated heterocyclic rings consisting of R 21
,R
22 and the nitrogen include azetidine, pyrrolidine, piperidine, perhydroazepine, morpholine. thiamorpholine, piperazine, homopiperazine, and the like; preferred specific examples include piperidine, morpholine, and thiamorpholine.
s represents 0 or 1 and t represents an integer of 0-2.
R
23 represents a hydrogen atom, hydroxy group, phenyl group, lower alkyl group, or lower alkoxy group. The Ci-C, lower alkyl group and C 1
-C
6 lower alkoxy groups as R 23 are the same as defined for the aforementioned substituents for a phenyl group or an aromatic heterocyclic group in R 1 and R 2 where the same examples can be given for the preferred specific examples
R
24 represents a hydrogen atom or phenyl group, where the phenyl group may be substituted by hydroxy group at any position.
R
25 represents a hydrogen atom, phenyl group, C 2 alkoxycarbonyl group, lower alkyl group, C -C 6 alkylthio group, or 3-indolyl group, where the phenyl group may be substituted by hydroxy group at any position. The C 2
-C
7 alkoxycarbonyl group and C 1
-C
6 lower alkyl group as R 25 are the same as defined for the aforementioned substituents for a phenyl group or an aromatic heterocyclic group in R 1 and R 2 where the same examples can be given for the WO 97/44329 PCT/US97/08577 preferred specific examples. The Ci-C, alkylthio group as R 25 means a group consisting of thio group and Cl-C, part of the aforementioned lower alkyl groups for substituent in R' and R 2 specifically, for example, methylthio group and ethylthio group.
R
26 represents a hydroxy group, amino group, C,-C 6 lower alkoxy group, or phenylalkyloxy group. The Ci-C 6 lower alkoxy group is the same as defined for the aforementioned C,-C 6 lower alkoxy group as substituent for a phenyl group or an aromatic heterocyclic group in R 1 and R 2 where the same examples can be given for the preferred specific examples. The phenylalkyl group means a group consisting of a phenyl group, a C,-C 6 alkylene group, and a oxy group, preferably and specifically for example, a benzyl oxy group.
On Invention 2
R
2
R
3 j, and k in the above formula [II] are as the same as defined in the respective terms for the above formula and the same examples can be listed for their preferred specific examples. R 4 in the above formula [II] includes R 4 defined in the respective terms for the above formula where the same examples can be listed for their preferred specific examples, and furthermore R 4 in the above formula [II] represents a hydrogen atom, Ci-C, alkanoyl group, or C 2
-C
7 alkoxycarbonyl group. However, the above formula [II] does not involve the same limitations as made in the above formula with respect to cases where R 3 represents a hydrogen atom, where R 3 represents a hydrogen atom and k represents 2, and where R 3 represents cyano group.
The cyclic diamine derivative represented by the formula [II] above or its pharmacologically acceptable acid adduct can be used to prepare a chemokine receptor antagonist preparation of the present invention by formulating the therapeutically required amount and a carrier and/or diluent into a pharmaceutical composition. Thus, the cyclic diamine derivative shown by the above formula [II] or its pharmacologically acceptable acid adduct can be administered orally or by parenterally, for example, intravenously, subcutaneously, intramuscularly, percutaneously or intrarectally.
The oral administration can be accomplished in the form of tablets, pills, granules, powder, solution, suspension, capsules, etc.
WO 97/44329 PCT/US97/08577 26 The tablets for example can be prepared using a vehicle such as lactose, starch and crystallized cellulose; binder such as carboxymethylcellulose, methylcellulose,, and polyvinylpyrrolidone; disintegrator such as sodium alginate, sodium bicarbonate and sodium lauryl sulfate, etc.
Pills, powder and granule preparations can be prepared by a standard method using the vehicles mentioned above. Solution or suspension can be prepared by a standard method using glycerin ester such as tricaprylin and triacetin or alcohols such as ethanol. Capsules can be made by charging granules, powder or solution in gelatin, etc.
Subcutaneous, intramuscular or intravenous preparations can be prepared as an injection using aqueous or nonaqueous solution. Aqueous solution for example may include isotonic sodium chloride solution. Nonaqueous solutions may include for example, propyleneglycol, polyethylene glycol, olive oil, ethyl oleate, etc., and optionally, one can add antiseptics and stabilizers. For injection, one can be sterilized by filtration through a bacterial filter or combination of disinfectant Percutaneous administration may be in the form of an ointment or cream, and ointment can be prepared in the standard manner using fatty oils such as castor oil and olive oil, or Vaseline, while creams can be made using fatty oils or emulsifying agent such as diethyleneglycol and sorbitan esters of fatty acid.
For intrarectal administration, one can use standard suppositories using gelatin soft capsules etc.
The cyclic diamine derivative of the present invention or its pharmacologically acceptable acid adduct is administered at a dose that varies depending on thetype of disease, route of administration, age and sex of patient, and severity of disease, but is likely to be 1-500 mg/day in an average adult.
Matter common throughout Invention 1 and Invention 2 Preferred specific examples for the cyclic diamine derivatives in the WO 97/44329 PCT/US97/08577 above formula or formula [II] include compounds having each substituent as shown in the following Tables 1.1 1.25.
Table 1.1 Table 1.25 WO 97/44329 PCT/US97/08577 Table 1.1 28 Compound R'
R
2 3 No. k
R
1 ON 2 2
-CH
2 -a3CN 2 4 CN 2 3 -cH2
CN
3 ON 2 3
-CH
2 ci 4 ON 2 3 CH2 011 CH3 0 H 0 3
-CH
2
-S---CH
3 0 6 -J H 1 3 -CH 2 Cj-.CH 3 0 7 -D H 2 2 -CH2 CH3 0 8 H 2 2 CH2 I 9 -4 H 2 2 -CH
CN
H 2 2 -CHa-- 6
CH
2
-C~
0 0 H 2 2 1CH2 11 -c-
HO
12 0 H 2 2 -CH -O N0 2 WO 97/44329 PCT/US97/08577 Table 1.2 29 Compound R'
R
2
R
3 j k R4 No.
13 4 \H 2 2 0 0 2
N
-CH
2 -C-N 10 OCH 3
HCH
14 H OCH 3 4 H-22 CH 2
-CJ-NH
SCH3 0 H 2 3 CH2 16 H 2 3 CHf-
C-N
H
17 0H 2 3 (CHI)2- N- cl
HI
18 H 2 3 -0 CHr C- N' C CH--O 19 -0-0H 2 3 (cH2)- 0- H 2 3
-(OH
2 2 N 21 -clH 2 31 S(CH2)2- N 22 H 2 3 9
-CH
2 -C-0-CH2--O 23 H 2 3 CH 2
NO
2 24 -C0 H 2 3 H2 N02 WO 97/44329 PCTIUS97/08577 Table 1.3 Compound
R
3 2 k No. R R k R4 26 27 28 29 31 32 33 34 36 -o -o -o -0 -0 -0 -0 -o -0 -o -o -0 -o -o -0
-K;
-K;
-0
-K;
-K;
-K;
-K;
H 2 3
CH
2 02N H 2 3
-CH
2 OCH 3 H 2 3 -CH2
OCH
3 H 2 3 -C2D/
H
3
CO
H 2 3
-Q
0 2
N
H 2 3 -CH 2
CN
I
H 2 3 H 2 3 H 2 3
CF
3 (C H2)2-&
NO
2 -(CH2)3-&N0 2 H 2 3 -CH cl H 2 3 -CH2 -Q N02
OCH
3 H 2 3 -CH S- CH3 0 WO 97/44329 Table 1.4 PCTIUS97/08577 Compound
R
3 k k No.
-o -o -o -o -o -o -o -o -o -o
-Q-F
-o -oQ CH3
OCH
3
-Q
OH
3
-Q
H
3
C
00&OH 3
OH
-aci &OCH 3
Q
F
H 2 3 CH 2
CO
2
CH
3 H 2 3 -CH 2 S CH 3 0 0 H 2 3 -CH CH3 0 0 0 H 2 3 -CH 2
CH
3 0 H 2 3 H 2 3 -CH 2
-CH
3 0 H 2 3 -CH 2
CH
3 0 H 2 3 -CH2 9 H 2 3 -CH S- CH3 H 2 3 CH2 -a 9 H 2 3 -C2 S CH3 -al WO 97/44329 PCTIUS97/08577 Table 1.5 32 Compound R k No. k
R
49 0 H 2 3 CH 101 CH3
F&
0 H 2 3 CH2 cl 51 H 2 3 0 52 H 2 3
H-&
53 H 2 3 CH -a F 54 CJ--F H 2 3
-CH
2
CI
H 2 3 -CHC
CONH
2 0 56 ci cl H 2 3 -CH 2 1 3CH '0 57 H 2 3 -CH 2
-&OH
58 H 2 3 -CH 2 1-0 CH 3 OH 0 59 H 2 3 -CH,
OH
3 HO 0 H 2 3 -CH 2
&CON(CH
3 2 WO 97/44329 Table 1.6 PCTIUS97/08577 Compound
R
3 k k No.
-0 -oCF G OCH3
-Q-OH
-Q
OH
-o\ -o0
&~CF
3
-Q
OH
Q
HO
-&~-OCH3
~-Q-OH
OH
&CO
2
C(CH
3 3 -1o -o C0 2 Cf4 3 0 H 23 CH-E
NH
2 0 H 2 3 CH ci H 2 3 -CH 2
CJCI
H 2 3 -CH cl H 2 3 CH 2
-C-CI
H 2 3 -CH 2
-CI
H 2 3 -CH 2 S- CH 3 0 H 2 3 -CH 2
-CH
3 0 0 H 2 3 -CH 2 S- CH 3 0
CH
2
CH
3 H 2 3 -CH-C N-0
CH
2
CH
3 NH O H 2 3 CH 2 N-S- -GCI H 23 0 H 2 3 C H2 CH3 -l WO 97/44329 PCTIUS97/08577 Table 1.7 34 Compound
R
3 j k No.
73
C
2 H H 2 3 CH-Z& S CH3 0 74 H 2 3
N
-~OC2CH3 H 2 3 -CH 2
NC
o HQ_ 76 H 2 3 -CH2- N N0 2 77 H 2 3 -CH 2 2
CH
2 CH3 78 ~H 2 3 gC 0.
79 I i H 2 3 -CH 2 -C-N-N-8 0 0 -(9H 2 3 OCH~ -NO 2 81 4!7 H 2 3 CH 2
NO
2 82 H 2 3H 0 80 H 2 3 CH 2 N- \CH\-Q 0 0 82 H 2 3 CH2- C. N-N- 6- WO 97/44329 PCT1US97108577 Table 1.8 Compound R k No. k R 0 0 4H 2 3 -CH 2 -1 H 2 -1
H
86 H 2 3 0 0
CH
2 N- N-C- N0 2 H 7 H 2 3 -CH 2
N-C-%
87 H 2 3 0 0 SCH2- C N- N- C&
C
H H 8 2 8o H 2 3 -CH 2 -CN
OH
0 0 H 2 3 -cH2-c N-N 0 2
N
91 0 0 91 H 2 3 -cHj,-Cy 4 Cg0CH,
H
92 H 2 3 So CC>N-N- 3
HH
-o H H
CH
2 H 94 0 9 H 2 3 -c CY-- N- r+9 -a OCF o 0 0 0 H 2 3 -CH- NIN->- CH 0 96 H 2 3 -CH 2C NCH 3 0 WO 97/44329 Table 1.9 PCT/US97/08577 Compound j k No.
97 98 99 100 101 102 103 104 105 106 107 108 -o -0 -o -o H
-Q
OH
-0CH 0 0 H 2 3 -CH 2 C. N- N-(CI 0 0- 0 H 2 3 -CH 2 N- C- Br H H H 2 3 -CH2-C-N-N-6 Q-CH3 0 H 2 3 -0H 2 4 H H OH 3
UF
0 0
CH
2 -II- t+H 2
H
H 3 3 CH 2 S- CH 3 0 19
OCH
3 2 3 HSC3 0 0
OCH
3 2 3 CH 2 -C CH 3 0 OCOCH3 2 3 S- CH CH2H 0 OH 2 3 CH 2 S CH3 0 OH 2 3 c 2 3 CH CI WO 97/44329 Table 1.10 PCTJUS97/08577 Compound
R
3 R k No. R k R 109
Q
OH
-Q
OH
OH 2 3 110 111 112 113
&CF
3
-Q-OCH
3
Q
OCH
3
OH
H
3
CO
C(CH
3 3
CF
3
&CF
3
OCH
3
OCH
3
OH
H
3
CO
C(CH
3 3 -O CF 3
OH
OH
OH
OH
2 3 2 3 2 3 CH CI -CH_,D--a.C CH ac -CH ac 2 3S CH3 114 115 116 117
OH
OH
OH
OH
2 3 -CH2 CH3 0 0 0 2 3-H 0 2 3 CH S CH3 0 23 CH2 0 23-& 9 118
Q
H
3
C
-Q
H
3
C
2 3 0 -CH2 S- CH 0 119
-&OH
-OH
120 0 1-0 0 2 3 CH3 0 0 2 3
-CH
2 CH 3 0 WO 97/44329 Table 1.1 1 PCT/US97/08577 U ompoun No.
I 3 i k 121 122
N(CH
3 2 a N(CH 3 2
OH
OH
0 2 3 H2S CH3 2 3 CH2 0 CH3 0
&OH
123
H
3
C
H
3 0 OH 2 3 CH -CI 124 125 126 127 128 129 130 131 132 -q
H
3
C
-0o
-Q
o
I
H
3
C
OH
OH
OH
OH
OH
OH
OH
OH
OH
0 2 3 CH
SCH
3 0 0 0 232 iCH3 0 2 3 -CH 2 CH 3 0 0 2 3 -CH 2 i CH 3 -a 1 0 2 3 -CH 2 jS-CH 3 0 0 2 3 CH CH 0 2 3 -CH2 3S-CH 2 3 -CH--~~CH 0 2 3 CH2 S-CH -0 -11 0
H
3 C H 3
C
OH
-Q
F
WO 97/44329 Table 1.12 Compound No.
133 134 135 136 137 138 139 140 141 142 143 PCTIUS97/08577 Ro
-OH
-Q
OH
R 2
Q
OCH
3
Q
CH
3
OH
F
Q
OH
F
-0, 01)
-Q
OCF
3 -Q -OCH 3
H
3 00
OCH
3
OCH
3
H
3
C'
R
3
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
k R4 0 2 3 -CH 2 -c1- CH 3 0 2 3 -CH 2 jS-CH 3 0 0 2 3 -CH S- CH 3 0 0 2 3 -CH 2 CH 3 0 0 2 3 -CH 2
-CH
3 0 2 3 -CH2 S- CH3 231 0 0 23t 2 3 -CH2 CH3 2 3 CH~ CH3 0 2 3 CH S-CH3 -al 144 0 0 H 23 -CH 2
CF
3 0 WO 97/44329 Table 1.13 PCTIUS97/08577 Compound j k No.
145 146 147 148 149 150 151 152 153 154 155 156
OH
-OH
-o
-OH
0
Q
HN- CH 3 0-
OH
OCH
3
OH
OCH
3 -0--OH -p
OH
OCH
3 -Q0
H
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
2 3 -CH 2
-CH
3 0 2 3 -CH2 CH3 0 2 3 -CH 2 S- CH 3 0 2 3 -CH 2 -j--CH CH2H 0 2 3 -CH 2 S-CH3 0 0 2 3 CH 2 -C
CH
3 0 2 3 -CH S- OH 3 0 0 2 3 -CH 2
-CH
all 0 2 3 CH S CH SCH3 232 3 0 2 3 -CH2 CH3 2 3 CH S CH3 -al WO 97/44329 Table 1.14 PCTIUS97/08577 Compound R1 R 2
R
3 j k R4 No.
157 158 159 160 161 162 163 164 165 166
Q
OH
Q
OH
-o
OH
F
Q
cl
-I
OCH
3 P- OH
H
Q
CF
3
Q
NH
2
H
-Qo0 HN4
OH
3
Q
F
ci
-Q
OCH
3 qOH
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
0 2 3 CH S CH3 0 0 2 3 -CH 2 -JS CH 3 0 _0 2 3 -CH 2
S-CH
3 -all 0 0 2 3 -CH2~9BH 0 2 3 -CH 2
CH
3 0 23 -0H 2
Q-CH
3 0 2 3 -CH 2 C CH 3 0 2 3 -CH- -CH 3 all 0 2 3 -CH-C SCH 3 0 23; 0 2 3 -CH 2
S-CH
3 0 23 0 2 3 C2 CH3 167 168
OH
OH
WO 97/44329 Table 1.15 PCTIUS97/08577 Compound j k No.
169 170 171 172 173 174 175 176 177 178 179 180
Q
OH
OH
OH
OH
OH
-Q
F
-Q
ci
OCH
3
OCH
3
Q
OCH
3
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
2 3 -CH 2 CH 3 0 9 2 3 CH 2
SCH
3 11 0 2 3 -CH 2 CH 3 0 0 2 3 -CH 2
H
3 0 2 3
CH
2 S- CH 3 0 0 0 2 3 -CH 2 S- CH(CH 3 0 2 3 CH 2 -C -S-(CH 2
)CH
3 0 2 3 CH 2 s- (CHCH3 0 2 3 CH2
?I
0 2 3 2 3 0
O=S-CH
3 CH2 0
CH
2
CH
3
CH
2
-O
WO 97/44329 Table 1.16 PCTIUS97/08577 43 Compound R' R 2
R
3 j k R4 No.
0 181 OH 2 3 0=S- (CH 2 2
CH
3 -0H 2
O
0 182 OH 2 3 cH S-CH(CH 3 2 0 183 OH 2 3 cHO=S-(CH 2 3
CH
3
CHH
OO=
184 OH 2 3 0 0 185 OH 2 3 CH 2
N-
OH H H
OH
186 OH 2 3 -0H 2 H"'-1 OH 0 187 OH 2 3 OH4
CH
2
HO
0 188 OH 2 3 -C2Ss'& H OH 0 0 19 189 OH 2 3 -CH 2 ItC 2
-C
OH H 190 OH 2 3 OH 0 191 -9OH 2 3 -c 9H-C N-N9~ OH H H a 192 OH 2 3 0 OH OH CH 2 -tc OH
OH
WO 97/44329 PCT/US97/08577 Table 1.17 44 Compound
R
3 j k No.
0 193 OH 2 3 CH 2 C- -W-Q-F OH
NO
2 It0 0 194 OH 2 3 0 Q CH 2 C- N- N- C- li OH H H 195 OH 2 3
CH
2 C- N- OH HHH NH 0 196 OH 2 3 C OH H 0 197 OH 3 3 CH cH3 0 198 OH 3 3 -CH 2
S-CH
3 OH OH 0 0 199 H 2 0 0 200 H 2 3 l 0 201 -Q H 2? p 2 3 C-GN 202 H 2 3 2H3 CH- N(CH 3 3 0 203 H 2 3 -C-CH 2
-N-CH
2 CH3 0 204 H 2 3Q
HN%
WO 97/44329 Table 1.18 PCTIUS97108577 Compound R1 R 2
R
3 j k R No.
205 206 207 208 209 210 211 212 213 214 215 216 -o -o -0 -o -o -o -o -0 -0 -o -o -o -o -0 -o
-G
-o ~-0 -o -o -o -o -o -o H 2 3 H 2 3 H 2 3 H 2 3 -(OH 2 2 00 2 0H 3
(CH
2 2 0H 3 0
OCH
3
-CH
2
H
OH
0 H 2 3 H 2 3 H 2 3 H 2 3 H 2 3 H 2 3 7 CH 2 C= CCH 3
-CH
2 CH
OH
0
(CH
2 )k-C2 N
(CH
22
-CON
N
-OH
2
N-
0 2 H. fO CH, H 2 3 ,CI3
H
3 C-\w WO 97/44329 PCT/US97/08577 Table 1.19 46 Compound
R
2
R
3 j k R No.
217 H 2 3 -CH- CE N 218 H 2 3 OH
CH
2
CHCH
2 0CH 2
CH
2
C=CH
0 219 -I aH 2 3 -CH-eC 220 H 2 3 -CH 2
C=CH
221 H 2 3 -(CH2)S-NlN 0 222 H 2 3 H 3
H
2
CHCH
2
OH
H
3 c, 223 H 2 3 o
CH
3 224 H 2 3 CH2-- C- N- N- C- OCH 2
CH
3 H H OH 0 225 H 2 3 -CH 2 -CH- CH-I 0 226 H 2 3 CH2- N-9
HO
HO
227 OH 2 3 (CH2SS N
OH
0
NH
228 OH 23N OHH 2 3 -(CH 2 3
N
0 OHb WO 97/44329 PCT/US97/08577 Table 1.20 Compound R' R2 R 3 j k R No.
229 OH 2 3
OH
OH
/CH
3 231 OH 2 3 OH
CH
232 OH 2 3 C- O
OH
0 CH 3 HNc 234 -1 ON 2 3 OH
H
235 OH 2 2 NCH H-CN 236 H 2 2 2 CCHN HH
S
237 H 2 2 .9 9 CH3 23o -o2 2 -CH 2 CNc-~ 238 H 2 3
N
H
H
3
C
239 H 2 3 2 N
H
3
C
240 H 2 3 CH 2
-CJN
WO 97/44329 Table 1.21 PCT1US97/08577 Compound 2 3 4 No. R' R R j k R 241 242 243 244 245 246 247 248 249 250 -o -o -o -o -o -o -o -o -o -o -o -o -o -o H 2 -a OCH 3
OH
-o H 2 3 H 2 3 H 2 3 CH2
N
CH-N
CH- CN H 2 3 -CH2-- CN 0 0 CH 3 H 2 3 -CH" H H s H 2 3 -CH 2 4 i
N-S
H 2 3
CH
2 N- I 0CI H 2 3 -CH 2 Ci- N- N- 81ZN H HI H 2 3 CH 2
WO
0 251 -o -o 0 0 H 2 3 CH 2 C- N- 11
U
H H 0 0 0 H 2 3 S 252 WO 97/44329 Table 1.22 Compound No.
253 254 255 256 257 258 259 260 261 262 263 264 PCTIUS97/08577
R
1 -o -o -0 -o -o -o -0 -o -o -o
OH
OH
OH
OH
-Q4
OH
OH
R
3 j k R
OH
H 2 3 -CH 2
CHCH
2 0CH2- 0 0 H 2 3 -CH 2 5
N-C-O,
H H N H 2 3 -CH 2 CNN- C- C H HQ .9 H 2 3 -CH 2 C- N' N-;S- HH" S' H 2 3 -CH 2 -b-N--6-(jf H H 11S OH 2 3 CH2-iN O OCH 3 OH 2 3 -CH 2 If HH s OH 2 3 -H2 -CN 0 0 CI OH 2 3 -CH2- N-
CI
O 0 OH 2 3 c- C- N- N-c-Qi HH S(CH 3 -0 -o -o -o -o 2 3 0 ,CH 2
CH
3 2 3 -CH 2
-C-N,
CH
2
CH
3 WO 97/44329 PCTUS97/08577 Table 1.23 Compound R1 R 2
R
3 j k R4 No.
0 ,CH 2
CH
3 265 9H 2 3 -CH -C-N
CH
2
CH
3 266 H 2 3 It
CH
2
NH
2 267 H 2 3 -CH 2 C-N- CH 2
CH
3
H
0 It 268 H 2 3 CH 2 C- N- CH(CH 3 2 269 -f H 2 3 -CH 2 -C-N S 0 (CH 2 5
CH
3 270 H 2 3 -CH 2
N
(CH
2 5
CH
3 0 (CH 2 2
CH
3 271 -f H 2 3 -CH 2 c- N\
(CH
2 2
CH
3 0 0 272 H 2 3 -CH 2 -1-H 2 C- OCH
H
'N I-N 9 9 273 -92-
CH
2 C- N- CH 2 C- NH 2 0 0 274 ~9- 4H 2 3 CH 2
N-CH
2
-C'OC(CH
3 3 275 H 2 3 0"9 CH-C- N- CH- CH 2 0H
H
0 276 3 -CHH 2 3
HO
WO 97/44329 Table 1.2 4 Compound No.
277 278 279 280 281 282 283 284 285 286 287 PCTIUS97/08577 Ro -o -o\
R
2 -o -o -o -o -o -0 -o -o -o -o -0
OH
H 2 3
-CH
2
-C-N-CH-CHOH
H
H 2 3 .9 Q.
CH
2 N-CHr CHOH
H
H 2 39 Q H 2 3 CH 2 N- CH-CHOH L
OCH
3 H 2 3 .9
OH
2 C- N- CHf-CHOH H'
H
H 2 3 pP ~CH2- CN- CH-CHOH
H
H 2 3 9-r
-CH
2 C- N- OH- CH 2 0H
H
.9 9 H 2 3 -OH 2
C-NH
2 0 0 -0H 2 OH-C-0OH 3 0 0 0 H 3 CKe-c- r~ OH-C-OCHr--- 0 0 H 2 3 -CH 2
-C-N-CH-C-OCH
3 L. CH(CH3) 0 0 0CH 2 N- OH-C- OCH3 H 2 3H Q
H
9 9 H 2 3 -CH 2 C'N- CH- C- OCH 3
SCH
2
SCH
3 R 3 k k 288 -o WO 97/44329 PCTJUS97/08577 Table 1.25 52 Compound Rj R2 R 3 k R4 No.
o o 290 H 2 3 CH2- C- N- OH CH(CH3)2 9 0 H 2 3 CH 2 C- N CH- C- OH 290
C
CH2SCH 3 0 0
CH-C-OH
292 H 2 3 CH-C 0,CH 2
CH
3 293 OH 2 3 cH- C- N, OH CH 2
CH
3 294 OH 2 3 9 C- OC(CH 3 3
OH
295 OH 2 3 -H
OH
296 OH 2 3 9 C- CH3
OH
0Q 297 H 2 3 -Cf-&-N-N-C-N
CH
2 0H 298H 2 31 -o -o H 2 3 N- CH- CH 2 O 2CH CH2OH 299 H 2 3 CH2-C N ~CHCHO H6 WO 97/44329 PCT/US97/08577 53 The present invention can also use acid adducts of the cyclic diamine derivatives where such acids include, for example, mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, carbonic acid, and the like, as well as organic acids such as citric acid, malic acid, tartaric acid, fumaric acid, methanesulfonic acid, trifluoroacetic acid, and the like.
The present invention may use racemates and all possible optically active forms of the cyclic diamine derivatives represented by the above formula [I] or [II].
Compounds represented by the above general formula and/or [II] can be synthesized by any of the general preparations given below.
(Preparation 1) A preparation which call for treating one equivalent of a cyclic diamine derivative represented by the formula [III] below
S
(CH2)i-N NH [m] 20 (CH )2 k [where R 1
R
2
R
3 j, and k are as defined respectively in the above formula [I] or with 0.1-10 equivalents of a compound represented by the formula [IV] below:
X
1 R' [IV] [wherein R 4 is the same as defined for the R 4 in the above formula or [II]; X' is a halogen atom, alkylsulfonyloxy group, or arylsulfonyloxy group. R 4 is not a group represented by the formula: -A 2
-R
1 in where A 2 and R" are the same as defined respectively in the above formula or [II] 1, either in absence or presence of solvent; alternatively treating 1 equivalent of a cyclic diamine given by the formula below: WO 97/44329 PCT/US97/08577 54 HN N-R 4
[V]
(CH 2)k [where R 4 and k are the same as defined respectively in the above formula [I] or with 0.1-10 equivalents of a compound represented by the formula [VI] below: 2 R 3 (CH 2 )j-X 1
[VI]
R
[where R 1
R
2
R
3 and j are the same as defined respectively in the above formula [I1 or X' represents a halogen atom, alkylsulfonyloxy, or arylsulfonyloxy group] either in the absence or presence of solvent.
Such reactions can be more smoothly run if a base is present. The base which may be used includes inorganic salts such as potassium carbonate, sodium carbonate, sodium hydrogencarbonate, and the like, or amines such as triethylamine, diisopropylethyl amine, and pyridine, and the like. In addition, the reactions in these preparations can also be promoted by iodide such as potassium iodide, sodium iodide, or the like.
X' in the above formulas [IV] and [VI] represents a halogen atom, alkylsulfonyloxy, or arylsulfonyloxy group. Such halogen atoms include preferably chlorine, bromine, and iodine atoms. Suitable specific examples for the alkylsulfonyloxy groups include methylsulfonyloxy and trifluoromethyl sulfonyloxy group and the like. A preferred specific example for the arylsulfonyloxy group includes a tosyloxy group.
(Preparation 2) A preparation which calls for treating 1 equivalent of a cyclic diamine derivative represented by the above formula [III] with 0.1-10 equivalents of a carboxylic acid, sulfonic acid represented by the formula [VII] below:
HO-A
2 -R" [VII] WO 97/44329 PCT/US97/08577 [where R 1 and A 2 are the same as defined respectively in the above formulas [I] or or its reactive derivative, either in the absence or presence of solvent.
The reactive derivatives for the carboxylic acids or sulfonic acids in the above formula [VII] include highly reactive carboxylic or sulfonic acid derivatives, which are usually used in synthetic organic chemistry, such as acid halides, acid anhydrides, mixed acid anhydrides. If esters are used, the reaction can be run smoothly by activating the cyclic diamine derivative represented by the above general formula [III], for example, by using triethylaluminum.
Such reactions can be more smoothly run by using suitable amounts of a dehydrating agent such as molecular sieve, condensing agents such as dicyclohexyl carbodiimide, N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide, carbonyldiimidazole, and the like, or bases similar to those used in the above preparation 1.
(Preparation 3) A preparation which calls for treating 1 equivalent of a cyclic diamine represented by the above formula [III], with 0.1-10 equivalents of an aldehyde represented by the formula [VIII] below
R
2
"-(CH
2 ),-CHO [VIII] [where in the formula R 27 represents either R 7 R or R 20 of the above formula or z represents an integer of either in the absence or the presence of solvent under reductive conditions, or else treating 1 equivalent of a compound represented by the above formula with 0.1-10 equivalents of an aldehyde represented by the formula [IX] below R
R
WO 97/44329 PCTIUS97/08577 56 [where in the formula R 1
R
2
R
3 and j are the same as defined respectively in the above formulas or [II] either in the absence or the presence of solvent under reductive conditions.
Such reactions are in general called reductive amination reactions and such reductive conditions may be generated by catalytic hydrogenation using a catalyst containing a metal such as palladium, platinum, nickel, rhodium, or the like, using complex hydrides such as lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, and the like, boranes, or electrolytic reduction, and the like.
(Preparation 4) A preparation which calls for treating 1 equivalent of a cyclic diamine derivative represented by the formula below: 0
R
28 0-C (CH 2 N-R 4
[X]
(CH 2)k [where in the formula j, k, and R' are the same as defined respectively for the above formula or [II] and R 28 represents a Ci-C, lower alkyl group] or 1 equivalent of a cyclic diamine derivative represented by the formula [XI] below: 0 I I
R'-C-(CH
2 1
N-R
4
[XI]
(CH 2)k [where j, k, and R 4 are the same as defined respectively for the above formula or with 0.1-10 equivalents of an organometallic reagent represented by the formula [XII] below:
R
29 -M [XII] [wherein the formula R 29 is the same as defined for the R 1 and R 2 in the above formula or M is a metal atom or its halide or complex] in the presence of solvent.
WO 97/44329 PCT/US97/08577 57 The organometallic reagents used in such preparations may be those suitably selected organometallic reagents known to cause a nucleophilic reaction toward esters and/or ketones in general in synthetic organic chemistry, such as Grignard reagents (M MgXZ), organolithium reagents (M Li), organocerium reagents (M CeX 2 2
(X
2 represents a halogen atom). These organometallic reagents may be prepared by known methods from the corresponding halides. The halides preferably include chlorides, bromides, iodides.
If the substrates submitted to each of the above preparations contains a substituent which reacts under each reaction condition in general in synthetic organic chemistry or is thought to adversely affect the reaction, that functional group can be protected by a known suitable protecting group followed by the reaction of the above preparations and deprotection using a known procedure to obtain the desired compound.
Each of the above preparations may use solvents for the reaction such as halogenated hydrocarbons such as dichloromethane, chloroform, or the like, aromatic hydrocarbons such as benzene, toluene, and the like, ethers such as diethyl ether, tetrahydrofuran, or the like, esters such as ethyl acetate, aprotic polar solvents such as dimethylformamide, dimethyl sulfoxide, acetonitrile, and the like, alcohols such as methanol, ethanol, isopropyl alcohol, and the like.
The reaction temperature in either of the preparations should be in the range of -78 +150 preferably 0 _C 100 After completion of the reaction, the usual isolation and purification operations such as concentration, extraction, recrystallization, chromatography, and the like may be used to isolate the desired cyclic diamine derivatives represented by the above formula or These can be converted into pharmacologically acceptable acid adducts by the usual method.
Potential Industrial Utilities The chemokine receptor antagonist, which contain the cyclic diamine derivative or its pharmacologically acceptable acid adducts of this invention, which inhibits chemokines such as MIP-la and/or MCP-1 and the like from action WO 97/44329 PCT/US97/08577 58 on target cells, are useful as therapeutic agents and/or preventive preparation for diseases such as atherosclerosis, rheumatic arthritis, psoriasis, asthma, ulcerative colitis, glomerulonephritis, multiple sclerosis, pulmonary fibrosis, myocarditis, and the like, in which tissue infiltration of blood monocytes, lymphocytes, and the like plays a major role in the initiation, progression, and maintenance of the disease.
WO 97/44329 PCT/US97/08577 59 Examples The present invention is now specifically described by the following examples. However, the present invention is not limited to these compounds described in these examples. Compound numbers in these examples represent numbers attached to these compounds listed as suitable specific examples in Tables 1.1 1.18.
Example 1: Synthesis of 1-(3,3-Diphenylpropyl)-4-(4nitrobenzyl)homopiperazine (Compound No. 23).
A mixture of 120 mg of homopiperazine, 206 mg of homopiperazine dihydrochloride, and 3 mL of ethanol was heated to 70 _C to prepare a solution.
375 mg of sodium iodide and 287 mg of 3,3-diphenylpropyl methanesulfonate were added sequentially to the solution and the mixture was stirred at 70 _C for 14 hours. The mixture was allowed to cool to room temperature and the ethanol was removed under reduced pressure, followed by adding 20 mL of 2N aqueous sodium hydroxide solution and extracting with 20 mL x 2 of ethyl acetate. The organic layers were combined, washed with 20 mL of saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated to give 1- (3,3-diphenylpropyl)homo piperazine.
The resulting 1-(3,3-diphenylpropyl )homopiperazine was dissolved in 3 mL of acetonitrile followed by adding 213 mg of 4-nitrobenzyl bromide and 144 mg of potassium carbonate. The mixture was stirred at 70 _C for 14 hours and allowed to cool to room temperature and the solvent was removed under reduced pressure. 20 mL of aqueous 2N sodium hydroxide was added and the mixture was extracted with 20 mL x 2 of ethyl acetate. The organic layers were combined, washed with 20 mL of saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, ethyl acetate) to obtain 255 mg of the titled compound. This was treated with a hydrogen chloride solution in ether and the solvent was removed under reduced pressure; and the residue was dried to obtain the hydrochloride salt of the titled compound.
Compound No. 23 (Free Base) had the following 'H NMR (CDCl 3 270 MHz) 6 (ppm): 1.73-1.82 2 2.16-2.25 2 2.40-2.46 2 2.64-2.71 8 H), 3.71 2 4.01 J 7.6 Hz, 1 7.13-7.19 2 7.19-7.31 8 WO 97/44329 PCTIUS97/08577 7.50 J 8.6 Hz, 2 8.16 J 8.6 Hz, 2 H).
Example 2: Preparation of 1-Benzyl-4-(3,3diphenylpropyl)homopiperazine (Compound No. A mixture of 101 mg of homopiperazine, 175 mg of homopiperazine dihydrochloride, 3 mL of ethanol was heated to 70 _C into a solution. 0.115 mL of benzyl chloride was added and the mixture was stirred at 70 _C for 3 hours.
After cooling to room temperature, ethanol was removed under reduced pressure, and 20 mL of aqueous 2N sodium hydroxide solution was added to the solution, which was extracted with 20 mL x 2 of ethyl acetate. The organic layers were combined, washed with 20 mL of saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated to give 1benzylhomopiperazine.
The resulting benzylhomopiperazine was dissolved in 3 mL of ethanol, to which were added 296 mg of 3,3-diphenylpropyl methanesulfonate and 136 mg of potassium carbonate. The mixture was stirred at 70 _C for 15 hours and it was cooled to room temperature and the solvent was removed under reduced pressure.
mL of aqueous 2N sodium hydroxide was added and the solution was extracted with 20 mL x 2 of ethyl acetate. The organic layers were combined and washed with 20 mL of saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, ethyl acetate) to obtain 135 mg of the titled compound. This was treated with a hydrogen chloride solution in ether followed by removing the solvent under reduced pressure and drying to give the hydrochloride salt of the titled compound.
Compound No. 15 (free base) had the following H NMR (CDCl 3 270 MHz) 6 (ppm): 1.71-1.81 2 2.16-2.25 2 2.39-2.45 2 2.64-2.73 8 H), 3.62 2 4.01 J 7.9 Hz, 1 7.12-7.34 15 H).
Example 3: Preparation of 1-Benzoyl-4-(3,3diphenylpropyl )homopiperazine (Compound No. 199).
A mixture of 126 mg of homopiperazine, 218 mg of homopiperazine dihydrochloride, 3 mL of ethanol was heated to 70 _C into a solution. 378 mg of sodium iodide and 289 mg of 3,3-diphenylpropyl methanesulfonate were added sequentially to the solution and the solution was stirred at 70 _C for 15 hours.
After the solution was cooled to room temperature, the ethanol was removed under WO 97/44329 PCTfUS97/08577 61 reduced pressure followed by adding 20 mL of aqueous 2N sodium hydroxide and extracting with 20 mL x 2 of ethyl acetate. The organic layers were combined, washed with 20 mL of saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated to give 1-(3,3diphenylpropyl)homopiperazine The resulting 1-(3,3-diphenylpropyl )homopiperazine was dissolved in 3 mL of dichloromethane, followed by adding 107 mg of triethylamine and 140 mg of benzoyl chloride. After the mixture was stirred at room temperature for 6 hours, it was mixed with 20 mL of aqueous 2N sodium hydroxide and extracted with mL x 2 of ethyl acetate. The organic layers were combined, washed with mL of saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, hexane/ethyl acetate 4:6) to obtain 249 mg of the titled compound. This was treated with a hydrogen chloride solution in ether and the solvent was removed under reduced pressure and the residue was dried to give the hydrochloride salt of the titled compound.
Compound No. 199 (free base) had the following 'H NMR (CDC13, 270 MHz) 6 (ppm) 1.69-1.79 1 1.90-1.99 1 2.12-2.28 2 2.35-2.48 2 H), 2.54-2.61 2 2.64-2.69 1 2.75-2.80 1 3.39-3.46 2 H), 3.73-3.78 2 3.96-4.06 1 7.13-7.31 10 7.35-7.39
H).
Example 4: Preparation of 1-[4-(Dimethylaminomethyl) benzoyl]-4- (3.3-diphenylpropyl)homopiperazine (Compound No. 202).
The same method as that of Example 1 was used to obtain 1-(3,3diphenylpropyl)homopiperazine The resulting 1-(3.3-diphenylpropyl)homopiperazine was dissolved in 3 mL of toluene under argon, followed by adding 0.65 mL of a 15% trimethylaluminum solution in hexane. The mixture was stirred at room temperature for 15 minutes, mixed with 187 mg of methyl 4-(dimethylaminomethyl) benzoate, stirred at 60 _C for 22 hours. The mixture was cooled to room temperature, mixed with 2N hydrochloric acid, and stirred. 20 mL of aqueous 2N sodium hydroxide was added and the mixture was extracted with 20 mL x 2 of ethyl acetate. The organic layers were combined, washed with 20 mL of saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, concentrated, and purified by column SWO 97/44329 PCTIUS97/08577 62 chromatography (silica gel, ethyl acetate/methanol 6:4) to obtain 234 mg of the titled compound. This was treated with a hydrogen chloride solution in ether, the solvent was removed under reduced pressure and the residue was dried to give the hydrochloride salt of the titled compound.
Compound No. 202 (free base) had the following 'H NMR (CDC13, 270 MHz) 6 (ppm) 1.65-1.80 1H), 1.89-2.01 1H), 2.12-2.29 2H), 2.24 6H), 2.35-2.48 2 2.52-2.60 2 2.60-2.70 1 2.74-2.79 1 3.40- 3.48 2 3.43 2 3.32-3.77 2 3.96-4.06 1 7.16- 7.52 14 H).
Example 5: Preparation of 1- 3, 3-Diphenylpropyl (2quinolylmethyl )homopiperazine (Compound No. 237).
The same method as that of Example 1 was used to obtain 1-(3,3diphenylpropyl)homopiperazine The resulting 1-(3,3-diphenylpropyl)homopiperazine was dissolved in 3 mL of ethanol, mixed with 228 mg of 2-(chloromethyl)quinoline hydrochloride and 141 mg of potassium carbonate, and stirred at 70 _C for 14 hours. The mixture was cooled to room temperature and the ethanol was removed under reduced pressure, 20 mL of aqueous 2N sodium hydroxide was added and the mixture was extracted with 20 mL x 2 of ethyl acetate. The organic layers were combined, washed with mL of saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, ethyl acetate/methanol 95:5), to obtain 109 mg of the titled compound. This was treated with a hydrogen chloride solution in ether and the solvent was removed under reduced pressure and the residue was dried to give the hydrochloride salt of the titled compound.
Compound No. 237 (free base) had the following 1 H NMR (CDC1 3 270 MHz) 6 (ppm) 1.76-1.86 2 2.18-2.27 2 2.42-2.49 2 2.68-2.82 8 H), 3.96 2 4.02 J 7.6 Hz, 1 7.12-7.31 1 7.50 (dd, j 7.9, 7.9 Hz, 1 7.65-7.72 2 7.79 J 7.9 Hz, 1 8.05 J 8.3 Hz, 1 8.11 J 8.6 Hz, 1 H).
S 35 Example 6: Preparation of 1-(3,3-Diphenylpropyl)-4-(7-methoxy-2Hchromene-2-one-4-ylmethyl )homopiperazine (Compound No. 206).
The same method as that of Example 5 was used except for the use of SWO 97/44329 PCT/US97/08577 63 mg of 4-(bromomethyl)-7-methoxy-2 H-chromene-2-one to give 303 mg of the titled compound, and except for the use of ethanol/chloroform as the solvent for the reaction. Furthermore, the same method as that of Example 5 was used to obtain the hydrochloride salt of the titled compound.
Compound No. 206 (free base) had the following 'H NMR (CDCla, 270 MHz) 6 (ppm) 1.75-1.85 2 2.16-2.25 2 2.39-2.45 2 2.62-2.79 8 H), 3.72 2 3.87 3 4.02 J 7.6 Hz, 1 6.36 1 6.80-6.85 2 7.12-7.31 10 7.75 J 9.6 Hz. 1 H).
Example 7: Preparation of 1-(2-Benzimidazolylmethyl)-4- (3,3diphenylpropyl)homopiperazine (Compound No. 207).
The same method as that of Example 5 was used except for the use of 165 mg of 2-(chloromethyl)benzimidazole and 16 mg of sodium iodide to promote the reaction to give 91 mg of the titled compound. Furthermore, the same method as that of Example 5 was used to obtain the hydrochloride salt of the titled compound.
Compound No. 207 (free base) had the following 1H NMR (CDC1,, 270 MHz) 6 (ppm): 1.70-1.82 2 2.19-2.29 2 2.43-2.50 2 2.65-2.73 4 H), 2.76-2.81 4 3.96 2 3.99 J 7.6 Hz, 1 7.14-7.31 14 7.60-7.85 1 H).
Example 8: Preparation of 1- (2,2 -Diphenyl ethyl) 4 4- (methylsulfonyl)benzyl]homopiperazine (Compound No. 6).
A mixture of 120 mg of homopiperazine, 216 mg of homopiperazine dihydrochloride salt, 3 mL of ethanol was heated to 70 _C into a solution. To this solution were added sequentially 383 mg of sodium iodide and 250 mg of 4-(methylsulfonyl)benzyl bromide, followed by stirring at 70 _C for 14 hours.
After the solution was cooled to room temperature, ethanol was removed under reduced pressure and 20 mL of aqueous 2N sodium hydroxide was added and the mixture was extracted with 20 mL x 2 of ethyl acetate. The organic layers were combined, washed with 20 mL of aqueous saturated sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated to give 176 mg of 1-[4- (methylsulfonyl)benzyl]homopiperazine VWO 97/44329 PCT/US97/08577 64 The resulting 1- [4-(methylsulfonyl)benzyl]homopiperazine was dissolved in 5 mL of dichloromethane, followed by adding 223 mg of diphenylacetaldehyde and 217 mg of sodium triacetoxyborohydride. After the mixture was stirred at room temperature for 16 hours, it was mixed with 30 mL of aqueous saturated sodium hydrogencarbonate, and extracted with 30 mL x 2 of ethyl acetate. The organic layers were combined, washed with 30 mL of saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, ethyl acetate) to obtain 173 mg of the titled compound. This was treated with a hydrogen chloride solution in ether and the solvent was removed under reduced pressure, the residue was dried to give the hydrochloride salt of the titled compound.
Compound No. 6 (free base) had the following 'H NMR (CDC13, 270 MHz) 6 (ppm): 1.64-1.77 2 2.51-2.64 4 2.67-2.83 4 3.04 3 3.15 J 7.6 Hz, 2 3.61 2 4.14 J 7.6 Hz, 1 7.13-7.35 (m, 7.45 J 8.2 Hz, 2 7.84 J 8.2 Hz, 2 H).
Example 9: Preparation of 1-(3-Hydroxy-3,3-diphenylpropyl)-4-(4chlorobenzyl)homopiperazine (Compound No. 107).
A solution of 54 mg of methyl 3-[4-(4-chlorobenzyl) homopiperazinyl] propionate in 10 mL of ether was mixed with under nitrogen, 4 mL of 1 M phenyl magnesium bromide. The mixture was stirred at room temperature for 30 minutes, mixed with aqueous saturated ammonium chloride and the mixture was extracted with 50 mL of ethyl acetate. The extract was washed with 50 mL of saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, ethyl acetate/methanol 9:1) to give 65 mg of the titled compound. This was treated with a hydrogen chloride solution in ether and the solvent was removed under reduced pressure and the residue was dried to give the hydrochloride salt of the titled compound.
Compound 107 (free base) had the following 'H NMR (CDC 3 1, 270 MHz) 6 (ppm): 1.77-1.86 2 2.36-2.40 2 2.54-2.71 10 3.58 2 H), 7.15-7.20 2 7.26-7.32 8 7.44-7.48 4 H).
Example 10: Preparation of 1-(3,3-Diphenylpropyl)-4-(4oarbamoylbenzyl)homopiperazine (Compound No. WO 97/44329 PCT/US97/08577 A 20 mL solution of 175 mg of compound No. 30 in 20 mL of t-butyl alcohol was mixed with 570 mg of ground potassium hydroxide and the mixture was refluxed for 2.5 hours. The solution was cooled to room temperature and mixed with mL of water and 100 mL of ethyl acetate. The organic layer was separated and the aqueous layer was extracted with 50 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, ethyl acetate/methanol 4:1) to give 91 mg of the titled compound. This was treated with a hydrogen chloride solution in ether and the solvent was removed under reduced pressure and the residue was dried to give the hydrochloride salt of the titled compound.
Compound No. 55 (free base) had the following 1H NMR (CDC13, 270 MHz) 8 (ppm): 0.86-0.91 1 1.23-1.28 2 1.73-1.82 2 2.18-2.26 2 H), 2.42-2.47 2H), 2.65-2.73 6H), 3.67 2H), 5.6-6.2 (brs, 2H), 7.13-7.30 10 7.41 2 H, J 8.25 Hz), 7.75 2 H, J 8.25 Hz).
Example 11: Preparation of 1-[3,3-Di(2-furyl)-3-hydroxypropyl [4-(methylsulfonyl)benzyl]homopiperazine (Compound No. 129).
To a solution of 2-furyl lithium prepared in 50 mL of THF using 3 mL of furan and 2 mL of 1.63 M n-butyllithium was added dropwise at 0 C, a 10 mL solution in THF of 99 mg of methyl (methylsulfonyl)benzyl}homopiperazinyl] propionate. After stirring at 0 *C for 1 hour, the mixture was mixed with 50 mL of an aqueous saturated ammonium chloride, and extracted with 50 mL x 2 of ethyl acetate. The extracts were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, ethyl acetate) to give 62 mg of the titled compound.
Compound No. 129 had the following 'H NMR (CDC1 3 270 MHz) 8 (ppm): 1.80-1.89 2 2.32-2.36 2 2.56-2.60 2 2.74-2.78 2 2.66- 2.70 6 3.05 3 3.70 2 6.30-6.34 4 7.36-7.37 (m, 2 7.55 2 H J 8.25 Hz), 7.86 2 H, J 8.25 Hz).
Example 12: Preparation of 1-[3,3-Bis(4-hydroxyphenyl)-3hydroxypropyl]-4-[4-(methylsulfonyl)benzyl Ihomopiperazine (Compound No. 119).
To a 2.0 mL anhydrous THF solution of 120 mg of methyl chlorobenzyl)homopiperazinyl]propionate was added under nitrogen, 2.0 mL solution in THF of 1.5 mmol of 4-(tert-butyldimethylsilyloxy)phenyl magnesium 0 WO 97/44329 PCT/US97/08577 66 bromide. The mixture was stirred at room temperature for 30 minutes and an aqueous saturated ammonium chloride solution was added and the mixture was extracted with 20 mL x 3 of ethyl acetate. The extracts were washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, hexane/ethyl acetate 1:1) to give 33 mg of a silyl protected form of the titled compound.
The resulting oily product was dissolved in 3 mL of THF and mixed with 0.8 mL of a 1N THF solution of tributylammonium fluoride. The mixture was stirred at room temperature for 4 hours, mixed with aqueous saturated ammonium chloride and extracted with 20 mL x 3 of ethyl acetate. The extracts were washed with aqueous saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain 5 mg of the titled compound.
Compound No. 119 had the following H NMR (CDC1,, 270 MHz) 6 (ppm): 1.81-1.94 2 2.35 (broad s, 3 2.55-2.82 1 3.08 3 3.70 2 6.67 J 8.6 Hz, 4 7.14 J 8.9 Hz, 4 7.48 J 8.3 Hz, 2 7.81 J 8.3 Hz, 2 H).
Example 13: Preparation of l-[3-Hydroxy-3-(l-methyl-2-pyrrolyl) -3phenylpropyl]-4-[4-(methylsulfonyl )benzyl]homopiperazine (Compound No. 136).
mL of an anhydrous THF solution of 121 mg of methyl (methylsulfonyl)benzyl}homo piperazinyl]propionate was added under nitrogen to 6 mL of a THF solution of 1.5 mmol of 1-methyl-2-pyrrolyl cerium dichloride at -78 After stirring at -78 °C for 3 hours, the mixture was mixed with mL of water and it was filtered from insoluble matter using Celite, followed by extracting the filtrate with 30 mL x 2 of ethyl acetate. The extracts were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, ethyl acetate, ethyl acetate/methanol 10:1) to give 7 mg of the titled compound.
Compound No. 136 had the following 'H NMR (CDC1 3 270 MHz) 6 (ppm): 7.88 (d, J 8.4 Hz, 2 7.56 J 8.4 Hz. 2 7.32-7.16 5 6.48-6.47 (m, 1 6.22-6.20 1 6.06-6.04 1 3.72 2 3.26 3 3.06 3 2.87-2.39 11 2.05-1.83 3 H).
Example 14: Preparation of 1-[3,3-Bis(1-methyl-2-pyrrolyl)-3- Q WO 97/44329 PCTIS97/08577 67 hydroxypropyl]-4-[4- methylsulfonyl )benzyl homopiperazine (Compound No. 127).
mL of an anhydrous THF solution of 160 mg of 1-[4- (methylsulfonyl )benzyl 1-4-(3-oxo-3-phenyl propyl)homopiperazine was added under nitrogen at -78 °C to a 3 mL THF solution of 0.8 mmol of l-methyl-2pyrrolylcerium dichloride. The mixture was stirred at -78 *C for 3 hours and then it was mixed with 20 mL of water and filtered from insolubles, using Celite; the filtrate was extracted with 30 mL x 2 of ethyl acetate. The extracts were dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, hexane/ethyl acetate 1:3, ethyl acetate) to give 18 mg of the titled compound.
Compound No. 127 had the following 'H NMR (CDC 3 1, 270 MHz) 6 (ppm): 7.88 (d, J 8.3 Hz, 2 7.56 J 8.3 Hz, 2 6.50-6.48 2 6.24-6.22 (m, 2 6.03-6.00 2 3.71 2 3.21 6 3.05 3 2.8- 2.62 10 2.36-2.32 2 1.88-1.83 2 H).
Example 15: Preparation of 1-(3,5-Difluorophenyl)-3-hydroxy-3-(3hydroxyphenyl)propyl -4-[4-(methylsulfonyl )benzyl]homopiperazine (Compound No.
138).
To 1.0 mL anhydrous THF solution of 263 mg of 1-[4- (methylsulfonyl)benzyl] -4-[3-oxo-3-{3-(tertbutyldimethylsilyloxy)phenyl}propyl]homopiperazine was added 3 mL of a THF solution of 2.5 mmol of 3,5-difluorophenyl magnesium bromide under nitrogen at 0 The mixture was stirred at room temperature for 3 hours, and aqueous saturated ammonium chloride was added and the mixture was extracted with 40 mL x 2 with ethyl acetate. The extracts were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, ethyl acetate, ethyl acetate/methanol 10:1) to obtain 11 mg of a silyl protected form of the titled compound.
The resulting oil was dissolved in 5 mL of THF and mixed with 0.07 mL of a THF solution of 1 M tetrabutylammonium fluoride. The mixture was stirred at room temperature for 30 minutes and mixed with 20 mL of water and extracted with 30 mL x 3 of ethyl acetate. The extracts were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, ethyl acetate) to give 11 mg of the titled compound.
WO 97/44329 PCT/US97/08577 68 Compound No. 138 had the following iH NMR (CDCl 3 270 MHz) 6 (ppm): 7.88 (d, J 8.3 Hz, 2 7.54 J 8.3 Hz, 2 7.18 J 7.9 Hz, 1 7.02-6.93 4 6.70-6.58 1 3.68 2 3.06 3 2.72-2.60 2.33-2.28 2 1.85-1.76 2 H).
Example 16: Preparation of 1-[3-(4-Hydroxyphenyl)-3-phenylpropyl]- 4-[4-(methylsulfonyl)benzyl]homopiperazine (Compound No. 42).
mL solution in dichloromethane of 33 mg of methoxyphenyl)3-phenyl propyl]-4- [4-(methylsulfonyl )benzyl ]homopiperazine was cooled under nitrogen to -78 followed by adding 0.022 mL of boron tribromide. The mixture was gradually allowed to rise to room temperature, at which temperature the mixture was stirred for 3 hours, followed by adding 3 mL of an aqueous saturated sodium hydrogencarbonate solution and extracting with a 50 mL x 2 of ethyl acetate. The extracts were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (silica gel, ethyl acetate/methanol 9:1) to obtain 12 mg of the titled compound.
This was treated with a hydrogen chloride solution in ether and the solvent was removed under reduced pressure and residue was dried to give the hydrochloride salt of the titled compound.
Compound No. 42 (free base) had the following 1H NMR (CDC1 3 270 MHz) 6 (ppm): 1.75-1.8 2 2.15-2.3 2 2.4-2.9 10 3.04 3 H), 3.68 2 3.82 J 7.5 Hz, 1 6.59 J 8.6 Hz, 2 7.1-7.3 5 7.51 J 8.2 Hz, 2 7.86 J 8.2 Hz, 2 H).
Example 17: Preparation of 1-[3-Hydroxy-3-(3-methylaminophenyl)-3phenylpropyl]-4-[4-(methylsulfonyl)benzyl]homopiperazine (Compound No. 146).
To a solution of 34 mg of compound No. 143 in 1.2 mL of acetonitrile and 0.3 mL of water was added 14 mg of RhCl(PPh 3 3 and the mixture was stirred at 100 _C for 2 days. After the mixture was allowed to cool to room temperature, evaporation of acetonitrile and column chromatography (silica gel, ethyl acetate) gave 9.0 mg of the titled compound.
Compound No. 146 had the following 1H NMR (CDCl 3 270 MHz) S (ppm): 1.79-1.91 2 2.34-2.41 2 2.55-2.75 11 2.80 3 3.05 3 3.70 2 5.40 (broad s, 1 6.39-6.44 1 6.70-6.80 (m, 2 7.05-7.20 2 7.21-7.31 3 7.41-7.48 2 7.55 J WO 97/44329 PCT/US97/08577 69 8.1 Hz, 2 7.78 J 8.1 Hz, 2 H).
Example 18: Preparation of 1-[3-(3-Acetylaminophenyl)-3-hydroxy-3phenylpropyl]-4-[4-(methylsulfonyl )benzyl ]homopiperazine (Compound No. 162).
To a solution of 352 mg of compound No. 159 in 5 mL of dichloromethane was added 190 iL of triethylamine and 130 IL of acetic anhydride. The mixture was stirred at room temperature for 2 hours. 3 mL of water was added and the mixture was extracted with dichloromethane. The extract was concentrated and purified by column chromatography (silica gel, ethyl acetate/methanol 7:3) to give 224 mg of the titled compound as a white solid.
Compound No. 162 had the following H NMR (CDCl 3 270 MHz) 6 (ppm): 7.88 J 8.3 Hz, 2 7.57-7.45 5 7.22-7.16 6 3.70 2 H), 3.05 3 2.73-2.60 10 2.40-2.37 2 H),1.88-1.81 2 H) Examples 19-151.
The compounds of this invention were synthesized pursuant to methods of Example 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 14, 15, or 16, using the corresponding reactant respectively. The 'H NMR data, yields, and synthetic methods are summarized in Table 2.
27- Table 2 pages)--- Table 2 Compound 'H NMR Data Yield Synthetic No. (CDC13) 6 (ppm) method Example 19 5 1.69-1.82 2 2.58-2.70 4 2.69 J 5.9 Hz, 2 2.76 J 47 Similar to 5.9 Hz, 2 3.04 3 3.73 2 4.61 1 7.11-7.21 2 Example 2 7.26 (dd, J 7.3 Hz, 4 7.42 J 7.3 Hz, 4 7.56 J 8.6 Hz, 2 7.87 J 8.6 Hz, 2 H).
Example 20 7 2.15-2.35 4 2.35-2.60 8 3.04 3 3.57 2 3.97 44 Similar to J 7.3 Hz, 1 7.10-7.34 10 7.53 J 8.3 Hz, 2 7.88 J Example 1 8.3 Hz, 2 H).
Example 21 8 2.15-2.33 4 2.33-2.55 8 3.45 2 3.96 J 6.9 Hz, 1 54 Similar to 7.10-7.33 14 Example 1 Example 22 16 1.78-1.88 2 2.18-2.27 2 2.42-2.49 2 2.66-2.74 4 33 Similar to 2.78-2.87 4 3.26 2 4.03 J 7.6 Hz, 1 7.07-7.37 13 Example 1 7.57 J 7.6 Hz, 2 9.31 (br.s, 1 H).
Example 23 17 1.61-1.71 2 2.14-2.23 2 2.35-2.41 2 2.45-2.65 10 21 Similar to 2.93 J 5.3 Hz, 2 3.99 J 7.6 Hz, 1 5.30 1 7.13-7.31 Example 1 10 7.46 J 8.6 Hz, 2 7.80 J 8.6Hz, 2 H).
Example 24 18 1.67-1.77 2 2.12-2.24 2 2.35-2.41 2 2.55-2.64 4 43 Similar to 2.69-2.77 4 3.19 2 3.98 J 7.6 Hz, 1 4.47 J 5.9 Example 1 Hz, 2 7.13-7.35 10 7.63 (br, 1 Table 2 (continued) Compound 1H NMR Data Yield Synthetic No. (CDC13) 6 (ppm) method Example 25 19 1.76-1.85 2 2.19-2.28 2 2.41-2.48 2 2.65-2.75 4 51 Similar to 2.81-2.87 4 2.96 J 5.9 Hz, 2 4.00 J 7.6 Hz, 1 4.06 Example 1 J 5.9 Hz, 2 6.88-6.97 3 7.12-7.21 2 7.21-7.31
H).
Example 26 20 1.68-1.78 2 2.16-2.25 2 2.36-2.43 2 2.55-2.71 10 13 Similar to 3.28 (dt, J 5.9, 5.0 Hz, 2 3.97 J 7.6 Hz, 1 5.55 (br, 1 6.99-7.05 Example 1 1 7.13 J 7.34 Hz, 15 H).
Example 27 21 1.82-1.93 2 2.19-2.28 2 2.43-2.50 2 2.68-2.81 10 19 Similar to 3.52 (dt, J 5.6, 5.0 Hz. 2 3.99 J 7.6 Hz, 1 7.08 (br, 1 7.14-7.31 Example 1 10 7.38-7.52 3 7.81 J 6.6 Hz, 2 H).
Example 28 22 1.78-1.87 2 2.21-2.30 2 2.43-2.50 2 2.68-2.74 4 25 Similar to 2.81-2.88 4 3.44 2 3.99 J 7.6 Hz, 1 5.14 2 7.12-7.40 Example 1 15 H).
Example 29 24 1.73-1.83 2 2.17-2.26 2 2.41-2.47 2 2.63-2.73 8 50 Similar to 3.72 2 4.02 J 7.6 Hz, 1 7.12-7.20 2 7.20-7.31 8 Example 1 7.46 (dd, J 7.9, 7.9 Hz, 1 7.67 J 7.9 Hz, 2 8.09 (dd, J 7.9, Hz, 1 8.21 1 H).
Example 30 25 1.70-1.74 2 2.16-2.21 2 2.37-2.41 2 2.54-2.57 2 58 Similar to 2.59-2.66 6 3.89 2 4.01 J 7.7 Hz, 1 7.13-7.17 2 Example 1 7.23-7.28 8 7.34-7.37 1 7.48-7.51 1 7.56 J 7.7 Hz, 1 7.76 (dd, J 8.1, 1.1 Hz, 1 .1 J.
Table 2 (continued) Compound 'H NMR Data Yield Synthetic No. (CDC13) 6 (ppm) method Example 31 26 1.73-1.80 2 2.18-2.25 2 2.41-2.45 2 2.64-2.71 8 31 Similar to 3.57 2 3.79 3 4.00 J 7.8 Hz, 1 6.84 J 8.8Hz, 2 Example 1 7.13-7.18 2 7.21-7.28 10 H).
Example 32 27 1.74-1.80 2 2.18-2.24 2 2.40-2.45 2 2.62-2.71 8 37 Similar to 3.61 2 3.80 3 4.01 J 7.8 Hz, 1 6.77 (dd, J 8.3, 2.4 Example 1 Hz, 1 6.88-6.91 2 7.13-7.19 2 7.20-7.29 9 H).
Example 33 28 1.78-1.87 2 2.19-2.27 2 2.39-2.48 2 2.63-2.81 8 43 Similar to 3.71 2 3.81 3 4.01 J 7.8 Hz, 1 6.85 J 7.8 Hz, 1 Example 1 6.93 (dd, J 7.3, 7.3 Hz, 1 7.13-7.18 2 7.19-7.29 9 7.40 J 7.8 Hz, 1
I
Example 34 29 1.87-1.94 2 2.17-2.25 2 2.37-2.42 2 2.60-2.65 2 45 Similar to 2.70-2.75 2 3.28-3.34 2 3.35-3.40 2 3.99 J 7.8 Hz, Example 1 1 6.77 (ddd, J= 8.3, 6.8, 1.0 Hz, 1H), 7.02 (dd, J 8.8, 1.0 Hz, 1H), 7.14-7.19 2 7.20-7.29 8 7.35 (ddd, J 8.8, 6.8, 1.5 Hz, 1 7.71 (dd, J 8.3, 1.5 Hz, 1 H).
Example 35 30 1.7-1.85 2 2.15-2.3 2 2.4-2.5 2 2.6-2.75 8 3.67 38 Similar to 2 4.01 J 7.5 Hz, 1 7.1-7.35 10 7.44 J 8.3 Hz, 2 Example 1 7.59 J 8.3 Hz, 2 H).
Example 36 31 1.7-1.85 2 2.15-2.3 2 2.4-2.5 2 2.6-2.75 8 3.66 30 Similar to 2 4.01 J 7.5 Hz, 1 7.1-7.35 10 7.43 J 8.0 Hz, 2 Example 1 IH), 7.55 J 8.0 Hz, 2 H).
f- 1- Table 2 (continued) Compound 'H NMR Data Yield Synthetic No. (CDC13) 6 (ppm) method Example 37 32 1.75-1.88 2 2.20-2.32 2 2.39-2.50 2 2.62-2.90 12 53 Similar to 4.00 J 7.6 Hz, 1 7.11-7.25 10 7.34 J 8.6 Hz, 2 8.13 Example 1 J 8.6 Hz, 2 H).
Example 38 33 1.73-1.89 4 2.16-2.27 2 2.39-2.47 2 2.48 J 7.3 Hz, 55 Similar to 2 2.58-2.70 8 2.73 J 7.3 Hz, 2 4.00 J 7.6 Hz, 1 Example 1 7.12-7.20 2 7.20-7.30 8 7.33 J 8.6 Hz, 2 8.13 J 8.6 Hz, 2 H).
Example 39 34 1.75-1.85 2 2.2-2.35 2 2.45-2.55 2 2.6-2.8 8 3.58 26 Similar to 2 3.99 J 7.5 Hz, 1 7.1-7.35 14 Example 1 Example 40 35 1.7-1.85 2 2.15-2.3 2 2.4-2.5 2 2.6-2.75 8 3.66 48 Similar to 2 3.95 3 4.02 J 7.5 Hz, 1 6.96 J 6.9 Hz, 1 Example 1 7.1-7.35 11 7.81 J 8.2 Hz, 1 H).
Example 41 36 1.73-1.86 2 2.15-2.29 2 2.40-2.51 2 2.55-2.71 8 57 Similar to 3.04 3 3.71 2 4.01 J 7.6 Hz, 1 7.11-7.32 10 7.54 Example 1 J 8.2 Hz, 2 7.87 J 8.2 Hz, 2 H).
Example 42 37 1.72-1.84 2 2.16-2.28 2 2.39-2.48 2 2.61-2.74 8 37 Similar to 3.74 2 3.90 3 4.01 J 7.6 Hz, 1 7.11-7.20 2 7.20-7.31 Example 1 8 7.40 J 8.3 Hz, 2 7.97 J= 8.3 Hz, 2 H).
r 4 Table 2 (continued) Compound 1 H NMR Data Yield Synthetic No. (CDCl 3 6 (ppm) method Example 43 38 1.7-1.75 2 2.15-2.25 2 2.29 3 2.4-2.5 2 2.6-2.77 10 Similar to 8 3.05 3 3.70 2 3.97 J 7.6 Hz, 1 7.03-7.33 Example 1 9 7.54 J 8.2 Hz, 2 7.86 J 8.2 Hz, 2 H).
Example 44 39 1.7-1.75 2 2.15-2.25 2 2.30 3 2.4-2.5 2 2.6-2.8 26 Similar to 8 3.04 3 3.70 2 3.96 J 7.6 Hz, 1 6.9-7.3 Example 1 9 7.54 J 8.2 Hz, 2 7.86 J 8.2 Hz, 2 H).
Example 45 40 1.75-1.88 2 2.12- 2.22 2 2.28 3 2.4-2.6 2 2.6- 26 Similar to 2.85 8 3.05 3 3.71 2 4.23 J 7.6 Hz, 1 7.1-7.3 Example 1 8 7.35 J 7.5 Hz, 1 7.54 J 8.2 Hz, 2 7.88 J 8.2 Hz, 2 Example 46 41 1.7-1.85 2 2.1-2.25 2 2.35-2.5 2 2.55-2.75 8 3.05 19 Similar to 3 3.71 2 3.76 3 3.95 J 7.7 Hz, 1 6.81 J Example 1 8.6 Hz, 1 7.1-7.3 7 7.54 J 8.2 Hz, 2 7.87 J 8.2 Hz, 2 Example 47 43 1.75-1.85 2 2.13-2.15 2 2.41 J 7.3 Hz, 2 2.58-2.74 40 Similar to 8 3.05 3 3.70 2 4.00 J 7.7 Hz, 1 7.12-7.31 9 Example 1 7.54 J 8.2 Hz, 2 7.87 J 8.2 Hz, 2 H).
Example 48 44 1.7-1.85 2 2.12-2.2t 2 2.44 J 7 Hz, 2 2.55-2.75 8 15 Similar to 3.58 2 3.76 3 3.95 J 7.7 Hz, 1 6.81 J 8.8 Hz, Example 1 2 7.15 J 8.7 Hz, 2 7.15 -7.31 9 H).
Table 2 (continued) Compound 'H NMR Data Yield Synthetic No.
(CDC
3 1) 6 (ppm) method Example 49 45 1.74-1.84 2 2.12-2.23 2 2.37-2.45 2 2.60-2.71 8 35 Similar to 3.02 3 3.70 2 4.03 J 7.6 Hz, 1 6.85 (dt, J 6.6, 1.5 Example 1 Hz, 1 6.94 (td. J 10.2, 1.6 Hz, 1 7.02 J 7.6 Hz, 1 7.14-7.31(m, 6 7.54 J 8.6 Hz, 2 7.87 J 8.2 Hz, 2 H).
Example 50 46 1.72-1.88 2 2.15-2.30 2 2.40-2.60 2 2.60-2.90 8 39 Similar to 3.55 2 3.78 1 H, J 7.6 Hz 6.53 2 H, J 8.5 Hz), 6.98 Example 16 2 H, J 8.5 Hz), 7.1 7.3 9 H).
Example 51 47 1.75-1.85 2 2.12-2.21 2 2.39-2.45 2 2.65-2.77 8 36 Similar to 3.04 3 3.70 2 4.01 J 7.6 Hz, 1 6.90-6.98 4 7.12-7.26 Example 1 4 7.54 J 8.2 Hz, 2 7.87 J 8.2 Hz, 2 H).
Example 52 48 1.75-1.85 2 2.18-2.26 2 2.42-2.52 2 2.62-2.76 8 19 Similar to 3.04 3 3.75 2 4.01 J 7.6 Hz, 1 6.91-6.99 2 7.13-7.31 Example 1 7 7.54 J 8.6 Hz, 2 7.87 J 8.2 Hz, 2 H).
Example 53 49 1.74-1.85 2 2.17-2.28 2 2.43-2.52 2 2.63-2.72 8 45 Similar to 3.05 3 3.71 2 4.38 J 7.6 Hz, 1 6.94-7.21 4 7.25-7.31 Example 1 5 7.54 J 8.6 Hz, 2 7.87 J 8.2 Hz, 2 H).
Example 54 50 1.72-1.85 2 2.14-2.28 2 2.44 J 7.3 Hz, 2 2.60-2.76 14 Similar to 8 3.55 2 4.00 J 7.7 Hz, 1 7.10 -7.31 13 Example 1 Table 2 (continued) Compound 'H NMR Data Yield Synthetic No. (CDC13) 6 (ppm) method Example 55 51 1.74-1-85 2 2.15-2.25 2 2.43-2.52 2 2.60-2.75 8 8 Similar to 3.03 3 3.71 2 4.60 J 7.8 Hz, 1 7.06-7.39 9 7.54 Example 1 J 8.2 Hz, 2 7.87 J 8.2 Hz, 2 H).
Example 56 52 1.69-1-77 2 2.15-2.30 2 2.37-2.45 2 2.60-2.69 8 21 Similar to 3.57 2 4.00 J 7.7 Hz, 1 6.97 J-HF 8.9 Hz, 2 7.11-7.18 Example 1 2 7.21-7.30 10 H).
Example 57 53 1.71-1-79 2 2.10-2.20 2 2.33-2.40 2 2.57-2.69 8 23 Similar to 3.57 2 3.99 J 7.8 Hz, 1 7.10-7.15 4 7.20-7.25 8 Example 1 Example 58 54 1.70-1-79 2 2.11-2.17 2 2.33-2.41 2 2.60-2.68 8 15 Similar to 3.58 2 4.00 J 7.7 Hz, 1 6.90-6.99 4 7.12-7.20 4 Example 1 7.26 4 H).
Example 59 56 1.86-1-93 2 2.25-2.37 2 2.54-2.60 2 2.67-2.95 8 10 Similar to 3.05 3 3.71 2 4.00 J 7.9 Hz, 1 7.11-7.19 4 7.20-7.30 Example 1 4 7.53 J 8.2 Hz, 2 7.87 J 8.2 Hz, 2 H).
Example 60 57 1.73-1-86 2 2.22-2.31 2 2.43-2.52 2 2.65-2.80 8 29 Similar to 3.55 2 3.91 J 7.6 Hz, 1 6.3 (broad s,1 6.61 J 8.2 Hz, Example 1 2 7.08-7.32 12 H).
.1 C '1i Table 2 (continued) Compound 'H NMR Data Yield Synthetic No. (CDC1,) 6 (ppm) method Example 61 58 1.70-1.85 2 2.15-2.28 2 2.40-2.54 2 2.57-2.80 8 48 Similar to 3.05 3 3.69 2 3.90 J 7.3 Hz, 1 6.60-6.68 2 6.80 Example 1 J 7.9 Hz, 1 7.08-7.32 6 7.52 J 8.2 Hz, 2 7.87 J 8.2 Hz, 2 Example 62 59 1.90-2.10 2 2.40-2.97 12 3.05 3 3.75 2 4.40-4.50 44 Similar to 1 6.65-6.77 2 6.93 J 7.6 Hz, 1 7.00-7.10 1 7.15-7.35 Example 1 5 7.60 J 8.3 Hz, 2 7.89 J 8.3 Hz, 2 H).
Example 63 60 1.73-1-79 2 2.15-2.26 2 2.37-2.47 2 2.60-2.75 8 29 Similar to 2.98 (broad s, 3 3.10 (broad s, 3 3.64 2 4.00 J 7.6 Hz, 1 Example 1 7.15-7.33 10 7.35 4 H).
Example 64 61 1.70-1-76 2 2.10-2.24 2 2.35-2.45 2 2.58-2.70 8 10 Similar to 3.64 2 3.97 J 7.6 Hz, 1 4.90 (broad s.2 7.10-7.30 10 Example 1 7.42 J 8.1 Hz. 2 H) 7.82 J 8.1 Hz, 2 H).
Example 65 62 7.54 J 8.1Hz, 4 7.34 J 8.1Hz, 4 7.26 4 4.20 J 72 Similar to 7.6Hz, 1 3.58 2 2.69-2.61 8 2.42-2.37 2 2.25-2.17 Example 1 2 1.81-1.72 2 H).
Example 66 63 1.65-1.80 2 2.10-2.25 2 2.40-2.51 2 2.51-2.74 8 19 Similar to 3.53 2 3.84 J 7.6 Hz, 1 6.53 1 6.60 (dd, J 1.6, 7.9 Example 1 Hz, 1 6.76 J 7.6 .Hz, 1 7.06-7.33 10 H).
A 1.
Table 2 (continued) Compound 1 H NMR Data Yield Synthetic No. (CDC13) 6 (ppm) method Example 67 64 1.85-2.10 2 2.30-2.90 12 3.61 2H), 4.40-4.50 1H), 6.64-6.75 39 Similar to 2 6.93 J 7.9 Hz, 1 7.00-7.10 1 7.15-7.40 9 Example 1 Example 68 65 1.72-1.81 2 2.10-2.19 2 2.42-2.45 2 2.64-2.72 8 49 Similar to 3.58 2 3.76 6 6.80 4 H, J 8.91 Hz), 7.13 4 H, J 8.91 Example 1 Hz), 7.26 4 H).
Example 69 66 1.83-1.85 2 2.16-2.24 2 2.59-2.72 6 2.84-2.94 4 19 Similar to 3.62 2 3.76 1 6.69 4 H, J 8.58 Hz), 7.05 4 H, J 8.58 Example 1 Hz), 7.30 4 H).
Example 70 67 1.81-1.85 2 2.15-2.24 2 2.56-2.62 2 2.68-2.72 4 3 Similar to 2.81-2.91 4 3.10 3 3.73-3.78 3 6.68 4 H, J 8.58 Hz), Example 1 7.05 4 H. J 8.58 Hz), 7.59 2 H, J 8.58 Hz), 7.89 2 H, J 8.58 Hz)._ Example 71 68 1.74-1.80 2 1.90 (broad s, 2 2.12-2.28 2 2.40-2.76 10 1 Similar to 2.91 3 3.49 2 6.84-6.88 1 7.00-7.20 6 7.30-7.35 Example 1 2 7.43 J 8.4 Hz. 2 7.74 J 8.4 Hz, 2 H).
Example 72 102 1.38-1.52 2 1.72-1.86 2 1.98-2.12 2 2.52 J 7.6 Hz, 59 Similar to 2 2.58-2.75 8 3.05 3 3.69 2 3.89 J 7.9 Hz, 1 Example 1 7.11-7.31 10 7.53 J 8.2 Hz, 2 7.87 J 8.2 Hz, 2 H).
Table 2 (continued) Compound 'H NMR Data Yield Synthetic No. (CDC13) 6 (ppm) method Example 73 103 1.71-1.77 2 2.33-2.39 2 2.49-2.55 2 2.57-2.71 8 4 Similar to 3.05 3 3.07 3 3.67 2 7.15-7.36 10 7.52 J Example 1 8.3 Hz, 4 7.86 J 8.3 Hz, 2 H).
Example 74 104 1.63-1.80(m, 2 2.10-2.20 2 2.35-2.75 13 3.01 3 3.05 20 Similar to 3 3.61 2 6.55-6.67 4 6.80-6.90 2 7.03-7.13 Example 1 2 7.46 J 8.1 Hz. 2 7.84 J 8.1-Hz, 2 H).
Example 75 106 1.79-1.88 2 2.37-2.41 2 2.56-2.71 10 3.05 3 3.71 69 Similar to 2 7.15-7.20 2 7.26-7.32 4 7.45-7.48 4H), 7.56 2 Example 9 H, J 8.25 Hz), 7.88 2 H, J 8.58 Hz).
Example 76 108 1.75-1.86 2 2.29 6 2.32-2.36 2 2.53-2.71 10 3.57 26 Similar to 2 7.09 2 H, J 8.24 Hz), 7.26 4 7.33 2 H, J 8.25 Hz). Example 9 Example 77 109 1.57-1-61 2 2.12-2.24 2 2.32-2.57 10 3.45 2 4.75 75 Similar to (broad s, 3 6.40-6.51 (m,2 6.67-6.77 (m,4 6.88-7.00 (m.2 7.09-7.20 Example 12 4 (solvent: CD 3
OD)
Example 78 110 1.80-1.84 2 2.38-2.42 2 2.58-2.72 10 3.58 2 7.27 84 Similar to 4 7.54-7.62 8 Example 9 Table 2 (continued) Compound 'H NMR Data Yield Synthetic No.
(CDC
3 1) 6 (ppm) method Example 79 111 7.35 J 8.9Hz, 4 7.26 4 6.82 J 8.9Hz, 4 3.76 6H), 38 Similar to 3.56 2 2.70-2.53 10 2.33-2.29 2 1.83-1.78 2 Example 9 Example 80 112 7.26 4 7.26-7.70 6 6.36 (dd, J 7.9, 2.0Hz, 2 3.77 6 22 Similar to 3.57 2 2.71-2.55 10 2.36-2.32 2 1.83-1.79 2 Example 9 Example 81 113 1.84-1.88 2 2.46-2.48 2 2.66-2.76 10 3.04 3 3.72 89 Similar to 2 7.25-7.43 6 7.56-7.60 10 7.88 2 H, J 8.58 Hz). Example 9 Example 82 114 1.65-1.78 2 2.27-2.38 2 2.45-2.68 11 3.04 3 3.59 52 Similar to 2 6.62 J 7.9 Hz, 2 6.90-7.13 6 7.45 J 8.3 Hz, 2 Example 12 7.81 J 8.3 Hz, 2 H).
Example 83 115 7.87 J 8.2Hz, 2 7.66 J 7.6Hz, 2 7.54 J 8.2Hz, 2 7.18 83 Similar to J 7.6Hz, 2 6.97 J 7.6Hz, 2 6.78 J 7.7Hz, 2H), 3.69 Example 9 2 3.42 (s,6 3.05 3 2.78-2.50 12 1.86-1.81 2 H).
Example 84 116 1.28 18 1.84-1.86 2 2.34-2.38 2 2.54-2.72 10 3.05 83 Similar to 3 3.71 2 7.27-7.31 4 7.36-7.39 4 7.56 2 H, Example 9 J 8.58 Hz), 7.88 2 H, J 8.25 Hz).
0
N
0r
-I
0d 00 Table 2 (continued) Compound 'H NMR Data Yield Synthetic No. (CDCl 3 6 (ppm) method Example 85 117 7.89 J 8.3Hz, 2 7.58-7.54 10 3.72 2 3.05 3 2.72-2.59 61 Similar to 10 2.43-2.39 2 1.84-1.80 2 1.59 (br s, 1 Example 9 Example 86 118 1.80-1.90 2 1.85 6 2.45-2.52 4 2.65-2.80 8 3.05 13 Similar to 3 3.10 (broad s, 1 3.72 2 7.01 J 7.4 Hz, 2 7.13 Example 9 J 7.4 Hz, 2 7.20 J 7.4 Hz, 2 7.56 J 8.1 Hz, 2 7.77 (d, J 7.8 Hz, 2 7.88 J 8.1 Hz, 2 (solvent: CDC1 3
-CD
3
OD)
Example 87 120 1.85-1.97 2 2.39-2.49 4 2.67-2.85 9 2.85-2.95 2 10 Similar to 3.04 3 3.71 2 7.05-7.15 2 7.18-7.27 2 7.53-7.62 Example 9 4 7.67-7.80 4 7.88 J 8.3 Hz, 2 8.17 -8.31 4 H).
Example 88 121 1.75-1.89 2 2.28-2.33 2 2.51-2.57 2 2.58-2.75 9 33 Similar to 2.89 12 3.04 3 3.70 2 6.67 J 8.6 Hz, 4 7.29 Example 9 J 8.6 Hz, 4 7.55 J 8.3 Hz, 2 7.87 J 8.3 Hz, 2 H).
Example 89 122 1.81-1.86 2 2.26-2.30 2 2.58-2.73 10 3.06 3 3.71 84 Similar to 2 5.91 4 6.72-6.75 2 6.91-6.94 4 7.56 2 H, Example 9 J 8.25 Hz), 7.88 2 H, J 8.25 Hz).
IOs Example 90 1.73-1.81(m, 2 2.26-2.31 3.54 2 4.40 (broad g, 2 2.48-2.46 2 2.56-2.78 8 H), 3 6.72 J 8.6 Hz, 4 7.20 J 8.6 Similar Example IHz, 2 7.23-7.25 4 (solvent: CDCl 3
-CD
3 OD) I I Table 2 (continued) Compound 1 H NMR Data Yield Synthetic No. (CDC1,) 05 (ppm) method Example 91 125 7.88 J 8.3Hz, 2 7.63-7.55 3 7.40-7.04 (in, 8 6.60 1H), 24 Similar to 3.73 2 3.44 3 3.05 3 2.88-2.55 Cm. 11 2.80-2.11 (in, Example 14 1H), 1.92-1.85 2 Example 92 126 1.78-1.91 (in. 2 2.33-2.41 (in, 2 2.62-2.80 10 3.05 3 3.71 74 Similar to 2 6.91-6.98 4 7.19 (dd, J 3.3, 3.3 Hz, 2 7.57 J 8.6 Example 9 Hz, 2 7.88 J 8.6 Hz, 2 Example 93 128 1.78-1.91 2 2.25-2.35 (in, 2 2.55-2.78 10 3.05 3 3.71 19 Similar to 2 7.00 (dd, J 3.3 Hz, 2 H) 7.20-7.30 (in, 4 7.56 J 8.6 Example 11 Hz, 2 7.88 J 8.6 Hz, 2 Example 94 130 1.80-1.96 2 1.91 6 2.45-2.53 (in, 2 2.63-2.77 8 2.81 23 Similar to J 5.6 Hz, 2 3.06 3 3.71 Cs, 2 6.77 J 5.3 Hz, 2 Example 9 7.06 J 5.3 Hz. 2 7.56 J 8.3 Hz, 2 7.88 J 8.3 Hz, 2 Example 95 131 7.88 J =8.3Hz, 2 7.54 J =8.3Hz, 2H), 7.45 J =6.9Hz, 2H), 7.31-7.13 8 Similar to (in, 4 7.03-6.96 Cm, 2 6.68-6.65 Cm, 1 3.69 Cs, 2 3.05 3 Example 2.74-2.58 (in, 10 1.8 (br s, 1 2.39-2.35 2 1.85-1.81 2 Example 96 132 1.77-1.88 2 2.35-2.38 2 2.49-2.58 2 2.58-2.87 1OH), 30 Similar to 3.05 3H) 3. 68 2H) 3. 77 J 7.6 Hz, 1 H) 6.58-6. 72 6 H) 7.03-7. 12 Example 6_H),_7.50_Cd,_J 8.3_Hz,_2_H),_7.86_Cd,_J 8.3_Hz,_2_H).I 0
N
00 Table 2 (continued) Compound 'H NMR Data Yield Synthetic No. (CDCl 3 6 (ppm) method Example 97 133 1.79-1.89 2 2.35-2.40 2 2.55-2.76 11 3.05 3 3.70 30 Similar to 2 3.77 3 6.70-6.75 1 6.99-7.03 1 7.13-7.31 Example 4 7.45-7.49 2 7.56 J 8.4 Hz, 2 7.88 J 8.4 Hz, 2 H).
Example 98 134 1.66-1.75 2 2.17 3 2.19-2.26 2 2.40-2.76 11 2.91 21 Similar to 3 3.49 2 6.84-6.88 1 7.00-7.20 6 7.30-7.35 Example 2 7.43 J 8.4 Hz, 2 7.74 J 8.4 Hz, 2 H).
Example 99 135 1.79-1.88 2 2.35-2.41 2 2.54-2.78 11 3.03 3 3.70 11 Similar to 2 7.10-7.48 8 7.55 J 8.3 Hz, 2 7.87 J 8.3 Hz, 2 Example
H).
Example 100 136 1.77-1.88 2 2.35-2.40 2 2.55-2.76 11 3.05 3 3.70 7 Similar to 2 3.77 3 6.70-6.75 1 6.99-7.03 1 7.13-7.31 Example 4 7.45-7.49 2 7.56 J 8.4 Hz, 2 7.88 J 8.4 Hz, 2 H).
Example 101 137 7.86 J 8.3Hz, 2 7.52 J 8.3Hz, 2 7.42-7.37 2 7.15 12 Similar to J 7.9Hz, 1 7.07-6.89 7 6.69-6.65-6.47 1 3.65 2H), 3.05 Example 3 2.75-2.59 10 2.39-2.32 2 1.85-1.74 2 H).
Example 102 139 7.87 J 8.3 Hz, 2 7.60-6.94 9 6.67-6.63 1 5.75 1 6 Similar to 4.11-3.97 4 3.68 2 3.05 3 2.85-2.58 10 2.42-2.33 Example 2 1.88-1.72 2 Table 2 (continued) Compound 'H NMR Data Yield Synthetic No. (CDC13) 6 (ppm) method Example 103 140 1.65-1.78 2 2.20-2.29 2 2.41-2.61 10 2.77 3 2.90 17 Similar to 3 3.57 2 3.72-3.79 2 4.91-5.04 2 5.59-5.75 Example 1 6.39-6.44 1 6.55-6.62 1 6.80-6.83 1 6.96-7.08 (m, 3 7.10-7.18 2 7.30-7.39 2 7.43 J 8.2 Hz, 2 7.76 (d, J 8.2 Hz, 2 H).
Example 104 141 1.75-1.89(m, 2 2.35-2.48 2 2.48-2.85 11 3.03 3 3.46 28 Similar to 3 3.68 2 3.78 3 6.36 J 2.3 Hz, 1 6.53 (dd, J Example 8.6, 2.3 Hz, 1 7.09-7.17 1H), 7.18-7.31 2 7.35-7.45 2 H), 7.55 J 8.1 Hz, 2H), 7.80 J 8.6 Hz, 1 7.87 J 8.1 Hz, 2 H).
Example 105 142 1.75-1.89(m, 2 2.31-2.38 2 2.54-2.74 11 3.04 3 3.70 25 Similar to 2 3.75 6 6.30 J 2.2 Hz, 1 6.66 J 2.2 Hz, 2 Example 7.13-7.20 1 7.22-7.32 2H), 7.46 J 8.4 Hz, 2 7.55 J 8.4 Hz, 2 H).
Example 106 143 1.65-1.78(m, 2 2.20-2.29 2 2.41-2.61 10 2.77 3 2.90 17 Similar to 3 3.57 2 3.72-3.79 2 4.91-5.04 2 5.59-5.75 Example 1 6.39-6.44 1 6.55-6.62 1 6.80-6.83 1 6.96-7.08 (m.
3 7.10-7.18 2 7.30-7.39 2 7.43 J 8.2 Hz, 2 7.76 (d, J 8.2 Hz, 2 H).
Example 107 144 1.78-1.82 2 2.19-2.27 2 2.43-2.48 2 2.67-2.82 6 21 Similar to 3.40-3.45 1 3.76 2 3.99-4.05 2 7.14-7.30 10 7.65 Example 1 2 H, J 8.25 Hz), 7.96 2 H, J 8.25 Hz).
Example 108 145 7.87 J 8.2 Hz, 2 7.54 J 8.2 Hz, 2 7.36-6.94 7 6.68-6.64 10 Similar to 1 3.79 J 6.4 Hz, 2 3.67 2 3.05 3 2.81 J Example 6.4 Hz, 2 2.71-2.58 10 2.44-2.33 2 1.87-1.82 2 H).
0 1 cc
I~
Table 2 (continued) Compound 'H NMR Data Yield Synthetic No.
(CDC
3 1) 6 (ppm) method Example 109 147 1.79-1.90 2 2.30-2.41 2 2.58-2.79 11 3.04 3 3.66 26 Similar to 2 6.65-6.71 1 6.85-7.00 5 7.02-7.20 3 7.25-7.35 Example 2 7.35-7.45 2 7.52 J 8.3 Hz, 2 7.86 J 8.3 Hz, 2
H).
Example 110 148 1.78-1.90 2 2.30-2.40 2 2.53-2.79 11 3.05 3 3.71 24 Similar to 2 3.83 3 5.50 (broad s, 1 6.84 J 8.3 Hz, 1 6.90 (dd, Example J 8.3 Hz, 2.0 Hz, 1 7.04 J 2.0 Hz, 1 7.14-7.22 1 7.24-7.37 2 7.40-7.50 2 7.56 J 8.2 Hz, 2 7.88 J 8.2 Hz, 2
H).
Example 111 149 1.77-1.90 2 2.28-2.38 2 2.50-2.73 12 3.05 3 3.69 12 Similar to 2 3.74 3 6.23-6.26 1 6.55-6.58 1 6.61-6.64 Example 1 7.14-7.20 1 7.22-7.33 2 7.42-7.49 2 7.55 J 8.3 Hz, 2 7.88 J 8.3 Hz, 2 H).
Example 112 150 7.88 J 8.3 Hz, 2 7.55 J 8.3 Hz, 2 7.47 J 7.9 Hz, 2 67 Similar to 7.30-7.09 (m,7 7.07 1 6.90-6.71 1 5.88-5.75 2 5.16-5.08 Example 4 3.95-3.80 4 3.70 2 3.05 3 2.71-2.56 10 H), 2.37-2.33(m, 2 1.88-1.77 2 H).
Example 113 151 1.82-1.86 2 2.37-2.41 2 2.57-2.73 10 3.05 3 3.71 33 Similar to 2 4.64 2 7.15-7.21 4 7.26-7.32 4 7.56 2 H, Example J 8.25 Hz), 7.88 2 H, J 8.25 Hz).
Example 114 152 7.89 J 8.6 Hz, 2 7.56 J 8.6 Hz, 2 7.38-7.16 8 7.07 2 Similar to 1 4.39 J 11.8 Hz, 1 4.01 J 11.8Hz, 1 3.72 2 Example 3.06 J 13.3 Hz, 1H) 2.90-2.45 11 2.33-2.14 1 1.90-1.77 (a) 2 Table 2 (continued) Compound 'H NMR Data Yield Synthetic No. (CDC13) 6 (ppm) method Example 115 153 7.89 J 8.3 Hz, 4 7.76-7.72 2 7.57 J 8.3 Hz, 2 7.36-7.19 24 Similar to 3 3.72 2 3.04 3 2.82-2.56 11 2.39-2.30 1 Example 14 1.89-1.81 2 H).
Example 116 154 1.80-1.84 2 2.04 2 2.59-2.69 10 3.04 3 3.67 58 Similar to 2 3.89 3 6.64-6.67 1 7.00-7.19 5 7.41-7.44 1 Example 7.53 2 H, J 7.25 Hz), 7.61-7.72 2 7.85-7.91 3 H).
Example 117 155 0.84-0.89 3 1.23-1.37 12 1.55-1.58 2 1.78-1.79 2 51 Similar to 2.33 1 2.50-2.76 12 3.04 3 3.65 2 6.63-6.67 Example 1 6.95 1 H, J 7.59 Hz), 7.06-7.17 4 7.33 2 H, J 8.25 Hz), 7.52 2 H, J 8.25 Hz), 7.86 2 H, J 8.58 Hz). 0 Example 118 156 8.48 (br s, 1 7.72 J 8.3 Hz, 2 7.56 J 8.3 Hz, 2 7.50- 16 Similar to 7.47 2 7.33-7.17 3 6.68-6.66 1 6.17-6.06 2 3.71 Example 14 2 3.05 3 3.03 J 13.3 Hz, 1 2.80-2.50 10 2.39-2.28 (a) 1 2.13-2.13 9m, 1 1.88-1.79(m, 2 H).
Example 119 157 7.89 J 8.3 Hz, 2 7.66-7.62 2 7.56 J 8.3 Hz, 2 7.34-7.18 21 Similar to 3 7.00 2 3.71 2 3.04 3 3.06 J 13.3 Hz, 1 Example 14 2.79-2.51 11 2.30-2.17 1 1.87-1.78 2 Example 120 158 1.73-1.83 2 2.26-2.44 2 2.45-2.75 11 3.05 3 3.62 31 Similar to 2 6.60-6.68 1 6.88-6.95 1 7.00-7.02 1 7.07-7.15 Example 1 7.31-7.58 5 7.78-7.88 3 H).
2-(Trimethylsilyl)ethoxymethyl group was used as protective group.
Table 2 (continued) Compound 'H NMR Data Yield Synthetic No. (CDC13) 6 (ppm) method Example 121 159 7.88 J 8.3 Hz, 2 7.55 J 8.3 Hz, 2 7.46 J 8.6 Hz, 2 39 Similar to 7.32-7.05 4 6.84-6.82 2 6.54-6.50 1 3.71 2 3.05 Example 17 3 3.03 J 13.3 Hz, 1 2.86-2.53 10 2.46-2.33 2 H), 1.90-1.77 2 H).
Example 122 160 7.88 J 8.3 Hz, 2 7.58 J 8.3 Hz, 2 7.46 J 7.3 Hz, 2 12 Similar to 7.33-7.17 3 6.69-6.66 1 6.17-6.07 2 3.97 J 5.3 Hz, Example 14 2 3.74 2 3.33 J 5.3 Hz, 2 2.79-2.50 10 2.38-2.14 (b) 2 1.89-1.80 2 H).
Example 123 161 1.76 1.78 2 2.31 2 2.60 2.67 10 3.02 3 3.61 50 Similar to 2 5.75 1 6.62 6.65 1 6.90 6.93 1 7.03 1 Example 7.09 7.15 1 7.23 7.39 9 7.49 2 H, J 8.25 Hz), 7.83 2 H, J 8.25 Hz).
Example 124 163 The structure was confirmed by ESI/MS m/e 515.5 C 28
H
3
F
2
N
2 0 3 12 Similar to Example 9 Example 125 164 1.77-1.90 2 2.29-2.38 2 2.53-2.80 10 3.05 3 3.71 9 Similar to 2 6.35 (broad s, 1 6.90-7.05 4 7.35-7.45 4 7.55 Example 9 J 8.3 Hz, 2 7.88 J 8.3 Hz, 2 H).
Example 126 165 The structure was confirmed by ESI/MS m/e 547.5 C 2 ,HC1, 2
N
2 0S). 10 Similar to SExample 9 2-(Trimethylsilyl)ethoxymethyl group was used as protective group.
Compound No.160 was obtained as the by-product in preparation of compound No.156.
Table 2 (continued) Compound 1H NMR Data Yield Synthetic No. (CDCl 3 6 (ppm) method Example 127 166 The structure was confirmed by ESI/MS mle 547.5 C,,H,,C1,N,0 3 6 Similar to Example 9 Example 128 167 1.78-1.89 (in, 2 H) 2.30-2.38 (mn, 2 H) 2.54-2.76 (in, 11 H) 3.05 3 H) 3.70 12 Similar to 2 3.77 6 6.69-6.75 (mn, 2 6.97-7.03 (mn, 2 7.07-7.10 (in, Example 9 2 7.16-7.24 (mn, 2 7.55 J 8.3 Hz, 2 H) 7.88 J Hz, 2 H).
Example 129 168 The structure was confirmed by ESI/MS mle 539.5 C 30
H
3 67 Similar to Example 12 Example 130 169 1. 7 6-1. 92 2 H) 2 2 8 -2 .40 (mD, 2 H) 2. 5 2 -2 .77 (in 10 H) 3. 06 52 Similar to 311) 3. 70 211) 6. 68 (dd, J 7. 9 and I1.7 Hz, 1 H) 6. 82 93 (mn, I H) 6. 95-7. 03 (mn, 2 7. 13 31 (mn, 4 H) 7. 55 J 8. 6 Hz 2 H) 7. 88 J 8. 6Hz, 2 Example 131 170 1 7 7-1. 90 (in, 2 2.2 5 39 (mn, 2 H1), 2. 52- 2. 78 (mi, 1 0 3. 06 62 Similar to 311) 3. 70 211), 6. 68 (dd. J 9 a nd 2. 3Hz 1 H) 6. 92 02 Example (mn, 2 7.1 2 3 5 411), 7. 49 1 H) 7 55 J 8. 3 H z, HI), 7. 88 J 8. 3 Hz 2 H) .I Example 132 171 1 75-1 89 (in. 2 H) 2. 2 8-2. 40 (mI, 2 H),1 2.5 1 75 (mn, 10 3. 05 60 Similar to 3 3. 69 2 6. 67 (dd. J 7. 9 a nd 2. 3 Hz I 6. 9 4 Example J 8. 25 H z, I 6. 99 J 2. 3 H z, I H) 7. 16 (dd, J 7. 9 a nd 7. 9Hz, I1H), 7. 25 J 3Hz, 211) 7. 39 J 3 211) 7. 54 J 8. 3_Hz 2 7. 88 J 8. 3_Hz, 211) e t Table 2 (continued) Compound 1 H NMR Data Yield Synthetic No. (CDC13) 6 (ppm) method Example 133 172 1.70- 1.81 2H), 2.25- 2.34 2H), 2.50- 2.72 12H), 3.03 22 Similar to 3H), 3.60 2H), 3.69 6H), 6.23- 6.27 1H), 6.59- 6.68 3H), Example 6.88- 6.95 1H), 7.07- 7.17 2H), 7.48 J 8.3 Hz, 2H) 7.83 J 8.3 Hz, 2H).
Example 134 173 1.70- 1.81 2H), 2.26- 2.37 2H), 2.50- 2.70 12H), 3.03 33 Similar to 3H), 3.60 2H), 3.72 3H), 6.60- 6.72 2H), 6.90- 6.95 1H), Example 6.95- 7.00 1H), 7.01-- 7.19 4H), 7.48 J 8.3 Hz, 2H) 7.83 J 8.3 Hz, 2H).
Example 135 197 7.88 J 8.3Hz, 2 7.56 J 8.3Hz, 2 7.51-7.47 4 7.30- 41 Similar to 7.13 6 3.71 2 3.05 3 2.73-2.46 8 1.85-1.76 Example 9 4 1.62-1.59 2 H).
Example 136 198 7.83 J 8.3Hz, 2 7.43 J 8.4Hz, 2 7.17-7.07 4 6.91 11 Similar to J =7.6Hz, 2 3.56 2 3.04 3 2.62-2.42 12 1.8 (br Example 12 1.75-1.50 4 H).
Example 137 200 1.74-1.84 2 2.11-2.21 2 2.36-2.43 2 2.59-2.67 4 70 Similar to 3.31-3.37 4 3.97 J 7.6 Hz, 1 7.12-7.30 10 7.48 J Example 3 8.6 Hz. 2 7.72 J 8.6 Hz, 2 H).
Example 138 201 1.69-1.79 1 1.89-1.99 1 2.13-2.28 2 2.37-2.49 2 57 Similar to 2.54-2.62 2 2.64-2.69 1 2.75-2.80 1 3.33-3.39 2 Example 3 3.73-3.78 2 4.01 (dd, J 17.5, 7.6 Hz, 1 7.13-7.32 12 8.63-8.69 2 Table 2 (continued) Compound 'H NMR Data Yield Synthetic No. (CDC1 3 6 (ppm) method Example 139 203 1.70-1.85 2 2.14-2.25 2 2.30 J 2.0 Hz, 3 2.34-2.45 38 Similar to 2 2.49-2.57 2 2.60-2.68 2 3.15 J 7.9 Hz, 2 3.48-3.60 Example 4 6 3.99 (dt, J 2.0, 7.6 Hz, 1 7.12-7.32 15 H).
Example 140 205 0.87 J 7.3 Hz, 3 1.40-1.55 2 1.71-1.81 2 2.16-2.25 25 Similar to 2 2.37-2.45 4 2.52-2.71 8 4.00 J 7.9 Hz, 1 7.12-7.20 Example 2 7.20-7.31 8 H).
Example 141 208 1.74-1.83 2 2.17-2.26 2 2.40-2.47 2 2.63-2.75 8 30 Similar to 3.44 2 4.00 J 7.6 Hz, 1 5.51 1 7.13-7.32 10 Example 6 Example 142 209 1.72-1.81 2 2.17-2.27 2 2.39-2.49 2 2.47 J 7.6 Hz, 64 Similar to 2 2.63-2.73 8 2.84 J 7.6 Hz, 2 3.67 3 3.99 J Example 1 7.6 Hz, 1 7.12-7.20 2 7.22-7.31 8 H).
Example 143 235 2.17-2.35 4 2.35-2.60 8 3.50 2 3.97 J 7.3 Hz, 1 17 Similar to 7.11-7.35 12 8.53 J 5.9 Hz, 2 Example 8 Example 144 238 1.77-1.86 2 2.18-2.27 2 2.40-2.46 2 2.66-2.72 4 11 Similar to 2.78-2.88 6 2.91-2.98 2 4.01 J 7.6 Hz, 1 6.97 1 Example 7.01-7.31 12 7.35 J 7.9 Hz, 1 7.61 J 7.9 Hz, 1 7.94 (br, 1 H).
Table 2 (continued) Compound "H NMR Data Yield Synthetic No. (CDCl 3 (5 (PPM) method Example 145 239 1.68-1.78 (mn, 2H), 2.14-2.24 (mn, 2H), 2.24 3H), 2.32 3H), 2.36-2.43 (mn, 28 Similar to 2H), 2.53-2.67 (mn, 8H), 3.30 2H), 4.00 J 7.6 Hz, 1H), 7.12-7.19 (mn, 2H), Example 7 7.21-7.56 (in, 8H).
Example 146 240 1.75-1.82 (mn, 2H), 2.19-2.26 (mn, 2H), 2.43-2.47 (mn, 2H), 2.65-2.73 (mn, 8H), 3.63 50 Similar to 2H), 4.01 J 7.8 Hz, 1H), 7.14-7.19 (in. 2H), 7.23-7.29 (in, 10H), 8.52 Example 1 J =5.9 Hz, 2H). Example 147 241 1.74-1.83 (mn, 2 2.18-2.27 (mn, 2 2.42-2.48 (mn, 2 2.66-2.74 (in, 8 44 Similar to 3.63 2 4.00 J 7.6 Hz, 1 7.12-7.30 (mn, 11 7.66 (ddd, J 7.9, Example 1 1.7 Hz, 1 8.49 (dd, J 4.6, 1.7 Hz, 1 8.53 J 2.0 Hz, 1 Example 148 242 1.78-2.00 (in, 2 2.20-2.31 (in, 2 2.44-2.52 (in, 2 2.68-2.82 (mn, 8 57 Similar to 3.80 2 4.01 J 7.6 Hz. 1 7.12-7.30 (mn. 11 7.43 J 7.9 Example 1 Hz, 1 7.64 Oddd, J 7.9, 7.6, 1.7 Hz, 1 8.53 (ddd, J 5.0, 1.7, 1.0 Hz, Example 149 243 1.7-1.83 (in, 2 2.1-2.25 (mn, 2 2.43 J 7.4 Hz, 2 2.4-2.74 (mn, 8 32 Similar to 3.69 2 3.75 3 3.96 J 7.7 Hz, 1 6.81 J 8.9 Hz, Example 1 2 7.16 J 8.6 Hz, 2 7.2-7.35 (mn, 7 8.51 J 5.9 Hz, 2 H).
Example 150 245 1.70-1.85 (mn, 2 2.12-2.22 (mn, 2 2.37-2.45 (mn, 2 2.63-2.72 (mn, 8 8 Similar to 3.63 2 4.00 J 7.6 Hz, 1 7.15-7.29 (in, 11 7.87 J 4.6 Example 1 2 H).
Example 151 258 1.80-1.88 (dt, J 12.2, 5.9 Hz, 2 2.40 (ad, J 6.0, 5.2 Hz, 2 2.57- 8 Similar to 2.74 (mn, 10 3.63 2 7.15-7.20 (in, 2 7.26-7.32 (mn, 6 7.45-7.48 Example 1 4 8.52 (dd. J 4.3, 1.6 Hz, 2
U
-4 -4 .Wq V /Y4A 92 PCIYUS97IU8577 General Alkylation Procedure of 1- (3-Hydroxy-3, 3diphenyipropyl )homopiperaziLne for Examples 152-162.
A solution of 1-C 3-hydroxy-3 ,3-diphenyipropyl )homopiperazine (0.12 mmol) in 0.5 mL of acetonitrile was treated with alkylating reagent (0.10 mmol) and potassium carbonate (0.15 mmol) and the reaction mixture was heated to C f or 5 h. Polystyrene -linked benzyl isocyanate resin 65 mmol/g, 0. 05 mmol) and dichioromethane 5 mL) was added and the mixture was stirred at room temperature for 1 h. The mixture was filtered and washed with dichloromethane mL). The filtrate and washing were combined, and the solvent was removed under reduced pressure to afford the N,N-dialkylated material.
Example 152: Compound No.
alkylation procedure. ESI/MS mie 174 (65 mg) 493.0 Example 153: C()mpound No. 175 (51 mg) ESI/MS Wle 507.5 alkylation procedure.
Example 154: alkylation procedure.
Example 155: alkylation procedure.
Compound
ESI/MS
Compound
ESI/MS
No. 176 (48 mg) m/e 507.5 No. 177 (51 mg) mle 521.5 was prepared
C
29
H
3 6
N
2 0 3
S).
was prepared
C
30
H
38
N
2 0 3
S)
was prepared
C
3 0
H
3 8
N
2 0 3 was prepared
C
31
H
4
ON
2 0 3 S) was prepared
C
32
H
36
N
2 0 3
S)
by above general by above general by above general by above general Example 156: CC alkylation procedure.
)mpound No.
ESI/MS Wie Example 157: Compound No.
alkylation procedure. ESI/MS mle Example 158: Compound No.
alkylation procedure. ESI/MS m/e Example 159: Compound No.
178 (56 mg) 541.5 179 (41 mg) 479.0 180 (42 mg) 493.0 (M+1.
181 (42 mg) by above general was prepared
C
2
,H
3 4
N
2 0 3
S).
was prepared
C
39
H
36
N
2 0 3 S) was prepared
C
3
,H
38
N
2 0 3
S).
by above general by above general by above general alkylation procedure. ESI/MS m/e 507.5 Example 160: Compound No. 182 (53 mg) was prepared by above general alkylation procedure. ESI/MS mle 507.5 C 3
,H
38
N
2 0 3
S).
'r -WO 97/44329 PCT/US97/08577 Example 161: Compound No. 183 (40 mg) was prepared by above general alkylation procedure. ESI/MS m/e 521.5 C 31
H
40
N
2 0 3
S).
Example 162: Compound No. 184 (52 mg) was prepared by above general alkylation procedure. ESI/MS m/e 541.5 C 33
H
36
N
2 0 3
S).
Preparation of 1-(3,3-Diphenylpropyl)homopiperazine A suspension of homopiperazine (2.9 g, 28.9 mmol) and homopiperazine dihydrochloride (5.0 g, 28.9 mmol) in EtOH was heated to 70 °C for 2 h, at which point a homogeneous solution of monohydrochloride salt (2.5 equiv) was obtained.
The reaction mixture was treated with 3,3-diphenylpropyl methanesulfonate (6.7 g, 23.1 mmol, 1 equiv) andNal (8.65 g, 57.7 mmol, 2.5 equiv) and heated to reflux for 16 h. The reaction mixture was cooled to 25 °C and the solvent was removed in vacuo. The crude product was partitioned between 2N aqueous NaOH (100 mL) and EtOAc (100 mL), and the aqueous layer was extracted with EtOAc (3 x 50 mL).
The combined organic phase was washed with saturated aqueous NaCl (1 x 100 mL), dried (MgSO,) and concentrated. Chromatography (SiO 2 4 x 20 cm, 10% CH 3
OH-
Et 3
N-CH
2 Cl 2 afforded the monoalkylated product (6.44 g, 6.79 g theoretical, 95%) as an amber oil.
General Alkylation of 1-(3,3-Diphenylpropyl)homopiperazine for Examples 163-194.
A solution of 1-(3,3-diphenylpropyl)homopiperazine (132 mg, 0.449 mmol) was treated with alkylating reagent (0.492 mmol, 1.1 equiv) and Et 3 N (75 mL, 0.54 mmol, 1.2 equiv) and the reaction mixture was heated to 70 *C for 16 h.
The solvent was removed under vacuum. Chromatography (SiO 2 2 x 20 cm,
CH
3 OH-EtOAc) afforded the N,N-dialkylated material (10-95%).
Chromatography Methods.
HPLC analyses was performed with following methods.
1. Methods A and B.
Column Method A: Micra Analytical Column (4.6 mm x 3.3 cm) Method B: Monitor C18 column (50 mm x 4.6 mm) Buffer for methods A and B Buffer A: 0.05% TFA in HO0 WO 97/44329 94 Buffer B: 0. 035% TFA in 10% H 0/CHCN Gradient 1 (10-11 min) 1% Buffer B for 0.5 min 1 to 31% Buffer B in 5.0 min 31% to 51% Buffer B in 2.0 min 51% Buffer B for 0.5 min 51% to 1% Buffer B in 0.5 min 1% Buffer B Hold Gradient 2 (4 min) 10% Buffer B for 0.5 min 61% Buffer B in 1.8 min 91% Buffer B in 1.5 min 91% Buffer B for 0.8 min 91% to 10% Buffer B in 0.4 mmn 10% Buffer B Hold PCTfUS97/08577 2.
Column Method C C18 column 4.6 mm Gradient 1% Buffer B for 3 min 1% to 61% Buffer B in 20 min 61% Buffer B For 4 min 61% to 1% Buffer B in 1 min 1% Buffer B for 5 min hold Example 163: Compound No. 265 (82 mg, 39%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (151.7 mg, 0.513 mmol) and N,Ndiethylacetamide (78 mL, 0.567 mmol, 1.1 equiv) employing general alkylation procedure. RPLC t, 4.93 min 220 rim (Method ESI/MS m/e 408.4
C
2 6
H
37
N
3 0).
Example 164: Compound No. 210 (53 mg, 34%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (131 mg, 0.446 mmol) and 1-bromo-2-butyne (42 mL, 0.479 mmol, 1.1 equiv) employing general alkylation procedure. RPLC tR 18.18 min 220 nm (Method ESI/MS mle 347.2 C 2
,H
3 ,-WO 97/44329 .~WO97/4329PCTIUS97/08577 Example 165: Compound No. 211 (102 mg, 75%) was prepared from 1- (3,3-diphenylpropyl)homopiperazile (115 mg, 0.391 mmol) and (bromomethyl) cyclopropane (42 mL, 0.433 mmol, 1.1 equiv) employing general alkylation procedure. RPLC t, 17.91 min 220 nm (Method ESI/MS mie 349.4 C 24 Example 166: Compound No. 266 (150 mg, 95%) was prepared from 1- 3-diphenylpropyl)homopiperazine (132 mg, 0.449 mmol) and 2-bromoacetamide (68 mg, 0.492 mmol, 1.1 equiv) employing general alkylation procedure. RPLC t, 6.10 min 220 run (Method ESI/MS mle 352.2 C 22
H
2 Example 167: Compound No. 212 (21 mg, was prepared from 1-(3,3diphenylpropyl)homopiperazine (151 mg, 0.513 mmol) and 7-acetoxy-4- (bromomethyl)coumarin (168 mg, 0.565 mmol, 1.1 eguiv) employing general alkylation procedure. RPLC t, 5.73 min 220 nm (Method ESI/MS m/e 469.4 C,,H 32
N
2 0 3 Example 168: Compound No. 213 (164 mg, 94%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (136.6 mg, 0.465 mmol) and bromovaleronitrile (60 mL, 0.511 mmol, 1.1 equiv) employing general alkylation procedure. RPLC tR 17.75 min 220 rmn (Method ESI/MS mle 376.4
C
26
H
33
N
3 Example 169: Compound No. 70 (132 mg, 89%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 mg, 0.340 mmol) and 2-chloro-N- (2,6-diethylphenyl)acetafide (70 mg, 0.310 nunol, 0.9 equiv) employing general alkylation procedure. RPLC tRt 6.97 min 220 rn (Method ESI/MS m/e 484.4 (M t
C
32
H,,N
3 0).
Example 170: Compound No. 214 (49 mg, 42%) was prepared from 1- (3.3-diphenylpropyl)homopiperazine (100 mg, 0.340 mmol) and 3bromopropionitrile (31 mL, 0.374 mmol, 1.1 equiLv) employing general alkylation procedure. RPLC tR 4.36 min 220 run (Method ESI/MS rn/a 348.2
C
23
H
29
N
3 Example 171: Compound No. 215 (71 mg, 58%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 mg, 0.340 mmol) and 4- WO 97/44329 WO 9744329PCTIUS97/08577 bromobutyronitrile (37 mL, 0.374 mmol, 1.1 equiv) employing general alkylation procedure. RPLC tR 3.91 min 220 run (Method ESI/MS mle 362.2
C
24
H
31
NO)
Example 172: Compound No. 267 (31 mg, 24%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 mg, 0.340 mmol) and Nethyichioroacetamide (45 mg,* 0. 374 mmol, 1. 1 equiv) employing general alkylation procedure. RPLC tR 4.07 min 220 rim (Method ESI/MS m/e 380.4
C
2 4
H
33
N
3 0).
Example 173: Compound No. 204 (29 mg, 17%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (105.4 mg, 0.359 mmol) and methyl 2-[3- (2-chloroethyl) ureido ]benzoate (110 mg, 0.394 mmol, 1.1 equiv) employing general alkylation procedure. RPLC t, 4.95 min 220 nm (Method ESI/MS m/e 483.4 C,,H 3
,N
4 0 2 Example 174: Compound No. 216 (79 mg, 36%) was prepared from 1- 3-diphenyipropyl )homopiperazine (136.7 mg, 0.465 mmol) and Maybridge SPB03660 (108. 8 mg, 0. 511 mmol, 1. 1 equiv) employing general alkylation procedure.
RPLC t, 5.83 min 220 run (Method ESIIMS mle 471.4 C 2
,H
3 4
N
4 0 2 Example 175: Compound No. 246 (59 mg, 33%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 mg, 0.340 mmol) and Maybridge GK02253 (87 mg, 0.374,mmol) employing general alkylation procedure. RPLC tR 5.11 min 220 run (Method ESI/MS m/e 491.4 C 2
,H
3
,N
4 0 2 Example 176: Compound No. 217 (66 mg, 58%) was prepared from I- (3,3-diphenylpropyl)homopiperazile (100 mg, 0.340 mmol) and bromoacetonitrile, (26 mL, 0.374 mmol) employing general alkylation procedure. RPLC tR 5.21 min 220 rn; ESI/MS mle 334.4 C 22
H
2 7
N
3 Example 177: Compound No. 71 (59 mg, 33%) was prepared from 1-(3,3diphenylpropyl)homopiperazine (100 mg, 0.340 mmol) and Maybridge CD08063 (100 mg, 0.374 mmol, 1.1 equiv) employing general alkylation procedure. RPLC tR= 6.23 min 220 nm (Method ESI/MS m/e 525.2 C,,H 3 3 C1N 4 0 2
S).
Example 178: Compound No. 247 (35 mg, 22%) was prepared from 1i, WO 97/44329 i' W 97/4329PCTIUS97/08577 3-diphenylpropyl)homopiperazine (100 mg, 0. 340 rnmol) and Maybridge SEW03'081 (63 mg. 0.374 mmol) employing general alkylation procedure. RPLC tR 6.20 min 220 run (Method ESI/MS mle 427.4 (M 4
C,,H
27 C1N 4
S).
Example 179: Compound No. 74 (42 mg, 23%) was prepared from 1-(3,3diphenylpropyl)homopiperazine (100 mg, 0. 340 mmol) and Maybridge, S52956 (85 mg, 0.374 mmol) employing general alkylation procedure. RPLC tR 21 min 220 rim (Method ESI/MS m/e 486.4 (M t
C
3 1
H
3 9
N
3 0 2 Example 180: Compound No. 248 (105 mg, 41%) was prepared from 1- 3-diphenyipropyl )homopiperazine (133.5 mg, 0.454 mmol) and Maybridge GK1350 (149 mg, 0.500 mmol, 1.1 equiv) employing general alkylation procedure. RPLC tR 6.60 min 220 rim (Method ESI/MS mle 556.4 C 3 2
H
3 7 N,,0 2
S).
Example 181: Compound No. 249 (80 mg, 34%) was prepared from 1- 3 -diphenylpropyl) homopiperaz ine 12 6.7 mg, 0 .4 30 mmol and Maybridge RF 0 04 04 (134 mg. 0.474 mmol, 1.1 equiv) employing general alkylation procedure. RPLC t, 5.96 min 220 rn (Method ESI/MS Wle 540.4 C 2
,H
3 1 C1 2
N
5 0 2 Example 182: Compound No. 219 (69 mg, 38%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 mg, 0.340 mmol) and Maybridge S07335 (117 mg, 0.408 mmol, 1.2 equiv) employing general alkylation procedure. RPLC t, 4.68 min 220 rum (Method ESI/MS mle 526.4 hydrolysis product
C,,H
37
N
3 0 2 Example 183: Compound No. 269 (20 mg, 13%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 mg, 0.340 mmol) and Maybridge CD07922 (67 mg. 0.374 mmol, 1.1 equiv) employing general alkylation procedure. RPLC t, 4.65 min 220 rum (Method ESI/MS mWe 438.3 C,,H3 6 N,0S).
Example 184: Compound No. 250 (24 mug, 19%) was prepared from 1- 3-diphenylpropyl)homopiperazine (100 mug, 0. 340 mmol) and Maybridge SEW00285 (89 mug) employing general alkylation procedure. RPLC tR 4.70 min 220 rim (Method ESI/MS m/e 377.3 C 2 3
H
2 8
N
4 0)- Example 185: Compound No. 220 (67 mug, 63%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 mug, 0. 340 mmol) and propargyl bromide iWO 97/44329 ~.WO97/4329PCTIUS97/08577 (38 mg, 0.32 mmol) and potassium iodide (0.037 g, 0.22 mmol) employing general alkylation procedure. TLC Rf 0.29 (10% CH 3
OH-CH
2 Cl 2 RPLC tR 4.21 min 220 rn (Method ESI/MS m/e 333.3 C 23
H
3
,N
2 Example 186: Compound No. 221 (51 mg, 32%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 mg, 0.34 mmol) and l-(3chloropropyl)-1,3-dihydro-2 H-benzimidazol-2-one (85 mg, 0.408 mmol) employing general alkylation procedure. RPLC t, 4.70 min 220 nm (Method ESI/MS m/e 469.3 C 30
H
36
N
4 0).
Example 187: Compound No. 222 was synthesized from 1-(3,3diphenylpropyl)homopiperazine (200 mg, 0.680 mmol) and 2-(tertbutyldiphenylsilyl) -3-bromo-2-methyl- 1-propanol (125 mg, 0.32 mmol) employing general alkylation, procedure. Rf 0.53 (10% CHOH-CH 2 Cl 2 The purif ied intermediate was dissolved in anhydrous THF and treated with tert-butylammonium fluoride (0.35 mL, 0.35 mmol, 1.1 equiv). The reaction mixture was stirred at *C for 2 h and concentrated. Chromatography (S10 2 40 g, 20% CH 3 OH-EtOAc) af forded the desired product (30 mg,* two steps) TLC Rf 0. 17 (conditions) RPLC t, 4.16 min 220 rn (Method ESI/MS mWe 367.3 C 24
H
34
N
2 0).
Example 188: Compound No. 75 (91 mg, 65%) was prepared from 1-(3,3diphenylpropyl)homopiperazine (100 mg, 0.339 mmol) and c-bromo-o-tolunitrile mg, 0.406 mmol) employing general alkylation procedure. RPLC t, 6.52 min 220 nm (Method ESI/MS mle 410.3 C,,H 3
,N
3 Example 189: Compound No. 76 (63 mg, 37%) was prepared from 1-(3,3diphenylpropyl)homopiperazine (100 mg. 0.339 mmol) and 2-bromoacetamido-4nitrophenol (111 mg, 0.406 mmol) employing general alkylation procedure. RPLC t, 6.55 min 220 rn (Method ESI/MS m1e 489.3 C2,H3 2
N
4 0 4 Example 190: Compound No. 77 (103 mg, 61%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 mg, 0.339 mmol) and ethyl 4-(2chloroacetamido) benzoate (98 mg, 0.406 mmol) employing general alkylation procedure. RPLC tR 6.52 min 220 run (Method ESI/MS m/e 500.3
C
31
H
37
N
4 0 3 Example 191: Compound No. 223 (84 mg, 49%) was prepared from 1oWO 97/44329 ~WO 9744329PCT1US97/08577 (3,3-diphenylpropyl)homopiperazine (100 mg. 0.339 rumol) and 1-(3chioropropyl) theobromine, (104 mug, 0.406 rumol) employing general alkylation procedure. RPLC tR 5.25 mi-n 220 nm (Method ESI/MS mle 515.3 (M*.iH,
C
30
H
38
N
6 0 2 Example 192: Compound No. 80 (81 mg, 47%) was prepared from 1-(3,3diphenylpropyl)homopiperazine (100 mg, 0.339 rumol) and 4-nitrobenzyl bromoacetate (111 mug, 0.406 rumol) employing general alkylation procedure. RPL C t, 7.35 mi-n 220 rum (Method ESI/MS mle 488.3 C29H3 3
N
3 0 4 Example 193: Compound No. 81 (139 mg, 92%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 rmg, 0.339 rumol) and nitrobenzyl bromide (90 rug, 0.406 rumol) employing general alkylation procedure.
RPLC t, 5.90 mi-n 220 rn (Method ESI/MS m/e 446.3 C 2 ,11 31
N
3 0 3 Example 194:, Compound No. 268 (34 rug, 25%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 Mug. 0.340 rumol) and N- (chloroacetyl)isopropylamine (51 mug, 0.374 mmol) employing general alkylation procedure. RPLC t, 5.47 muin 220 rum (Method ESI/MS mle, 394.4
C
25
H
35
N
3 0).
General Epoxide Opening with 1-(3,3-Diphenylpropyl)homopiperaziLne f or Examples 195-197.
A solution of 1- (3,3-diphenylpropyl)homopiperazine (100 rug, 0. 340 rumol) in CHCN (1.8 ruL) was treated with epoxide (0.374 numol. 1.1 equiv) and 'Pr 2 NEt (71 mL, 0. 41 rumol, 1. 2 equiv), and the reaction mixture was heated to 70 *C f or 16 h. The solvent was removed under reduced pressure. Chromatography (SiO 2 2 x 20 cm, 20% CH 3 OH-EtOAc) afforded the N,N-dialkylated material (23-83%).
Example 195: Compound No. 218 (114 mug, 83%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 rug, 0.340 ruruol) and Maybridge NRB00767 (42 mg, 0.375 rumol) employing general epoxide opening procedure. RPLC tR 3.77 ruin 220 rim (Method ESI/MS mle 407.4 C 27
H
36
N
2 0 2 Example 196: Compound No. 253 (35 rug, 23%) was prepared from 1- (3,3-diphenylpropyl)homopiperazine (100 rug, 0.339 rumol) and furfuryl glycidyl ether (63 rug. 0.406 rumol) employing general epoxide opening procedure. RPLC WO 97/44329 PCT/US97/08577 tR 5.70 min 220 nm (Method ESI/MS m/e 449.3 C 2
H
36
N
4 0 3 Example 197: Compound No. 225 (69 mg, 70%) was prepared from 1-(3,3diphenylpropyl )homopiperazine (40.3 mg, 0.137 mmol) and N-(2,3epoxypropyl)phthalimide (42.6 mg, 0.150 mmol) employing general epoxide opening procedure. TLC Rf 0.40 (10% CH 3
OH-CH
2 Cl 2 RPLC tR 5.96 min 220 nm (Method B-10 min); ESI/MS m/e 498.3 CH 3 sN 3 0 3 Preparation of N,N-Diethyl-(l-homopiperazinyl) acetamide.
Acetyl chloride (3.90 mL, 54.9 mmol) was dissolved in EtOH (166 mL) and the mixture was stirred for 30 min at 25 A solution of homopiperazine g, 50 mmol, 1 equiv) in EtOH (20 mL) was added to the reaction mixture in one portion. The flask was fitted with a reflux condenser with a CaCI 2 drying tube and the reaction mixture was heated to reflux for 1 h. N,N- Diethylchloroacetamide (3.37 g, 0.5 equiv) was added and the reaction was heated to reflux for an additional 16 h. The reaction mixture was allowed to cool and the solvent was removed in vacuo. The product was partitioned between EtOAc (150 mL) and saturated aqueous NaHCO 3 (100 mL). The aqueous phase was extracted with EtOAc (1 x 100 mL). The combined organic phase was dried (Na 2 filtered and concentrated to yield the symmetrically dialkylated material (0.950 g, 17%).
The aqueous phase was basicified with 1 M NaOH (100 mL) and was extracted CH 2 Cl, (1 x 150 mL, 2 x 100 mL). The combined organic phase was dried (Na 2 filtered and concentrated to afford the pure monoalkylated homopiperazine (2.4 g, Preparation of 1- (4-Cyanobenzyl )homopiperazine.
To a solution of homopiperazine (9.2 g, 92 mmol, 2 equiv), in EtOH (115 mL) was added 1 M HCl-EtOH (92 mL) dropwise over 1 h. The suspension was heated to 70 C for 1 h at which point a homogeneous solution of monohydrochloride salt was obtained. a-Bromo-p-tolunitrile (9.0 g, 46 mmol, 1 equiv) was added and the reaction mixture was heated to reflux for 5 h. After cooling, the solvent was removed by rotary evaporation and the residue was partitioned between CHC1 2 (100 mL) and 2N aqueous KOH (100 mL). The aqueous layer was extracted with CH 2 C1 2 x 50 mL) and the combined organic phase was washed with saturated aqueous NaCl (1 x 150 mL) and dried (MgSO 4 Chromatography (SiO 2 4 x 20 cm, 20% CH 3
OH
5% Et 3
N-CH
2 Cl 2 afforded the desired monoalkylated material (6.78 g, 10.1 g theoretical, 67%) as an amber oil.
WO 97/44329 PCT/US97/08577 Preparation of 1- [4-(Methylsulfonyl) benzyl ]homopiperazine To a 2-neck, 2-L round bottom flask containing anhydrous EtOH (800 mL) and equipped with a mechanical stirrer and condenser was added acetyl chloride (20.2 mL, 0.267 mol, 1.1 equiv). The solution was stirred for 0.5 h and homopiperazine (24.3 g, 0.243 mol) was added. The mixture was heated to reflux for 2 h. The reaction mixture was cooled to 25 4-(methylsulfonyl )benzyl chloride (25 g, 0.122 mol, 0.5 equiv) was added and the reaction mixture heated to reflux for 16 h. The reaction mixture was cooled to 25 "C and the solvent was removed under vacuum. The residue was diluted with EtOAc (500 mL) and was washed with 2N KOH (2 x 500 mL). The aqueous layer was extracted with EtOAc (1 x 500 mL). The organic phase was combined, washed with 2N KOH (1 x 300 mL), dried (MgSO,) and concentrated. The crude solid was washed with hot EtOAc to yield pure desired product (8.03 g, 32.7 g theoretical. 25%) as an off-white solid. TLC R, 0.04 (10% CH 3
OH-CH
2 Cl 2 'H NMR (CDC1 3 300 MHz) 6 9.82 (br s, 1 7.92 J 8.0 Hz, 2 7.60 J 7.7 Hz, 2 3.80 (br s, 2 3.36 (br m, 2 3.07 3 2.93 (br s, 2 2.80 (br s, 2 2.12 (br m, 2
H)
Preparation of 1-(4-Picolyl )homopiperazine A solution of acetyl chloride (6.34 mL, 0.084 mol, 4 equiv) dissolved in anhydrous EtOH (50 mL) was stirred for 0.5 h and added to a solution of homopiperazine (10.4 g. 0.1 mol, 5 equiv) in EtOH (250 mL). The reaction mixture was heated to reflux for 1 h, cooled to 25 C and a solution of 4-picolyl chloride hydrochloride 93.44 g, 0.021 mol) in EtOH (40 mL) was added. The reaction mixture was heated to reflux for 16 h, cooled to 25 *C and the solvent was removed under vacuum. The residue was diluted with CH 2 C1 2 (300 mL) and was washed with 2N KOH (1 x 300 mL). The aqueous layer was extracted with CH 2 Cl 2 (1 x 300 mL) and the organic phase was washed with 2N KOH (150 mL), dried (MgSO 4 and concentrated.
Chromatography (SiO,, 5% H 2 0-5% NH 4 OH-'PrOH) afforded the desired product (2.88 g, 4.01 g theoretical, 72%) as a yellow oil. TLC Rf 0.45 H 2 0-5% NH 4 OH-IPrOH): 'H NMR (CDC1 3 300 MHz) 6 8.77 J 5.9 Hz, 2 7.53 J 5.7 Hz, 2 H), 3.91 2 3.19 4 2.92 4 2.04 2 H).
Preparation of 1- (4-Chlorobenzyl )homopiperazine.
Acetyl chloride (11.7 mL. 0.165 mol) was added to anhydrous EtOH (500 mL) and the mixture was stirred for 30 min at 25 Homopiperazine (15.0 g, 0.150 mol) was added and the mixture was heated to reflux for 4 h. 4-Chlorobenzyl ,WO 97/44329 102 PCT/US97/08577 chloride (13.96 g, 0.087 mol) was added and the reaction mixture was heated to reflux for 16 h before concentrating. The residue was dissolved in EtOAc (500 mL) and washed with IN aqueous KOH (50 mL). The aqueous layer was extracted with EtOAc (200 mL). The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. Chromatography (double separation, SiO 2 20 x 7 cm, 'PrOH-HO-NH 4 OH, 80:12:6 to 70:20:10 gradient elution) afforded the desired product (10.6 g, 53.4%) and the dialkylated homopiperazine (2.36 g, 16.5%).
GC/MS m/e 224 C 12
H
17
N
2 C1).10 CH 3
OH-CH
2 C1 2 RPLC tR 5.96 min 220 nm (Mm (Method ESI/MS m/e 498.3 C 31
H
35
N
3 0 3 Preparation of 1-(4-Methyl-2-thienyl)-2-(lhomopiperazinylacetyl)hydrazine.
1-(tert-butyloxycarbonyl)homopiperazine (1.0 g, 5.0 mmol) in CH 3 CN mL) was treated with Maybridge GK 02253 (1.2 g, 5.0 mmol) and Pr 2 NEt (1.04 mL, 6.0 mmol, 1.2 equiv). The reaction mixture was heated to 70 _C for 16 h. After cooling, the solvent was removed under reduced pressure and the residue was purified by chromatography (SiO2, 4 x 20 cm, 5% CH 3
OH-CH
2 C1 2 to afford the Boc-protected monoalkylated material as a white foam (1.33 g, RPLC t, 5.20 min 220 nm (Method ESI/MS m/e 397.0 C,,H 3
,N
4 0 4 The product (1.1 g, 2.8 mmol) was dissolved in 3 M HCl-CH 3 OH (14 mL) and stirred at 25 _C for 30 min. The solvent was removed by rotary evaporation and the deprotected homopiperazine HCI salt was dissolved in t BuOH-HO0 25 mL).
Dowex Anion exchange resin was added until pH 9. The resin was removed by filtration and evaporation afforded the pure mono-alkylated product (703 mg, RPLC t, 0.78 min 220 nm (Method ESI/MS m/e 297.1
C
14
H
30
N
4 0 2
S).
General Alkylation with 4-Bromo-2,2-diphenylbutyronitrile for Examples 198-203.
Monosubstituted homopiperazine (100 mg, 0.468 mmol, 1.0 equiv) in CH 3
CN
(3 mL) was treated sequentially with 4-bromo-2,2-diphenylbutyronitrile (168 mg, 0.561 mmol, 1.2 equiv) followed by 'Pr 2 NEt (60 mg, 0.468 mmol, 1.2 equiv). The reaction mixture was heated to 70 °C with stirring for 16 h. The mixture was allowed to cool and the solvent was removed in vacuo. The product was purified by chromatography (SiO 2 3 x 5 cm, 20% CH 3 OH-EtOAc) to afford the desired dialkylated material (48 mg, 24%).
t-WO 97/44329 103 ~.WO97/4329PCTIUS97/08577 Example 198: Compound No. 264 (48 mg, 24%) was prepared from N,Ndiethyl-(1-homopiperazinyl) acetamide (100 mg, 0.468 mmol) and 4-bromo-2,2diphenylbutyronitrile (168 mg, 0.561 mmol) employing general alkylation procedure. TLC Rf =0.30 (20% CHOH-EtOAc); RPLC tR 4.58 min 220 run (Method ESI/MS m/e 433:3 C 2 7
H
3 6
N
4 0).
Example 199: Compound No. 233 (225 mg, 73%) was prepared from l-(4picolyl)homopiperazine (200 mg, 1.05 mmol) and 4-bromo-2,2diphenylbutyronitrile (225 mg,* 0. 75 mmol employing general alkylation procedure.
TLC R, 0.33 (10% CH 3
OH-CH
2 Cl 2 RPLC t, 4.27 min 220 rn (Method B); ESI/MS m/e 411.3 C 27
H
30 Example 200: Compound No. 2 (155 mg, 52%) was prepared from 1-(4cyanobenzyl )homopiperazine (150 mg, 0.684 mmol) and 4-bromo-2,2diphenylbutyronitrile (226 mg, 0.752 nunol, 1.1 equiv) employing general alkylation procedure. RPLC t, 4.93 min 220 rn (Method ESI/MS m/e 435.3 C 2
,H
3 0
,N
4 Example 201: Compound No. 3 (16 mg, 12%) was prepared from 1-(4chlorobenzyl )homopiperazine (68 mg, 0.30 mmol) and 4-bromo-2,2diphenylbutyronitrile (100 mg,* 0. 33 mmol) employing general alkylation procedure.
TLC R, 0.32 CH 3
OH-CH
2 Cl 2 RPLC tR 5.27 min 220 run (Method A); ESI/MS mle 444.3 C,,H 30 C1N 2 Example 202. Compound No. 4 (251 mg, 69%) was prepared from 1-f 4- (methylsulfonyl)benzyiL]homopiperazine (200 mng, 0.75 mmol) and 4-bromo-2.2diphenylbutyronitrile (270 mg, 0. 9 mmol) employing general alkylation procedure.
TLC Rf 0.53 (10% CH 3 OH-CHCl,); RPLC tft 4.73 min 220 rin (Method A); ESI/MS mle 488.3 C 29
H
33 N 2 0 2
S)'
Example 203: Compound No. 234 (9 mg. was prepared from 1-(4methyl-2-thienyl) -homopiperazinylacetyl )hydrazine (95 mg, 0.32 mmol) and 4-bromo-2,2-diphenylbutyronitrile (96 mg, 0.32 mmol) employing general alkylation procedure. RPLC tR 6.03 min 220 run (Method B-10 min); ESI/MS mle 516.3 C 29
H
33
N
5 0 2
S).
Preparation of 1- (4-Cyanobanzyl )piperazine.
A.WO 97/44329 104 PCT/US97/08577 To a solution of piperazine (5.17 g, 60 mmol, 2 equiv) in EtOH (40 mL) was added 1 M HCl-EtOH (60 mL) dropwise over 1 h and the suspension was heated to 70 "C for 1 h. a-Bromo-p-tolunitrile (5.88 g, 30 mmol, 1 equiv) was added and the reaction was heated to reflux for 16 h. After cooling the solvent was removed by rotary evaporation and the residue was partitioned between CHC1, mL) and 2N aqueous KOH (70 mL) and the combined organic phase was washed with saturated aqueous NaCI (100 mL) and dried (MgS04). Chromatography (SiO 2 CH30H-5% Et 3
N-CH
2 Cl 2 afforded the monoalkylated material (2.6 g, 6.0 g theoretical, 43%) as an amber oil.
General Alkylation of 1-(4-Cyanobenzyl )piperazine for Examples 204 and 205.
A solution of 1-(4-cyanobenzyl)piperazine (150 mg, 0.745 mmol) was treated with alkylating reagent (0.745 mmol, 1 equiv) and 1 Pr 2 NEt (156 mL, 0.894 mmol, 1.2 equiv). The reaction mixture was heated to 70 C and stirred by vortex for 16 h. After cooling, the reaction mixture was subjected directly to chromatography (SiO,, 3-7% CH 3
OH-CH
2 Cl 2 gradient elution) to afford the desired N,N-dialkylated piperazine (11-77%).
Example 204: Compound No. 9 (142 mg, 48%) was prepared from 1-(4cyanobenzyl)piperazine (150 mg, 0.745 mmol) and 3,3-diphenylpropyl methanesulfonate (216 mg, 0.745 mmol, 1 equiv) employing general alkylation procedure. RPLC t, 6.47 min 220 nm (Method ESI/MS m/e 396.2 (M +H,
C
27
H
29
N
3 Example 205: Compound No. 1 (166 mg, 53%) was prepared from 1-(4cyanobenzyl )homopiperazine (150 mg, 0.745 mmol) and 4-bromo-2,2diphenylbutyronitrile (224 mg, 0.745 mmol) employing general alkylation procedure. RPLC t, 6.82 min 220 nm (Method ESI/MS m/e 422.3
C
28
H
28 eNJ) General Preparation of Hydrazide Alkylating Agents The hydrazide starting material (7.93 mmol) was dissolved in CH 3 CN mL) and treated with chloroacetyl chloride (0.95 mL, 11.93 mmol, 1.5 equiv) and Et 3 N (1.11 mL, 7.96 mmol, 1.02 equiv). The mixture was stirred at 25 °C for 16 h and concentrated. The residue was dissolved in EtOAc (300 mL), washed with 1N aqueous HCI (10 mL) saturated aqueous NaCl (20 mL), dried (MgSO 4 and vWO 97/44329 ~.WO97/4329PCTIUS97/08577 concentrated in vacuo. The desired compound- was isolated by trituration with EtOAc, followed by washing with hexane or chromatography (Si0 2 General alkylation procedure for Example 163-194 was then used to afford the desired homopiperazine analogs.
Example 206: 1-Benzoyl-2-(chloroacetyl)hydrazine (850 mg, 54%) was prepared f rom benzhydrazide 0 g, 7. 34 mmol) and chloroacetyl chloride (0.5 8 mL, 7.34 mmol. 1 equiv) using general procedure. Compound No. 78 (300 mg, 51%) was prepared f rom 1- 3- diphenyipropyl) hornopiperazine (100 mg, 0. 34 mmol) and 1-benzoyl-2-(chloroacetyl)hydrazine (80 mg, 0.38 mmol) employing general alkylation procedure. TLC Rf 0.44 (10% CH 3
OH-CH
2 Cl 2 RPLC tR 5.85 min 220 run (Method ESI/MS mle 471.3 C 29
H
34
N
4 0 2 Example 207: 1-(Chloroacetyl)-2-(phenylacetyl)hydrazine (1.24 g, 82%) was prepared from phenylacetohydrazide (1.00 g, 6.66 mmol) and chloroacetyl chloride (0.53 mL. 6.66 mmol, 1 equiv) using general procedure. Compound No.
79 (71 mg, 43%) was prepared from 1-(3,3-diphenylpropyl)homopiperazine (100 mg, 0.34 mmol) and 1-(chloroacetyl)-2-(phenylacetyl)hydrazine (85 mg, 0.38 mmol) employing general alkylation procedure. TLC Rf 0.40 (10% CH 3
OH-CH
2 Cl 2
RPLC
t, 6.02 min 220 ram (Method ESI/MS mle. 485.5 C3,H3 6 NI0 2 Example 208: 1-(2-Furoyl)-2-(chloroacetyl)hydrazine (1.21 g, 75%) was prepared from 2-furoic acid hydrazide (1.06 g, 7.93 mmol) and chloroacetyl chloride (0.95 mL, 11.9 mmol, 1.5 equiv) using general procedure. Compound No.
251 (63 mg, 40%) was prepared from 1-(3,3-diphenylpropyl)homopiperazine (100 mg, 0.34 mmol) and 1-(2-furoyl)-2-(chloroacetyl)hydrazine (76 mg, 0.38 mmol) employing general alkylation procedure. TLC Rf 0.42 (10% CH 3
OH-CH
2 Cl 2
RPLC
t= 5.60 min 220 rim (Method ESI/MS mle 461.3 (M 4
C
27
H
3 2
N
4 0 3 Example 209: 1- (2-Thiophenecarbo nyl) (chloroacetyl)hydrazine (1.14 g, 74%) was prepared from 2-thiophenecarbohydrazide (1.00 g, 7.03 mmol) and chloroacetyl chloride (0.86 mL, 10.6 mmol, 1.5 equiv) using general procedure.
Compound No. 252 (88 mg, 54%) was prepared from 1-(3,3diphenylpropyl)homopiperazine (100 Mg. 0.34 mmol) and 1-(2- Thiophenecarbonyl )-2-(chloroacetyl)hydrazine (82 mg, 0.38 mmol) employing general alkylation procedure. TLC Rf 0.47 (10% CH 3
OH-CH
2 Cl 2 RPLC tR 5.92 min 220 run (Method ESI/MS mle 477.3 (M t
C
27
H
32
N
4 0 2
S).
v WO 97/44329 106 ~.WO97/4329106PCTIUS97/08577 Example 210: 1- (Diphenylcarbamoyl) (2-chioroacetyl) semicarbazide (1.30 g, 65%) was prepared from 4,4-diphenylsemicarbazide (1.5 g, 6.60 mmol) and chioroacetyl chloride 79 mL 9.92 mrnol, 1. 5 equiv) using general procedure.
compound No. 297 (46 Mg, 24%) was prepared from 1-(3,3diphenyipropyl )homopiperazine (100 Mg, 0.34 mmol) and 1- (diphenylcarbamoyl) (2-chioroacetyl) semicarbazide (114 mg, 0.38 mmol) employing general alkylation procedure. TLC Rf =0.44 (10% CHOH-CH 2 Cl 2
RPLC
t, 6.55 min 220 nm (Method ESI/MS mWe 562.5 C 3
,H
3 ,N,0 2 Example 211: 1- (Phenylcarbamoyl) (2-chloroacetyl) semicarbazide (1.19 g, 67%) was prepared from 4-phenylsemicarbazide (1.00 g, 6.62 mmol) and chioroacetyl chloride (0.79 mL, 9.92 nimol) using general procedure. Compound No. 82 (33 mg, 20%) was prepared from 1-(3,3-diphenylpropyl )homopiperazine (100 mig, 0.34 nimol) and 1- (phenylcarbamoyl) (2-chioroacetyl) semicarbazide (85 mg, 0.37 nimol) employing general alkylation procedure. TLC Rf 0.41
CH
3
OH-CH
2 Cl 2 RPLC tR 5.96 min 220 rum (Method ESI/MS mle 486.4
C
29
H,,N
5 0 2 Example 212: 1- (Ethylcarbamoyl) (chloroacetyl)hydrazine 31 g, 76%) was prepared from ethyl carbazate (1.00 g, 9.61 rnmol) and chloroacetyl chloride (1.15 niL, 10.16 nimol, 1 equiv) using general procedure. Compound No.
224 (81 mg, 54%) was prepared from 1-(3,3-diphenylpropyl)homopiperazine (100 mg, 0.34 nimol) and 1-(ethylcarbamoyl)-2-(chloroacetyl)hydrazine (68 mig, 0.37 mmol) employing general alkylation procedure. TLC Rf =0.44 (10% CH 3
OH-CH
2 Cl 2 RPLC tR 5.91 min 220 rim (Method ESI/MS mle 439.3 C 3
,H,,N
4 0 3 Example 213: 1- (4-Nitrobenzoyl) (chloroacetyl )hydrazine was prepared from 4-nitrobenzhydrazide (1.00 g, 5.52 inmol) and chioroacetyl chloride (0.66 mL, 8.29 nimol) using general procedure. Trituration from EtOAc gave the hydrazine in quantitative yield, which was used without further purification.
Compound No. 86 (56 Mg, 32%) was prepared from l-(3.3diphenylpropyl)homopiperazine (100 Mg. 0.34 nimol) and 1-(4-nitrobenzoyl)-2- (chloroacetyl)hydrazine (96 mg, 0.37 nimol) employing general alkylation procedure. TLC Rf =0-46 (10% CH 3
QH-CH
2 Cl 2 RPLC tR 5.56 min 220 rum (Method ESI/MS mle 516.3 C 29
H
33
N
5 0 4 p WO 97/44329 WO 9744329PCT/US97I08577 Example 214: 1-(Toluoyl)-2-(chloroacetyl)hydrazine was prepared from 4-toluic hydrazide (1.00 g, 6.66 mmol) and chioroacetyl chloride (0.80 ML, 9.99 mmol) using general procedure. Trituration from EtOAc gave the hydrazine in quantitative yield, which was used without further purification. Compound No.
87 (61 mg, 37%) was prepared from 1-(3.3-diphenylpropyl)homopiperazine (100 mg, 0.34 mmol) and 1-(toluoyl)-2-(chloroacetyl)hydrazine (74 mg, 0.37 mmol) employing general alkylatlon procedure. TLC Hf 0.44 (10% CH 3 OH-CHCl,); RPLC t, 5.51 min 220 rn (Method ESI/MS mle 485.4 C 30
H
36
N
4 0 2 Example 215: 1- (4 -Hydroxybenzoyl) (chloroacetyl)hydrazine was prepared from 4-hydroxybenzhydrazide (1.00 g, 6.57 mmol) and chloroacetyl chloride (0.79 mL, 9.92 mmol) using general procedure. Trituration from EtOAc gave the hydrazine in quantitative yield, which was used without further purification. Compound No. 89 (71 mg, 43%) was prepared from 1-(3,3diphenylpropyl )homopiperazine (100 mg, 0.34 mmol) and 1- (4-hydroxy benzoyl)-2-(chloroacetyl)hydrazine- (85 mg, 0.37 mmol) employing general alkylation procedure. RPLC t, 6.21 min 220 nm (Method B-10 min); ESI/MS m/e 487.3 C 29
H
34
N
4 0 3 Example 216: 1- (2-Nitrobenzoyl) (chloroacetyl)hydrazine (0.579 g, 41%) was prepared from 2-nitrobenzhydrazide (1.00 g, 5.52 mmol) and chloroacetyl chloride (0.66 mL, 8.83 mmol) using general procedure. Compound No. 90 (82 mg, 47%) was prepared f rom l- diphenylpropyl. )homopiperazine (100 mg, 0. 34 mmol) and 1-(2-nitro benzoyl)-2-(chloroacetyl)hydrazine (96 mg, 0.37 mmol) employing general alkylation procedure. TLC R, =0.40 (10% CH 3
OH-CH
2 Cl 2 RPLC tR 6.04 min 220 rn (Method ESI/MS m/e 516.1 C, 9
H
33
N
5 0 4 Example 217: 1-(4-Methoxybenzoyl)-2-(chloroacetyl)hydrazine (1.783 g, 54%) was prepared from 4-methoxybenzhydrazide (1.00 g, 6.00 mmol) and chloroacetyl chloride (0.72 mL,. 9.00 mmol) using general procedure. Compound No. 92 (63 mg, 51%) was prepared from 1-(3,3-diphenylpropyl )homopiperazine (100 mg, 0.34 mnmol) and 1-(4-methoxy benzoyl)-2-(chloroacetyl)hydrazine (91 mg, 0.37 mmol) employing general alkylation procedure. TLC R, 0.52 (10% CH 3
OH-CH
2 Cl 2 RPLC t, 5.46 min 220 rn (Method ESI/MS m/e 501.1 C,,H 3
,N
4 0 3 Example 218: 1- (Nicotinoyl)-2-(chloroacetyl)hydrazine (1.29 g, 83%) was prepared f rom nicotinohydrazide (1 .00 9, 7.29 mmol) and chloroacetyl chloride WO 97/44329 108 QWO 9744329PCTIUS97/08577 (0.87 mL, 10.94 mmnol) using general procedure. Compound No. 254 (100 mg, 66%) was prepared from 1-(3,3-diphenylpropyl )homopiLperazine (100 mg, 0.34 nunol) and 1- (nicotinoyl) (chioroacetyl )hydrazine (87 mg, 0 .41 mmol) employing general alkylation procedure. TLC Rf =0.12 (10% CHOH-CH 2 Cl 2 RPLC tR 5.61 min 220 ran (Method ESI/MS mle 472.3 C,,H 33 N,0 2 Example 219: 1- (2-Benzo[blthiophenecarbonyl) -2- (chloroacetyl)hydrazine (0.578 g. 94%) was prepared from (2benzo[blthiophenecarbonyl)hydrazine (0.50 g, 2.60 mmol) and chloroacetyl chloride (0.31 roL, 3.90 mmol) using general procedure. Compound No. 255 (73 mg, 41%) was prepared from 1-(3.3-diphenylpropyl)homopiperazine (100 mg, 0.34 mmol) and 1- (2-benzo~b] thiophenecarbonyl) (chloroacetyl )hydrazine (88 mg, 0. 37 mmol) employing general alkylation procedure. TLC Rf 26 (10% CH 3
OH-
CH
2 RPLC tR 6.96 min 220 rm (Method ESI/MS m/e 527.3
C
3
,H
34
N
4 0 2
S).
Example 220: 1- (4-Bromobenzoyl) (chloroacetyl)hydrazine (0.886 g, 73%) was prepared from 4 -bromobenzhydrazide 00 g, 4.64 mmol) and chloroacetyl chloride (0.55 mL, 6.90 mmol) using general procedure. Compound No. 98 (143 mg, 76%),was prepared from 1-(3,3-diphenylpropyl)homopiperazine (100 mg, 0.34 mmol) and 1-(4-bromobenzoyl)-2-(chloroacetyl)hydrazine (98 mg, 0.37 mmol) employing general alkylation procedure. TLC R, =0.50 (10% CH 3
OH-CH
2 Cl 2
RPLC
t, 6.76 min 220 ru (Method ESI/MS mle 551.0 C2,H3N 4
O
2 Br).
Preparation of Sodium (4-C 3, 3-DiLphenyipropyl )homopiperazine- 1yl Iacetate.
1-(3,3-Diphenylpropyl)homopiperazine (2.0 g. 6.79 Inmol) was dissolved in CHCN (60 mL) and treated with methyl bromoacetate (1.56 g, 10.18 mmol) and Et 3 N (1.42 mL, 10.18 mmol). The mixture was ref luxed for 18 h and subsequently concentrated in vacuo. The residue was subjected to flash silica gel column chromatography (eluent: CH 2 Cl,/MeOH, 96/4, v/v) to give Methyl diphenylpropyl)homopiperazine- 1-yl Iacetate (1.93 g) in 78% yield. TLC Rf 0.53
CH
3
OH-CH
2 Cl 2 RPLC tR =4.71 min 220 ran (Method ESI/MS mie 367.1 C 23
H
3
,N
2 0 2 Methyl 4- 3-diphenylpropyl)homopiperazine- 1-yll acetate (0.327 g, 0.89 mmol) was dissolved in a mixture of dioxane (3.1 mL), MeOH (1.1 mL) and 4N NaOH 22 niL) After stirring for 30 min, 5 More drops of 4N NaOH were added 'WO 97144329 PCT[US97/08577 109 and stirring was continued until hydrolysis of the methyl ester was complete.
The mixture was concentrated in vacua and the residue subjected to f lash silica gel column chromatography (eluent: CHCl,/MeOH, 1/1, v/v) to give sodium (4- (3,3-diphenylpropyl)homopiperazine- 1-yl] acetate (0.278 g) in 88% yield. TLC Rf 0.22 (10% CHOH-CH 2 Cl 2 RPLC t, 1.98 min 220 rim (Method ESI/MS m/e 353.3 C, 2
H
29
N
2 0 2 General Procedure for Coupling to Sodium Diphenyipropyl )homopiperazine- 1-yl] acetate f or Examples 221-253.
sodium 4- 3-diphenylpropyl)homopiperazine- 1-yl] acetate (30 mg, 0. 08 mmol) was suspended in dry CH 2 Cl 2 (1 mL) and HOBt (12 mg, 0.089 mmol) and the amine, hydrazide or amino acid 88 mmol) were added. After cooling the mixture to 0 EDCI (30 mg, 0.10 mmol) was added, the pH adjusted to 7-8 with Et 3
N
and the mixture was stirred f or 15 min at 0 _C and 16 h at rt. Concentration in vacuo of the mixture gave a residue which was not worked up but purified directly by HPLC.
Example 221: Compound No. 270 (55.6 mg. 70%) was prepared from sodium sodium 4 -(3,3-diphenylpropyl)homopiperazine- 1-yl Iacetate (53.6 mg. 0.15 mmol) and dihexylamine (39 mL, 0. 167 mmol) employing general coupling procedure. TLC R, =0.
4 6 (10% CHOH-CH 2 RPLC tR 8.27 min 220rn (Method ESI/MS m/e 520.6 C 3 5 3
N
3 Example 222: Compound No. 83 (30 mg, 39%) was prepared sodium sodium [4-(3,3-diphenylpropyl)homopiperazmne-1-yllacetate (60.2 mg, 0.17 mmol) and benzylhydrazine dihydrochloride (40 mg, 0. 205 mmol) employing general coupling procedure. TLC Rf =0.39 (10% CH 3
OH-CH
2 Cl 2 RPLC t, 6.16 min 220 nm (Method ESI/MS m/e 457.3 C 2 9
H
3 6
N
4 Example 223: Methyl 2-benzoylhydrazinoacetate (0.418 g, 27%) was prepared from benzhydrazide (1.00g, 7.34 mmol) and methyl bromoacetate (0.76 mL, 80.3 mmol) employing general procedure. Compound No. 84 (37 mg, 44%) was prepared f rom sodium 3-diphenylpropyl)homopiperazine-1-yl] acetate (56 mg, 0. 158 mmol) and methyl 2-benzoylhydrazinoacetate (36 mg, 0. 17 mmol) employing general coupling procedure. TLC Rf =0.49 (10% CH 3
OH-CH
2 Cl 2 RPLC t, 6.21 min 220 rn (Method ESI/MS nile 543.1 (Me-H. C 3 2
H
3
,N
4 0 4 ,I WO 97/44329 PCT/US97/08577 110 Example 224: Compound No. 85 (59 mg, 75%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yl]acetate (62 mg, 0.166 mmol) and 2-aminoacetophenone hydrochloride (33 mg, 0.195 mmol) employing general coupling procedure. TLC R, =0.40 (10% CHOH-CHCl 2 RPLC t, 5.51 min 220 nm (Method ESI/MS m/e 470.3 C 30
H
35
N
3 0 2 Example 225: Compound No. 88 (41 mg, 58%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yl]acetate (50 mg, 0.14 mmol) and 4-chlorobenzhydrazide (27 mg, 0.156 mmol) employing general coupling procedure.
RPLC t, 5.
7 1min 220 nm (Method ESI/MS m/e 505.2 C 29
H
33 N,0 2 C1).
Example 226: Compound No. 91 (55 mg, 68%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yl]acetate (60 mg, 0.16 mmol) and 2-amino-4 '-methoxyacetophenone hydrochloride (36 mg. 0.176 mmol) employing general coupling procedure. TLC R, =0.55 (10% CH 3 OH-CHCl 2 RPLC t, 6.50 min 220 nm (Method ESI/MS m/e 500.2 C 3
,H
3
N
3 0 3 Example 227: Compound No. 271 (51 mg, 73%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yl]acetate (60 mg, 0.16 mmol) and dipropylamine (24 mL, 0.176 mmol) employing general coupling procedure. TLC Rf =0.56 (10% CH 3
OH-CH
2 Cl 2 RPLC tR 5.51 min 220 nm (Method ESI/MS m/e 436.3 C 28
H
41
N
3 0).
Example 228: Compound No. 186 (34 mg, 23%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yl]acetate (100 mg, 0.267 mmol) and benzenesulfonohydrazide (54 mg, 0.31 mmol) employing general coupling procedure.
TLC R, =0.47 (10% CH 3
OH-CH
2
C
2 RPLC tR 6.31 min 220 nm (Method B); ESI/MS m/e 507.5 C 28
H
34
,,N
4 0 3
S).
Example 229: Compound No. 93 (79 mg, 81%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yl]acetate (75 mg, 0.20 mmol) and 4-aminobenzhydrazide (34 mg, 0.22 mmol) employing general coupling procedure.
TLC Rf =0.26 (10% CH 3 ,0H-CH 2 C1 2 RPLC tR 5.61 min 220 nm (Method B); ESI/MS m/e 486.3 C 9
,H
3 ,NsO 2 Example 230: Compound No. 94 (24.4 mg, 17%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yll]acetate (100 mg, 0.267 mmol) and oWO 97/44329 PCTIUS97/08577 4-methoxybenzenesulfonohydrazide (59.4 mg. 0.29 mmol) employing general coupling procedure. TLC Rf =0.45 (10% CHOH-CH 2 Cl 2 RPLC tR 6.71 min 220 rn (Method ESI/MS mle 537.3 C 2
,H,,N
4 0 4 Example 231: Compound No. 95 (27.9 mg, 20%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazifle-1-yllacetate (100 mg, 0.267 mmol) and p-toluenesulfonohydrazide (55 mg, 0.295 mmol) employing general coupling procedure. TLC Rf =0.52 (10% CHOH-CH 2 Cl 2 RPLC tR 6.91 min 220 rim (Method ESI/MS mle 521.3 C 2
,H
36
N
4 0S).
Example 232: Compound No. 272 (34 mg, 65%) was prepared from sodium 3-diphenylpropyl)homopiperazine- 1-yl]acetate (30 mg, 0. 08 mmol) and glycine methyl ester hydrochloride (10.6 mg, 0.084 sunol) employing general coupling procedure. TLC Rf =0.42 (10% CH 3
OH-CH
2 Cl 2 RPLC tR 6.96 min 220 rn (Method ESI/MS mle 424.3 C 2
,H
3
,N
3
O
3 Example 233: Compound No. 273 (37 mg, 72%) was prepared from sodium 3-diphenylpropyl)homopiperazine-1-yl] acetate (30 mg, 0. 08 mmol) and glycinamide hydrochloride (9.3 mg, 0.084 unmol) employing general coupling procedure. TLC Rf =0.32 (10% CH 3
OH-CH
2 Cl 2 RPLC t, 5.76 min 220 run (Method ESI/MS m/e 409.3 C 24
H
32
N
4 0 2 Example 234: Compound No. 274 (24 mng, 47%) was prepared sodium [4- 3-diphenylpropyl)homopiperazine- 1-yll acetate (30 mg, 0.08 mmol) and glycine tert-butyl ester hydrochloride (14.1 mg, 0.084 mmol) employing general coupling procedure. This compound was purified by diluting with CH 2 Cl 2 washing with NaHCO 3 brine, drying (MgSO 4 f iltering and evaporat Ing of f the solvent in vacuo. Final purif ication by silica gel column chromatography. TLC Rf 0. 41 (10% CH 3
OH-
CH
2 Cl 2 RPLC tR 6.56 min 220 nm (Method ESI/MS m/e 466.5
C
28
H
39
N
3 0 3 Example 235: Compound No. 275 (26.9 mg, 43%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yllacetate (30 mg, 0.08 mmol) and (D)-(-)-2-phenylglycinol (13.2 mg, 0.096 mmol) employing general coupling procedure. TLC Rf =0.42 (10% CHOH-CH 2 Cl 2 RPLC t, 6.21 min 220 sn (Method ESI/MS m/e 472.0 (M 4
C
30
H
37
N
3 0 2 v (,WO 97/44329 ~WO 9744329PCT/US97/08577 Example 236: Compound No. 226 (27.0 mg, 43%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yllacetate (30 mg, 0.08 mmol) and (IS, 2R) -cis- 1-amino-2-indanol (14.3 mg, 0.096 mmol) employing general coupling procedure. TLC Rf =0.42 (10% CH 3 OH-CHCl,); RPLC tR 6.36 min 220 nm (Method ESI/MS mle 484. 0 C 3
,H
37
N
3 0 2 Example 237: Compound No. 276 (24.9 mg, 20%) was prepared from sodium (4 3-diphenylpropyl)homopiperazine- 1-yl Iacetate (30 mg, 0.08 mmol) and (1R, 2S) -cis- 1-amuno-2-indanol (14.3 mig, 0.096 mmol) employing general coupling procedure. TLC R, 0.42 (10% CHOH-CHCl,); RPLC t, 6.26 min 220 nm (Method ESI/MS mle 484.0 C 31
H
3 7
N
3 0 2 Example 238: Compound No. 277 (29.9 mg, 43%) was prepared sodium 3-diphenylpropyl)homopiperazine-1-yl]acetate (30 mg, 0. 08 nimol) and dI-octopamine hydrochloride (18.2 mg, 0.096 mmol) employing general coupling procedure. TLC Rf =0.24 (10% CHOH-CH 2 C1 2 RPLC t, 5.76 mini 220 rn (Method ESI/MS mWe 488.0 C 3
,H
37
N
3 0 2 Example 239: Compound No. 278 (28.3 mg, 43%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yllacetate (30 mg, 0.08 mmol) and dl-norphenylephrine hydrochloride (18.2 mg, 0.38 nimol) employing general coupling procedure. TLC Rf =0.24 (10% CH 3
OH-CH
2 Cl 2 RPLC tR 5.91 min 220 ran (Method ESI/MS m/e 488.0 C 30
H
37
N
3 0 3 Example 240: Compound No. 279 (27.7 mg, 43%) was prepared from sodium 3-diphenylpropyl)homopiperazune-1-yl]acetate (30 mg, 0. 08 mmuol) and (lS,2S)-(+)-2-amino-3-methoxy-1-phenyl-1-propanol (17.4 mg, 0.096 nimol) employing general coupling procedure. TLC R, =0.46 (101% CH 3
OH-CH
2 Cl 2 RPLC t, =6.36 mini 220 ran (Method ESI/MS m/e 516.0 C 32 4,N3O3).
Example 241: Compound No. 280 (29.9 mg, 43%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yllacetate (30 mg, 0.08 nimol) and norephedrmne hydrochloride (18.0 mg, 0.096 nimol) employing general coupling procedure. TLC Rf =0.46 (10% CH 3 OH-CHCl,); RPLC tR 6.06 mini 220 nmn (Method ESI/MS m/e 486.3 C 3 1
H
3 9
N
3 0 2 Example 242: Compound No. 281 (22.4 mg, 20%) was prepared from sodium vWO 97/44329 PCTfUS97/08577 113 [4-(3,3-diphenylpropyl)homopiperazine-1-yllacetate (30 mg, 0.08 mmol) and 2 -amino- 1-phenylethanol (16.2 mg, 0.118 mmol) employing general coupling procedure. TLC Rj 0.53 (10% CHOH-CH 2 Cl 2 RPLC t, 6.11 min 220 nm (Method ESI/MS in/G 472.3 C 30
H
37
N
3 0 2 Example 243: Compound No. 298 (26.9 mg, 43%) was prepared from sodium 3-diphenylpropyl)homopiperazine-1-yl~acetate (30 Mg, 0. 08 mmol) and 2 -amino- 1, 3-propanediol (11.0 Mg. 0.121 mmol) employing general coupling procedure. TLC Rf =0.16 (10% CH 3
OH-CH
2 Cl 2 RPLC t, 5.51 min 220 nim (Method ESI/MS mle 426.0 CZS5H 3
SN
3
O
3 Example 244: Compound No. 282 (26.9 Mg, 43%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yllacetate (30 mg, 0.08 mmol) and L-phenylalaninol (17.8 Mg, 0.118 mmol) employing general coupling procedure.
TLC R, =0.53 (10% CH 3
OH-CH
2 C1 2 RPLC tR 6.31 min 220 rim (Method B); ESI/MS m/e 486.3 C 3 1
H
3
,N
3 0 2 Example 245: Compound No. 283 (27.0 mg, 46%) was prepared from sodium 3-diphenylpropyl)homopiperazine-1-yl~acetate (30 mg, 0. 08 mmol) and DL-phenylalaninamide hydrochloride (19.3 mg, 0.096 mmol) employing general coupling procedure. TLC Rf =0.25 (10% CH 3
QH-CH
2 Cl 2 RPLC t, 2.16 min 220 ran (Method ESI/MS m/e 499.4 C 3
,H
3
,N
4 0 2 Example 246: Compound No. 284 (24 Mg, 42%) was prepared from sodium 3-diphenylpropyl)homopiperazine-1-yl]acetate (30 mg, 0.08 mmol) and DL-aspartic acid dimethyl ester hydrochloride (19.0 mg, 0.096 mmol) employing general coupling procedure. TLC Rf =0.46 (10% CH 3
OH-CH
2 Cl 2 RPLC tR 2.16 min 220 ram (Method B ESI/MS mle 496.4 C, 28
H
3
,N
3 01) Example 247: Compound No. 285 (32.4 mg, 49%) was prepared from sodium (4-(3,3-diphenylpropyl)homopiperazine-1-yl]acetate (30 Mg, 0. 08 mmol) and DL-phenylalanine benzyl ester p-toluenesulfonic acid salt (34.3 mg. 0.08 mmol) employing general coupling procedure. TLC Rf =0.53 (10% CH 3
OH-CH
2 Cl 2 RPLC tR =2.53 min 220 run (Method ESI/MS m/e 590. 6 C 3
,H
43
N
3 0 3 Example 248: Compound No. 286 (22.5 mg, 40%) was prepared from sodium 3-diphenylpropyl)homopiperazine- 1-yllacetate (30 mg, 0. 08 mmol) and 1 WO 97/44329 PCT/US97/08577 114 DL-leucine methyl ester hydrochloride (17.5 mg, 0.096 mmol) employing general coupling procedure. TLC R, =0.53 (10% CH 3 OH-CHCl,); RPLC t, 2.21 min 220 nm (Method ESI/MS m/e 480.5 C 29
H
41
N
3 0 3 Example 249: Compound No. 287 (23 mg, 20%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yl]acetate (30 mg, 0.08 mmol) and DL-tyrosine methyl ester hydrochloride (22.3.0 mg, 0.096 mmol) employinggeneral coupling procedure. RPLC tR 2.01 min 220 nm (Method ESI/MS m/e 530.2
C
3
,H
3
,N
3 Example 250: Compound No. 288 (23.8 mg. 43%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yl]acetate (30 mg, 0.08 mmol) and DL-methionine methyl ester hydrochloride (19.2 mg, 0.096 mmol) employing general coupling procedure. RPLC t, 2.01 min 220 nm (Method ESI/MS m/e 498.2 C 2
,,H
39
N
3 0S).
Example 251: Compound No. 289 (21.6 mg, 30%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yl]acetate (30 mg, 0.08 mmol) and DL-Tryptophan methyl ester hydrochloride (24.5 mg, 0.096 mmol) employing general coupling procedure. RPLC tR 2.27 min 220 nm (Method ESI/MS m/e 553.4
C
34
,,H
4
N
4 0 3 Example 252: Compound No. 299 (20.9 mg, 43%) was prepared from sodium [4-(3,3-diphenylpropyl)homopiperazine-1-yl]acetate (30 mg, 0.08 mmol) and (1s,2R)-(+)-2-amino-1,2-diphenylethano (20.5 mg, 0.096 mmol) employing general coupling procedure. RPLC t, 2.12 min 220 nm (Method ESI/MS m/e 548.4 C, 36
H
41
N
3 0 2 Example 253: Compound No. 291 (23.8 mg, 41%) was prepared from sodium 14-(3.3-diphenylpropyl)homopiperazine-1-yl]acetate (30 mg, 0.08 mmol) and DL-methionine methyl ester hydrochloride (19.2 mg, 0.096 mmol) employing general coupling procedure. RPLC t, 2.21 min 220 nrim (Method ESI/MS m/e 484.4 C,,H,,N 3 0S).
Preparation of (4-(3,3-Diphenylpropyl)-1homopiperazinyl] acetohydrazide.
Methyl [4-(3,3-diphenylpropyl)-1-homopiperazinyl]acetate (0.607 g, i-WO 97/44329 PCTIUS97/08577 115 1.66 mmol) was dissolved in ethanol (20 mL) and hydrazine hydrate (1 mL) was added. The mixture was refluxed for 19 h and subsequently concentrated in vacuo.
The residue was taken up in EtOAc, washed with brine, dried (MgSO,) and concentrated in vacuo to afford the title compound as an oil (0.547 g) in yield. TLC R, 0.35 (10% CH 3 OH-CHCl,); RPLC tR 1.93 min 220 nm (Method ESI/MS m/e 367.1 C,, 22
H,,N
4 0,O).
General Coupling Procedure for [4-(3,3-Diphenylpropyl)-1homopiperazinyllacetohydrazide for Examples 254-256.
[4-(3,3-Diphenylpropyl) -l-homopiperazinyl]acetohydrazide (60.5 mg, 0.165 mmol) was dissolved in dry CH 2 Cl 2 (2 mL) and CH 3 CN (0.5 mL). Pyridine (19 mL, 0.23 mmol) and the sulfonyl chloride (0.195 mmol) were added and the mixture was stirred at room temperature for 16 h. After concentration of the mixture in vacuo, flash silica gel column chromatography was used to isolate the desired product.
Example 254: Compound No. 96 (69 mg, 70%) was prepared from [4- (3,3-Diphenylpropyl)-1-homopiperazinyl] acetohydrazide (65 mg, 0.177 mmol) and N-acetylsulfanilyl chloride (46 mg, 0.195 mmol) employing general coupling procedure. TLC R, 0.35 (10% CH 3
OH-CH
2 Cl); RPLC tR 6.36 min 220 nm (Method ESI/MS m/e 564.3 C 3
,H
37 NO04S).
Example 255: Compound No. 97 (63.5 mg, 71%) was prepared from [4- (3,3-Diphenylpropyl)-1-homopiperazinyl]acetohydrazide (60.5 mg, 0.165 mmol) and 4-chlorobenzenesulfonyl chloride (38.3 mg, 0.181 mmol) employing general coupling procedure. RPLC tR 7.01 min 220 nm (Method ESI/MS m/e 541.3 C 28
H
33
N
4 ,OSC1).
Example 256: Compound No. 256 (40 mg, 53%) was prepared from [4- (3,3-Diphenylpropyl)-l-homopiperazinyllacetohydrazide (55 mg, 0.15 mmol) and 2-thiophenesulfonyl chloride (30 mg, 0.164 mmol) employing general coupling procedure. RPLC t, 6.61 min 220 nm (Method ESI/MS m/e 513.3
C
26
H
32
N
4 0 3
S
2 Example 257: Compound No. 99 (55 mg, 64%) was prepared by dissolving [4-(3,3-Diphenylpropyl)-1-homopiperazinyllacetohydrazide (51 mg. 0.139 mmol) in dry CH,C1, (2 mL) and adding HOBt (21 mg, 0.155 mmol) and 4- WO 97/44329 PCTIS97/08577 116 (methylsulfonyl)benzoic acid (29 mg, 0.146 mmol). This mixture was cooled (0 and treated with EDCI (45 mg, 0.151 mmol) followed by Et 3 N such that the pH was around 8. After stirring for 16 h at room temperature, the mixture was diluted with CH 2
C
2 washed with saturated NaHCO 3 brine, dried (MgSO 4 filtered and concentrated in vacuo. The residue was applied to silica gel column chromatography (eluent: gradient of 96/4 to 94/6 CHCl 2 /MeOH, v/v) to afford the desired compound. TLC Rf =0.45 (10% CH 3 OH-CHCl 2 RPLC tR 6.06 min 220 nm (Method ESI/MS m/e 549.3 Co 3
H
3
,N
4 0 4
S).
Example 258: Compound No. 100 (45 mg, 64%) was prepared by dissolving [4-(3,3-Diphenylpropyl)-l-homopiperazinyl]acetohydrazide (49 mg, 0.134 mmol) in dry CHC1 2 (2 mL) and adding HOBt (20 mg, 0.148 mmol) and 4-acetylbenzoic acid (23 mg, 0.14 mmol). This mixture was cooled (0 and treated with EDCI (44 mg, 0.148 mmol) followed by Et 3 N such that the pH was around 8. After stirring for 16 h at room temperature, the mixture was diluted with CH 2 Cl 2 washed with saturated NaHCO 3 brine, dried (MgSO 4 filtered and concentrated in vacuo. The residue was applied to silica gel column chromatography (eluent: gradient of 96/4 to 94/6 CH 2 Cl 2 /MeOH, v/v) to afford the desired compound. TLC Rf =0.46
CH
3 OH-CHCl 2 RPLC t, 6.26 min 220 nm (Method ESI/MS m/e 513.3
C
3 1 H3eN 4 0 3 Example 259: Compound No. 290 (6.6 mg, 64%) was prepared by treatment of Compound No. 286 (10.5 mg, 0.015 mmol) with 0.44 mL of 0.25 NLiOH (MeOH/H 2 0, 3/1, v/v) at room temperature for 16 h. After acidifying the reaction mixture with TFA and evaporating off the solvents, the residue was purified using a small C-18 column (eluent: water followed by MeOH). RPLC t, 2.28 min 220 nm (Method ESI/MS m/e 466.4 C 2
H
39
,N
3 0 3 Example 260: Compound No. 292 (6.0 mg, 64%) was prepared by treatment of Compound No. 289 (9.6 mg, 0.0123 mmol) with 0.35 mL of 0.25 N LiOH (MeOH/H 2 0, 3/1, v/v) at room temperature for 16 h. After acidifying the reaction mixture with TFA and evaporating off the solvents, the residue was purified using a small C-18 column (eluent: water followed by MeOH). RPLC tR 2.41 min 220 nm (Method ESI/MS m/e 539.3 C 33
H
3
,N
4 0 3 Example 261: Preparation of Compound No. 69.
A solution of 1-[4-(methylsulfonyl)benzyl]homopiperazine (314 mg, 1.17 WO 97/44329 PCTIUS97/08577 117 mmol) in CH 3 CN (50 mL) was treated sequentially with 3-[4-(tertbutoxycarbonyl)phenyl]-3- phenylpropyl methanesulfonate (456 mg, 1.17 mmol, 1 equiv) and Na 2
CO
3 (124 mg, 1.17 mmol, 1 equiv). The reaction mixture was heated to 70 °C for 16 h, cooled to 25 filtered and concentrated. Chromatography (SiO 2 2 x 20 cm, 5% CH 3
OH-CH
2 Cl 2 afforded the desired material (346 mg, 53%) RPLC t, 7.63 min 220 nm (Method ESI/MS m/e 563.2 C 33
H
42
N
2 0 4
S).
Example 262: Preparation of Compound No. 72 and 73.
A solution of compound No. 69 (278 mg, 0.494 mmol) in CH 3 OH (2 mL) was treated with a 1.0 M solution of HCl-Et20 (5 mL) and stirred at 25 °C for 1 h.
Concentration and chromatography (SiO2, 2 x 20 cm, 5% CH 3 0H-CH 2 C1 2 to CH 3
OH,
gradient elution) afforded the compound No. 72 (132 mg, 51%) and compound No.
73 (88 mg, Compound No. 72: RPLC t, 4.78 min 220 nm (Method A); ESI/MS m/e 521.2 CoH3 6 sN 2 0 4 For compound No. 73: RPLC t, 4.08 min 220 nm (Method ESI/MS m/e 507.2 C 2
,H
34
N
2 0 4
S).
Example 263: Preparation of 1-(tert-Butyloxyoarbonyl)-4-[3-hydroxy- 3-(3-hydroxyphenyl)-3-phenylpropyl]homopiperazine (Compound No. 294) 1. A solution of di- tert-butyl dicarbonate (25 g, 115 mmol.) in CH 2 Cl 2 (100 mL) was added over a period of 20 min to a solution of homopiperazine (57 g, equiv) in CH 2 Cl 2 (200 mL). The reaction mixture was stirred at room temperature for 3 days. H0, (150 mL) was added to the reaction mixture and the mixture was extracted with CH 2 Cl 2 (2 x 100 mL). The combined extracts were washed with brine and dried over MgSO,. The solvent was removed under reduced pressure to afford an oil which was purified by simple distillation to give tert-butyloxycarbonyl)homopiperazine: 13.68 g, 59% yield, colorless oil; The purity was determined by GC/MS m/e 200.1 (M C, 0
H
2 oN 2 0 2 2. 3-Chloropropiophenone (7.14 g, 24.4 mmol), K 2 CO, (8.79 g, 1.50 equiv) and KI (1.41 mg, 0.2 equiv) were added to a solution of the purified l-(tertbutyloxycarbonyl)homopiperazine (8.486 g, 42.4 mmol) in CH 3 CN (60 mL). The reaction mixture was stirred at 70 'C for 17 h and then AcOEt (200 mL) was added to the cooled mixture. The precipitated solid was removed by filtration and washed with AcOEt (50 mL). The combined filtrate was evaporated to afford an oil which was purified by column chromatography (SiO 2 0%-20% CHCN/AcOEt) to give 1-(tert-Butyloxycarbonyl)-4-(3-phenyl-3-oxopropyl)homopiperazine 11.27 g, 80% yield, pale yellow oil; 'H NMR (CDC1,, 300 MHz) 6 1.40-1.65 9 H), jWO 97/44329 PCTIUS97/08577 118 1.80-1.95 2 2.65-2.85 4 3.01 2 H, 3 6.9 Hz), 3.19 2 H, J 6.9 Hz) ,.3.35 -3.55 4 H) 7.47 2 H, J 7,7 Hz), 7.55-7.65 (in, 1 7.90-8.02 (mn, 2 The purity was determined by RPLC/MS (Method RPLC tR 5.53 min 220 nin; ESI/MS mle 333.4 C,,H 2
,N
2 0 3 3. A solution of 3-(tert-butyldimethylsilyloxy)phenylmagnesm bromide [prepared from 3-(tert-butyldimethylsilyloxy)bromobenzene (28.5 g, 99.2 minol) and magnesium turnings (2.30 g, 94.5 nufol) in Et 2 O (65 mL) I was added at 0 _C to a solution of the purified 1- (tert-Butyloxycarbonyl) (3-phenyl-3oxopropyl)homopiperazine (11.25 g, 33.8 mmiol) in dry THF (150 inL). The mixture was warmed to room temperature with stirring and the stirring was continued for 3 h. Saturated aqueous NH.Cl (300 inL) was added to the reaction mixture, the mixture was stirred f or 15 min and extracted with AcOEt (3 x 150 mL). The combined extracts were washed with brine and dried over MgSO,. The solvent was removed under reduced pressure to afford an oil (31.00 g) which was purified by column chromatography (5102, 3%-25% AcOEt/hexane) to give 1-(tertbutyloxycarbonyl) 3- tert-butyldimethylsilyloxy)phenyl)-3-hydroxy-3phenylpropyljhoinopiperazine 9.00 g, 49% yield, pale yellow oil; 1H NMR (CDC 3 300 MHz) 8 0.00 6 0.81 9 1.32 9 1.4-1.5 (in, 2 1.7-1.8 (in, 2 2.2-2.3 (in, 2 2.4-2.55 (in, 4 3.25-3.45 4 6.50-6.56 (in, 1 6.80-6.92 2 6.99-7.10 (in, 2 7.11-7.20 (in, 2 7.28- 7.34 (in, 2 The purity was determined by RPLC/MS (Method RPLC tR 7.13 min 220 n; ESI/MS m/e 541.3 C 3
,H,
9
N
2
O
2 Sjj.
4. A solution of tetrabutylaromonium fluoride (1.0 M solution in THF, mL, 4.0 iniol, 1.03 equiv) was added to a solution of the purified 1-(tertbutyloxycarbonyl) tert-butyldimethylsilyloxy)phenyl}-3-hydroxy-3phenylpropyllhomopiperazine (2.11 g, 3.90 iniol) in THF (35 mL). The mixture was stirred at room temperature for 30 min. H 2 0 (100 inL) was added to the reaction mixture and the mixture was extracted with AcOEt (3 x 100 inL). The combined extracts were washed with brine and dried over MgSO 4 The solvent was removed under reduced pressure to afford an oil (3.11 g) which was purified by column c hromatography (Si0 2 50% AcOEt/hexane) to give 1-(tert-butyloxycarbonyl)- 4- (3-hydroxy-3- (3-hydroxyphenyl) -3-phenylpropyllhoinopiperazine (compound No.
294): 1.381 g, 83% yield, colorless oil; 'H NMR (CDCl 3 300 MHz) 6 1.47 3 1.50 6 1.9-2.1 (in, 2 2.45-2.9 (mn, 8 3.3-3.8 (in, 4 6.7-7.0 (in, 2 7.05-7.28 (in, 2 7.3-7.38 Cm, 2 7.42-7.50 Cm, 2 The purity k. 1-WO 97/44329 PCT[US97/08577 119 was determined by RPLC/MS (Method RPLC tfi= 5.30 min 220 un; ESI/MS mle 427.3 C 2
,H
35 N.0 4 Example 264: Preparation of 1- C3-Hydroxy-3- (3-hydroxyphenyl)-3phenylpropyljhomopiperazlne (Compound No. 295) p-Toluenesulfonic acid monohydrate (1.90 g, 10.0 minol. 4.0 equiv) was added to a solution of the purified 1-(tert-butyloxycarbonyl)-4-(3-hydroxy- 3- (3-hydroxyphenyl) -3-phenyipropyl ]homopiperazine (Compound No. 294,* 1.066 g, 2.50 nunol) in CHCN (15 mL) The reaction mixture was stirred at room temperature for 2.0 h and then, H,0 (50 mL) and CH 3 0H (20 mL) were added. Anion exchange resin (11.5 g, DOWEX 1x2-200, washed with aqueous NaOH) was added and the mixture was gently agitated at room temperature for 5 min. The resin was removed by filtration and washed with CHOH (3 00 mL) The combined f iltrate was evaporated to afford an oil (1.35 g) which was purified by column chromatography (Sb 2
CH
3 OH, 5% TEA/CH 2 Cl 2 to give 1-[3-hydroxy-3-(3-hydroxyphenyl)-3phenylpropyllhomopiperazine (Compound No. 295): 657 mg, 81% yield, colorless oil; 1H NMR (CDCl 3 300 MHz) 6 1.8 2.0 (in, 2 2.35-2.45 (in, 2 2.55- 2.80 (in, 611), 3.0-3.15 (in, 4 6.68-6.75 (in, 1 6.82-6.88 (in, 1 7.10-7.38 (mn, 5 7.42-7.52 (in, 2 The purity was determined by RPLC/MS (Method B).
RPLC tR= 4.27 min 220 n; ESI/MS m/e 327.3 C 2 0
H
2 7
N
2 0 2 Example 265: General Alkylation of 1-[3-Hydroxy-3-(3hydroxyphenyl) -3 -phenyipropyl Ihomopiperazine (Preparation of Compound No.
185).
1l-Benz oyl- 2 -(chloroacetyl) hydraz Ine (60 mg, 0.281 inmol, 1.2 equiv) and Et 3 N (118 mg, 1.17 inmol, 5.0 equiLv) were added to a solution of 1-[3hydroxy-3- (3-hydroxyphenyl) -3-phenylpropyllhoinopiperazine (Compound No. 295, 100 mg, 0. 306 inmol) in CH 3 CN 0 mL) The reaction mixture was stirred at 60 C for 13 h. The solvent was evaporated to afford an oil which was purified by column chromatography (Si0 2 10% CH 3
OH/CH
2 Cl 2 to give Compound No. 185: 71 mg, 46% yield, colorless oil; 'H NMR (CD 3 OD. 300 MHz) 6 1. 85-2. 00 (in, 2 2.45-2.55 (in, 2 2.65-2.75 (in, 2 2.78-3.00 (mn, 8 3.36 2 6.62-6.65 (in.
1 6.90-6.98 (mn, 2 7.10-7.35 (mn, 4 7.40-7.65 (mn, 5 7.88 2 H, J 5. 4 Hz) The purity was determined by RPLC /MS (Method B) RPLC tR 5. 08 min 220 run; ESI/MS m/e 503.2 C 2
,H,,N
4 0 4 Example 266: Compound No. 259, di-TFA salt (54.8 mg. 15%) was prepared (-WO 97/44329 PCT/US97/08577 120 from 1-[3-hydroxy-3-(3-hydroxyphenyl)-3-phenylpropyl]homopiperazine (Compound No. 295, 158 mg, 0.486 mmol) and Maybridge GK02253 (136 mg. 1.2 equiv) employing general alkylation procedure. The product was purified by preparative RPLC. RPLC t, 4.60 min 220 unm (Method ESI/MS m/e 523.2
C
2
,H
3 sN 4 0 4
S).
Example 267: Compound No. 227 (20 mg, 35%) was prepared from 1-[3hydroxy-3-(3-hydroxyphenyl)-3-phenylpropyl homopiperazine (Compound No. 295, 36 mg, 0.11 mmol) and N-(3-bromopropyl)phthalimide (32 mg, 1.1 equiv) employing general alkylation procedure. RPLC tR= 5.23 min 220 nm (Method ESI/MS m/e 514.3 (M4+H, C 3
H
36
N
3 0 4
O).
Example 268: Compound No. 227260 (105 mg, 67%) was prepared from 1- [3-hydroxy-3-(3-hydroxyphenyl)-3-phenylpropyl] homopiperazine (Compound No.
295, 100 mg, 0.306 mmol) and l-(chloroacetyl)-2-(2-thiophenecarbonl)hydrazine (61 mg, 1.2 equiv) employing general alkylation procedure. RPLC t 4.95 min 220 nm (Method ESI/MS m/e 509.2 C 2
,H
33
N
4 0 4
,OS).
Example 269: Compound No. 261 (94 mg, 53%) was prepared from 1-[3hydroxy-3- (3-hydroxyphenyl -3-phenylpropyl homopiperazine (Compound No. 295, 100 mg, 0.306 mmol) and Maybridge RF00404 (79 mg, 1.2 equiv) employing general alkylation procedure. RPLC tR= 5.52 min 220 nm (Method ESI/MS m/e 572.2 C,, 28
H
32 C1 2
N
5 0 4 Example 270: Compound No. 293 (65 mg, 48%) was prepared from 1-[3hydroxy-3-(3-hydroxyphenyl)-3-phenylpropyl]homopiperazine (Compound No. 295, 100 mg, 0.306 mmol) and N,N-diethylacetamide (150 mg, 4.3 equiv) employing general alkylation procedure. RPLC tR= 4.68 min 220 nm (Method ESI/MS m/e 440.2 C 26
H
38
N
3 0 3 Example 271: Compound No. 228 (97 mg, 63%) was prepared from 1-[3hydroxy-3- (3-hydroxyphenyl) -3-phenylpropyl] homopiperazine (Compound No. 295, 100 mg, 0.306 mmol) and l-(3-chloropropyl)-1,3-dihydro-2 H-benzimidazol-2-one (230 mg, 4.6 equiv) employing general alkylation procedure. 4.98 min 220 nm (Method ESI/MS m/e 501.1 C 36
H
3 N,0 3 Example 272: Compound No. 229 (60 mg, 63%) was prepared from 1-[3- I WO 97/44329 PCT/US97/08577 121 hydroxy-3- 3-hydroxyphenyl) 3-phenylpropyl] homopiperazine (Compound No. 295.
59 mg, 0.182 mmol) and 4-bromo-2-butenyl phenyl sulfone (50 mg, 1.0 equiv) employing general alkylation procedure. RPLC 5.20 min 220 nm (Method ESI/MS m/e 521.3 C,,H,,N 2 0 4
S).
Example 273: Compound No. 262 di-TFA salt (88 mg, 48%) was prepared from 1-[3-hydroxy-3- 3-hydroxyphenyl) 3-phenylpropyl ]homopiperazine (Compound No.
295, 80 mg, 0.245 mmol) and methylthiophenecarbonl)hydrazine (68 mg, 1.2 equiv) employing general alkylation procedure. The Product was purified by preparative RPLC. RPLC tR 5.23 min 220 nm (Method ESI/MS m/e 523.3 C 28
H,,
35
N
4 0 4
,OS).
Example 274: Compound No. 187 di-TFA salt (19 mg, was prepared from 1-[3-hydroxy-3-(3-hydroxyphenyl)-3-phenylpropyl]homopiperazine (Compound No. 295, 80 mg, 0.245 mmol) and Salor 52,688-4 (88 mg, 1.2 equiv) employing general alkylation procedure. The Product was purified by preparative RPLC. RPLC t, 5.22 min 220 nm (Method ESI/MS m/e 589.0 (M+H,
C
33
H
37
N
2 0 6
S).
Example 275: Compound No. 189 (26 mg, 42%) was prepared from 1-[3hydroxy-3-(3-hydroxyphenyl)-3-phenylpropyl]homopiperazine (Compound No. 295, mg, 0.123 mmol) and N-(phenacyl)chloroacetamide (32 mg, 1.2 equiv) employing general alkylation procedure. RPLC tR= 5.73 min 220 nm (Method ESI/MS m/e 502.3 C 30
H
36
N
3 0 4 Preparation of 1-[4-(Bromomethyl)benzenesulfonyl]pyrrole.
NaH (60% dispersion in mineral oil, 40 mg, 1.0 mmol) was added to a solution of pyrrole (67 mg, 1.0 mmol) in THF (2.0 mL) and the mixture was stirred at room temperature for 5 min. Then 4-(bromomethyl)benzenesulfonyl chloride (269 mg, 1.0 mmol) was added to the mixture. After stirring at room temperature for additional 10 min, brine (15 mL) was added and the mixture was extracted with AcOEt (40 mL x The combined extracts were dried over MgSO 4 The solvent was removed under reduced pressure to afford an oil which was purified by column chromatography (SiO 2 10% AcOEt/hexane) to give 1-[4- (bromomethyl)benzenesulfonyl]pyrrole: 46 mg, 15% yield, colorless oil. The purity was determined by GC/MS m/e 299 C 1 0 NOBrS).
WO 97/44329 PCT/US97/08577 122 Example 276: Compound No. 190 (27 mg, 40%) was prepared from 1-[3hydroxy-3- 3-hydroxyphenyl)-3-phenylpropyl]homopiperazine (Compound No. 295, mg, 0.123 mmol) and 1-[4-(bromomethyl)benzenesulfonyl]pyrrole (46 mg, 1.24 equiv) employing general alkylation procedure. RPLC 5.85 min 220 rnm (Method ESI/MS m/e 546.3 C 3
H
36 N,0 4
S).
Example 277: Compound No. 191 (39 mg, 61%) was prepared from 1-[3hydroxy-3-(3-hydroxyphenyl) -3-phenylpropyl homopiperazine (Compound No. 295, mg, 0.123 mmol) and 1-(chloroacetyl)-2-(4-hydroxybenzoyl)hydrazine (28 mg, 1.0 equiv) employing general alkylation procedure. RPLC tR= 4.72 min 220 nm (Method ESI/MS m/e 519.3 C 29
H
35
N
4 0s).
Example 278: Compound No. 194 di-TFA salt (39 mg, 42%) was prepared from 1- [3-hydroxy-3-(3-hydroxyphenyl)-3-phenylpropyl]homopiperazine (Compound No.
295, 40 mg, 0.123 mmol) and 1-(chloroacetyl)-2-(4-chlorobenzoyl)hydrazine (31 mg, 1.0 equiv) employing general alkylation procedure. The Product was purified by preparative RPLC. RPLC tR= 5.48 min 220 nm (Method ESI/MS m/e 537.0 (M 4
C
29
H
34 C1N 4 Example 279: Compound No. 195 di-TFA salt (30 mg, 33%) was prepared from 1- 1[3-hydroxy-3-( 3-hydroxyphenyl)-3-phenylpropyl]homopiperazine (Compound No.
295, 40 mg, 0.123 mmol) and 1-chloroacetyl-4-phenylsemicarbazide (28 mg, equiv) employing general alkylation procedure. The Product was purified by preparative RPLC. RPLC 5.18 min 220 nm (Method ESI/MS m/e 518.3
(M
4
C,,H
3 ,NsO, 4 Example 280: Compound No. 231 di-TFA salt (29 mg, 42%) was prepared from 1-[3-hydroxy-3-(3-hydroxyphenyl)-3-phenylpropyl] homopiperazine (Compound No.
295, 30 mg, 0.092 mmol) and bromobimane (28 mg, 1.0 equiv) employing general alkylation procedure. The product was purified by preparative RPLC. RPLC t,= 1.87 min 220 nm (Method ESI/MS m/e 517.4 C 3
,H
37
N
4 0 4 Example 281: Compound No. 196 di-TFA salt (33 mg, 46%) was prepared from 1-[3-hydroxy-3-(3-hydroxyphenyl)-3-phenylpropyl]homopiperazine (Compound No.
295, 30mg, 0.092mmol) andMaybridge CD08063 (29mg, 1.2 equiv) employing general alkylation procedure. The product was purified by preparative RPLC. RPLC t,= 2.07 min 220 rnm (Method ESI/MS m/e 557.2 (M 4
C
2
,H
34 C1N 4 0 4
S).
(-WO 97/44329 PCT/US97/08577 123 Example 282: Compound No. 232 tr±-TFA salt (6.6 mg, was prepared from 1-1 3-hydroxy-3- (3-hydroxyphenyl) -3-phenylpropyllhomopiperazine (Compound No. 295, 30 mg, 0.092 mmol) and Maybridge BTB12299 (18 mg, 1.2 equiv) employing general alkylation procedure. The product was purified by preparative RPLC. RPLC tR= 1.48 min 220 ru (Method ESI/MS mle 451.2
C
25
H
31
N
4 0 4 Example 283: Compound No. 296 (16 mg, 18%) was prepared from 3hydroxy-3- (3-hydroxyphenyl) -3-phenylpropyllhomopiperazine (Compound No. 295, 78 mg, 0.24 mmol) and acetyl chloride (19 mg, 1.0 equiv). Acetyl chloride and Et 3 N (121 mg, 1.2 mmol, 5.0 equiv) were added to a solution of 1-[3hydroxy-3- (3-hydroxyphenyl) -3-phenylpropyllhomopiperazine (Compound No. 295) in CH 3 CN (2.0 mL). The reaction mixture was stirred at room temperature for min. saturated aqueous NaHCO 3 (10 niL) was added to the reaction mixture and the mixture was extracted with AcOEt (3 x 15 mL). The combined extracts were dried over MgSO 4 The solvent was removed under reduced pressure to afford an oil which was purified by column chromatography (Si0 2 3-10% CH 3
OH/CH
2 C1 2 to give 1acetyl-4- [3-hydroxy-3- (3-hydroxyphenyl) -3-phenylpropyllhomopiperazine (Compound No. 296): 16 mig, 18% yield, colorless oil; RPLC tR= 4.75 min 220 rim (Method ESI/MS m/e 369.3 C 2 2
H
29
N
2 0 3 Example 284: Compound No. 263 TFA salt (40 mig, 23%) was prepared from 1- [3 -hydroxy- 3- (3-hydroxyphenyl) -3 -phenylpropyl Ihomopiperazine (Compound No.
295, 80 mig. 0.25 mmol), 2-(4-chlorobutyryl)thiophene (70 mg, 0.3 mmol) and triethylamIne (174 niL, 1.25 mmol) employing general alkylation proc edure. TLC R, 0.58 EtN-10% CHOH-CH 2 Cl 2 RPLC t~t 4.98 min 220 ran (Method ESI/MS mle 479.3 C 2
,H,
3 4
N
2 0 3
S).
Example 285: Compound No. 188 TFA salt (31 mig, 17%) was prepared from 1-[3 -hydroxy- 3-(3 -hydroxyphenyl) -3 -phenylpropyl] homopiperazine (Compound No.
295, 80 mg, 0.25 nimol), 3-chloropropyl p-tolyl sulfone (70 mig, 0.3 rnmol) and triethylamine (174 mL. 1.25 nimol) employing general alkylation procedure. TLC Rf= 0.62 Et 3 N-10% CH 3
OH-CH
2 Cl 2 RPLC tR 5.25 min 220 m (Method ESI/MS mle 523.3 C 3
,H
3
,N
2 0 4 Example 286: Compound No. 192 TFA salt (34 mig, 19%) was prepared from WO 97/44329 PCTfUS97/08577 124 1- [3-hydroxy-3- (3-hydroxyphelyl) -3-phenyipropyl] homnopiperazine (Compound No.
295, 80 mg, 0.25 mmol), 4-(chloroacetyl)catechol (56 mg, 0.3 mmol) and triethylamine (174 mL, 1.25 mmol) employing general alkylation procedure. TLC Rf, 0.62 Et 3 N-10% CH 3 OH-CHCl,), RPLC tR 4.68 min 220 nm (Method ESI/MS mle 477.3 C,,H 3 2
N
2 0 5 Example 287: Compound No. 230 TFA salt (30 mg, 17%) was prepared from 1- [3 -hydroxy- 3- (3-hydroxyphenyl) -3 -phenylpropyl] homopiperazine (Compound No.
295, 80 mg, 0.25 mmol), glycidyl methacrylate (43 mg, 0.3 mmol) and triethylanine (174 mL, 1.25 mmol) employing general alkylation procedure. TLC Rf 0.6
CH
3
OH-CH
2 Cl 2 RPLC tR 4.95 min 220 run (Method ESI/MS m/e 469.0 C, 7
H
36 N,0 5 Example 288: Compound No. 193 TFA salt (44 mg, 49%) was prepared from 1- [3 -hydroxy- 3- (3-hydroxyphenyl) -3-phenyipropyl ]homopiperazine (Compound No.
295, 50 mg, 0.15 mmol), 2-chloro-4 -fluoro-3'-nitroacetanilide (50 mg. 0.12 mmol) and triethylamIne (104 mL, 0.75 mmol) employing general alkylation procedure. TLC R, 0.6 Et 3 N-10% CH 3
OH-CH
2 C1 2 RPLC t, 5.78 min 220 rn (Method ESI/MS rn/ 523.0 C 2
,H
3
,N
4 0 5
F).
Preparation of 1- 3- (3 -Hydroxyphenyl) 3 -phenyipropyl I hamopiperaz ine.
1. Trifluoroacetic acid (4.75 mL) was added to a solution of 1-[3hydroxy-3- (3-hydroxyphenyl) -3-phenylpropyll homopiperazine (Compound No. 295, mg, 0.184 mmol) in CH 2 C1 2 (0.25 mL). The reaction mixture was stirred at room temperature for 2.5 h. The trifluoroacetic acid was evaporated to afford 1- (3-hydroxyphenyl) -3-phenyl-2-propenyllhomopiperazine as a colorless oil used without further purification.
2. A solution of 1-[3-(3-hydroxyphenyl)-3-phenyl-2propenyllhomopiperazine in EtOH (6 mL) was hydrogenated at 1 atm for 1.5 h in the presence of 5% palladium on charcoal (60 mg) at room temperature. The catalyst was removed by filtration through Celite and washed with EtOH (30 mL).
The combined filtrate was evaporated to give 1-[3-(3-hydroxyphenyl)-3phenylpropyllhomopiperazine (2TFA salt, 100 mg, quantitative) as a white solid used without further purification. RPLC tR'= 1.62 min (Method ESI/MS rn/a 311.2 C 2
,H,,N
2 0).
-WO 97/44329 PCT/US97/08577 125 Example 289: General Alkylation of 1-[3-(3-Hydroxyphenyl)-3phenylpropyl]homopiperazine (Preparation of Compound No. 257).
Maybridge GK02253 (17 mg, 0.074 mmol, 1.2 equiv) and EtN (37 mg, 0.37 mmol, 6.0 equiv) were added to a solution of 1-[3-(3-hydroxyphenyl)-3phenylpropyl]homopiperazine 2TFA salt (33 mg, 0.061 mmol) in CH 3 CN (2.0 mL).
The reaction mixture was stirred at 70 *C for 15 h. The solvent was evaporated to afford an oil which was purified by preparative RPLC to give Compound No.
257 di-TFA salt: 8.0 mg, 18% yield, colorless oil. The purity was determined by RPLC/MS. RPLC tR= 1.90 min 220 nm (Method ESI/MS m/e 507.2 C28H 3 5N,03S).
Example 290: Compound No. 101 di-TFA salt (6.0 mg, 14%) was prepared from 1-[3-(3-hydroxyphenyl)-3-phenylpropyl]homopiperazine di-TFA salt (33 mg, 0.061 mmol) and N- (phenacyl)chloroacetamide (16 mg, 1.2 equiv) employing general alkylation procedure. The product was purified by preparative RPLC. RPLC t 1.92 min 220 nm (Method ESI/MS m/e 486.2 (M C 3 0
H
36
NO
3 3 Preparation of 1-(3,3-Diphenylpropyl)piperazine.
1-(tert-butyloxycarbonyl)piperazine (1.00 g, 5.4 mmol) was dissolved in
CH
3 CN (27 mL) and was treated with 3,3-diphenylpropyl mesylate (1.6 g, 5.6 mmol, 1.05 equiv) and 'PrNEt (1.40 mL, 8.05 mmol, 1.5 equiv). The reaction mixture was heated to 70 _C for 16 h, cooled and concetrated. The residue was purified by chromatography (SiO 2 1% CH 3
OH-CH
2 C12) to afford the desired Boc-protected material (988 mg, The product was treated with 3 M HCl-CHO3H (26 mL) and stirred at 25 _C for 1 h. The solvent was removed in vacuo and the residue was dissolved in tBuOH-H20 (26 mL). Dowex 500 anion exchange resin was added until pH 9. The resin was filtered and solution concetrated to afforded the desired product (702 mg, 98%).
General Alkylation of 1-(3,3-Diphenylpropyl)piperazine.
1-(3,3-Diphenylpropyl)piperazine (50 mg, 0.178 mmol) was dissolved in
CH
3 CN (1 mL) and was treated with alkylating agent (0.196 mmol, 1.1 equiv) and 'PrNEt 40 pL, 0.232 mmol, 1.3 equiv). The reaction mixture was heated to 70 _C for 16 h. The solvent was removed and the samples were purified by normal column chromatography or preparative RPLC.
Example 291: Compound No. 236 (di-TFA salt, 72 mg, 53%) was prepared -WO 97/44329 PCTIUS97/08577 126 from 1-(3,3-diphenylpropyl )piperazine (50 mg, 0.178 mmol) and Maybridge GK 02253 (46 mg, 0.196 nimol) employing general alkylation procedure.- RPLC tR 2.12 min 220 nm (Method A ESI/MS m/e 477.2 C 27
H,,N
4 0 2
S).
Example 292: Compound No. 10 (di-TFA salt, 36 mg, 27%) was prepared from 1-(3,3-diphenylpropyl )piperazine (50 nig, 0.178 mmol) and N- (phenacyl)chloroacetamide (42 mg, 0.196 mmol) employing general alkylation procedure. RPLC tR 2.41 min 220 rn (Method ESI/MS mle 456.5
C
29
H
33
N
3 0 2 Example 293: Compound No. 11 (di-TFA salt, 76 mg, 57%) was prepared from 1-(3,3-diphenylpropyl )piperazine (50 mg, 0.178 nimol) and 1-benzoyl-2- (cbloroacetyl)hydrazine (42 mg, 0.196 mmol) employing general alkylation.
procedure. RPLC tR= 2.26 min 220rn (Method ESI/MSm/e 457.4
C
2 sH 32
N
4 0 2 Example 294: Compound No. 12 (di-TFA salt, 54 mg, 46%) was prepared from 1 3 -diphenylpropyl.) piperaz ine (50 mg, 0.178 nimol) and nitrobenzyl bromide (46 mg. 0. 196 mmol) employing general alkylation procedure.
RPLC tR 2.20 min 220 rim (Method ESI/MS mle 432.2 (Mi-H, C, 6
H
29
N
3 0 3 Example 295: Compound No. 13 (43 mg, 49%) was prepared from 1-(3,3diphenylpropyl )piperazine (50 mg, 0.178 nimol) and N- (4-methoxy-2nitrophenyl) -2-bromoacetamide (46 mg, 0. 196 mmol) employing general alkylation procedure. RPLC tR 2.66 min 220 nin (Method ESI/MS m/e 489.2
C
2 0H 32
N
4 0 4 Example 296: Compound No. 14 (55 mig, 62%) was prepared from 1.13,3diphenylpropyl )piperazine (50 mig, 0.178 ninol) and N-(4-acetamido-3methoxyphenyl)-2-bromoacetamide (46 mig, 0.196 mmol) employing general alkylation procedure. RPLC tR =2.27 min 220 nm (Method ESI/MS mWe 501.2 C 3
OH
3 6
N
4 0 3 Example 297: Measurement of Inhibition of MIP-l a Binding to THP-l Cells by Test Compounds.
Human monocytic leukemia cell line THP-1 was suspended in assay buffer (RPMI-1640 (Gibco-BRL Co.) containing 0.1% BSA and 25 mM HEPES adjusted to pH *WO 97/44329 PCTIUS97/08577 127 7.4) to give a cell suspension of a concentration of 1 x 10' cells/mL. The test compound was diluted in the assay buffer and used as the test compound solution. Iodinated human MIP-la (DuPont NEN Co.) was diluted in assay buffer to 250 nCi/mL and used as the ligand solution. In a 96 well filter plate (Millipore 25 iL of test compound solution, 25 CIL of labeled ligand solution and 50 pL of cell suspension were aliquoted into each well in this order, stirred (total reaction volume 100 iL), and incubated for one hour at 18 °C.
After the reaction, the reaction solution was filtered, and the filter was washed twice with 200 AL of cold PBS (200 L of cold PBS was added and then filtered). The filter was removed and placed in an RIA tube (Iuchi Seieido Co.) and the radioactivity retained by the cells on the filter were measured using a gamma counter (Aloka Co.).
To calculate the ability of test compounds to inhibit binding of human MIP-la to THP-1 cells, non-specific binding determined by adding 100 ng of unlabeled human MIP-la (Peprotech Co.) in place of the test compound was subtracted, while the counts with no test compound added was taken as 100%.
Inhibition {1 (A x 100 counts with test compound added; B, counts with 100 ng of unlabeled human MIP-la added; C, counts with "12I]-labeled human MIP-la added).
When inhibition by the cyclic diamine derivative of this invention was measured, for example, the following compounds demonstrated >20% inhibitory activity at 100 VM. These compounds are compound Nos. 1, 2, 3, 9, 34, 52, 53, 54, 57, 59, 63, 64, 65, 66, 71, 75, 76, 78, 79, 81, 82, 106, 107, 108, 109, 111, 112, 123, 197, 204, 210, 211, 212, 213, 215, 216, 218, 220, 221, 222, 223, 233, 246, 250, 252. 253, 258, 264, 265, 269, 270, and 297.
Example 298: Measurement of Inhibition of MCP-1 Binding to THP-1 Cells.
1. Construction of recombinant baculovirus carrying the human MCP-1 gene Based on the previously published human MCP-1 gene sequence (for example T. Yoshimura et al., Febs Letters, 1989, 244, 487-493), two synthetic DNA primers WO 97/44329 PCT/US97/08577 128 (5'-CACTCTAGACTCCAGCATGA-3' and 5'-TAGCTGCAGATTCTTGGGTTG-3') flanked by restriction enzyme sites were used to amplify a DNA fragment from cDNA derived from human endothelial cells (purchased from Kurabow the amplified fragment was cut with the restriction enzymes (PstI and XbaI), ligated into a transfer vector pVL1393 (Invitrogen and the resulting vector was co-transfected along with infectious baculovirus into Sf-9 insect cells and the supernatant was plaque assayed to yield human MCP-1 gene baculovirus recombinant.
2. Synthesis of [1251]-labeled human MCP-1 expressed in baculovirus Using the method of K. Ishii et al. (Biochem Biophys Research Communications 1995, 206, 955-961), 5 x 106 Sf-6 insect cells was infected with x 10 7 PFU (plaque forming units) of the above human MCP-1 recombinant baculovirus and cultured for 7 days in Ex-Cell 401 medium. The culture supernatant was affinity purified using a heparin Sepharose column (Pharmacia Co.) and then further purified using reverse phase HPLC (Vydac C18 column) to prepare purified human MCP-1. The purified human MCP-1 was protein labeled by Amersham Co. using the Bolton Hunter method to yield [125I ]-labeled baculovirus expressed human MCP-1 (specific activity 2000 Ci/mmol).
3. Measurement of inhibition of binding of 125 I]-labeled baculovirus expressed human MCP-1 to THP-1 cells Human monocytic leukemia cell line THP-1 was suspended in assay buffer (RPMI-1640 (Gibco-BRL Co.) containing 0.1% BSA and 25 mM HEPES adjusted to pH 7.4) to give a cell suspension of a concentration of 1 x 107 cells/mL. The test compound was diluted in the assay buffer and used as the test compound solution. 125 1]-labeled human MCP-1 described above was diluted in assay buffer to 1 mCi/mL and used as the labeled ligand solution. In a 96 well filter plate (Millipore 25 [L of test compound solution, 25 [L of labeled ligand solution and 50 LL of cell suspension were aliquoted into each well in this order, stirred (total reaction volume 100 pL), and incubated for one hour at 18 °C.
After the reaction, the reaction solution was filtered, and the filter was washed twice with 200 pL of cold PBS (200 IL of cold PBS was added and then filtered). The filter was removed and placed in an RIA tube (Iuchi Seieido and the radioactivity retained by the cells on the filter were measured using q, WVO 97/44329 PCT/US97/08577 129 a gamma counter (Aloka Co.).
To calculate the ability of test compound to inhibit binding of human MCP-1 to THP-1 cells, non-specific binding determined by adding 100 ng of unlabeled human MCP-1 in place of the test compound was subtracted, while the counts with no test compound added was taken as 100%.
Inhibition (1 (A x 100 counts with test compound added; B, counts with 100 ng of unlabeled human MIP-Ia added; C, counts with 1 25 1]-labeled human MCP-1 added).
When inhibition by the cyclic diamine derivative of this invention was measured, for example, the following compounds demonstrated >20% inhibitory activity at 100 pM.
11, 36, 50, 51, 69, 72, 73, 75, These compounds are compound Nos. 1, 52. 55, 76, 78.
56, 58, 59, 80. 82, 83.
91, 92 109, 114, 129, 131, 142, 143.
156, 157, 190, 191, 222, 223.
234, 236.
258, 259, 273, 274, 93, 116, 132.
145.
158, 192.
224, 246, 260, 275, 96, 98, 99, 100, 101, 117, 133, 146.
159, 193, 225.
248, 261, 276, 119.
134, 147.
160, 194.
226.
249.
262, 277, 121.
135, 148, 161, 195.
227.
251.
263, 278, 122, 136, 149.
162, 196, 228, 252, 264, 279, 84, 103 123, 137, 151, 185, 213, 229.
253.
265, 280.
63, 85.
104 124.
138, 152, 186, 214, 230, 254.
267, 281, 2, 3, 64, 65 86, 87 106, 125, 139, 153, 187, 215.
231.
255.
269, 282, 4. 9, 67. 68.
88, 89, 107, 108, 126, 128, 140, 141, 154, 155, 188, 189, 220, 221, 232, 233, 256, 257.
271. 272, 284, 287, 288, 293, 294, 295, 296. 298, and 299.
Example 299: Measurement of Inhibition of Binding of [1251] -Labeled Human MCP-1 to Cells Expressing the MCP-I Receptor.
1. Derivation of cells expressing the MCP-1 receptor cDNA fragment containing the MCP-I receptor reported by S. Yamagami et al., Biochemical Biophysical Research Communications 1994, 202, 1156-1162) was cloned into the expression plasmid pCEP4 (Invitrogen Co.) at the NotI site, and the plasmid obtained was transfected into the human kidney epithelial cell line 293-EBNA using the Lipofectamine reagent (Gibco-BRL The cells were V -WO 97/44329 PCT/US97/08577 130 cultured in the presence of the selective agent (Hygromycin), and a stably expressing transfectant line was obtained. The expression of the receptor was confirmed by binding of 12 I]-labeled human MCP-1.
2. Measurement of inhibition of binding of 25 I]-labeled baculovirus expressed human MCP-1 to the MCP-1 receptor expressing cells The MCP-1 receptor expressing cells on tissue culture dishes were scraped using a cell scraper and suspended in assay buffer (D-MEM(Gibco-BRL Co.) containing 0.1% BSA and 25 mM HEPES adjusted to pH 7.4) to give a cell suspension of a concentration of 6 x 106 cells/mL. The test compound was diluted in the assay buffer to concentrations of 0.16, 0.8, 4, 20, and 100 PM. The remainder of the procedure was as described in Example 163.
When inhibition by the cyclic diamine derivative of this invention was measured, compound No. 36 for example showed dose dependent inhibition with inhibitory concentration (IC of 17 pM.
Example 300: Measurement of Inhibition of Cell Chemotaxis.
In order to determine the inhibition of cell chemotaxis by the compounds of this invention, we measured cell chemotaxis caused by monocyte chemotactic factor MCP-1 using the human monocytic leukemia cell line THP-1 as the chemotactic cell according to the method of Fall et al. Immunol. Methods, 190, 33, 239-247).
2 x 106 cells/mL of THP-1 cells (suspended in RPMI-1640 (Flow Laboratories Co.) 10% FCS) was placed in the upper chamber (200 pL) of a 96 well micro-chemotaxis chamber (Neuroprobe, registered tradename), and human recombinant MCP-1 in a same solution (Peprotech Co.) at a final concentration of 20 ng/mL was placed in the lower chamber, with a polycarbonate filter (PVP-free, Neuroprobe; registered tradename) placed between the two chambers. These were incubated at 37 °C for 2 hr in 5% CO 2 The filter was removed, and the cells which had migrated to the underside of the filter was fixed, stained using Diff Quick (Kokusai Shiyaku Co.) and then quantitated using a plate reader (Molecular Device Co.) at a wavelength of 550 nm to determine the index of cell migration as a mean of 3 wells. In addition, test compounds were placed in the upper chamber along with THP-1, and the inhibition of cell migration (inhibition IC,, was determined. Inhibition WO 97/44329 PCT/US97/08577 131 was defined as {(cells migration induced MCP-1 with no test compound in the upper chamber) (cells migration with no MCP-1 added in the lower chamber) 100%), and the concentration of the test compound which gave 50% inhibition was designated IC 50 When the inhibition of cyclic diamine derivatives of the present invention was measured, the 50% inhibition concentration (ICso) for compound No. 36 was 9 pM and for compound No. 240 was 30 M.
Example 301: Inhibition of Delayed Type Hypersensitivity Reaction in the Mouse DNFB Induced Contact Hypersensitivity Model.
7 week old male Balb/c mice (Charles River Co.) were maintained for 1 week, after which the hair was shaved with an electric razor from the abdomen to the chest. 1 day and 2 days later, the shaved areas were painted twice with 25 pL of 0.5% dinitrofluorobenzene (DNFB) (Wako Pure Chemicals Co.) in acetone:olive oil 4:1. At day 6, both side of the right ear was painted for an induction with 10 IL of 0.2% dinitrofluorobenzene (DNFB) (Wako Pure Chemicals Co.) in acetone:olive oil 4:1, while the left ear was painted with 10 PL of acetone:olive oil 4:1 not containing DNFB. As a test agent, compound No. 36 or compound No. 240 was dissolved in acetone to 20 mg/mL, and applied twice at min before and after the DNFB induction (25 iL/ear/dose).
In the control group (no drug administration group), the acetone solution not containing any test compound was applied. There were 8 mice per group in both the control group and the experimental group. In order to prevent licking off of the DNFB and test compound, the necklace for mice were used during the study (Natsume Seisakujo At 48 hr after DNFB induction, ear lobes were sampled using a spring loaded micrometer (Ozaki Seisakujo The change in the ear lobe thickness was calculated according to the following formula.
Increase 100 x ((right ear lobe thickness after sensitization right ear lobe thickness prior to sensitization)/right ear lobe thickness prior to sensitization (left ear lobe thickness after sensitization left ear lobe thickness prior to sensitization)/left ear lobe thickness prior to sensitization) After exanguination, the isolated ear was fixed in formalin, and hematoxylin-eosin stained histopathological sections were prepared for image analysis. Us-hg': digital camera (Fuji Color Service, HC-1000) installed on an upright microscope and a personal computer (Macintosh 8100/100AV. using Photoshop software), the color images were digitized, and analyzed using a second image analysis software (NIH Image). The parameters measured were epidermal thickening, edema (area of dermal and subcutaneous tissues), and cellular infiltration of tissue (number of nuclei in the dermis and subcutaneous tissues).
Both compounds showed significant inhibitory activity.
The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.
1 11 -_0 ooo *ooo o°* go*
Claims (16)
1. A cyclic diamine selected from the group consisting of a compound of the formula below: R 2 f 3 R 2 (CH 2 (C-N N- and a pharmaceutically acceptable acid addition salt thereof wherein R' and R' are the same or different from each other and are an unsubstituted or substituted phenyl group or aromatic heterocyclic group having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, nitrogen atoms or combinations thereof, in which the phenyl or aromatic heterocyclic group may be substituted by one or more halogen atoms, hydroxy groups, Ci-C 8 S lower alkyl groups, lower alkoxy groups, phenyl groups, benzyl groups, phenoxy groups, methylenedioxy groups, C,-C6 hydroxyalkyl groups, carboxy groups, C 2 alkoxycarbonyl groups, C 2 alkanoylamino groups, dioxolanyl groups, or by group represented by the formula: or is condensed with a benzene ring to form a condensed ring, wherein the substituents for the phenyl or aromatic heterocyclic group and the condensed ring condensed with S* a benzene ring are one or more groups selected from halogen atoms, hydroxy groups, or lower alkoxy groups, and R' and R' are the same or different from each other and are hydrogen atoms, lower alkyl groups, or Cz-C 6 :o lower alkenyl groups; R represents a hydrogen atom, hydroxy group, cyano group, lower S alkoxy group or lower alkanoyloxy group; represents an integer of 0-3; .k represents 2 or 3; R' is a group represented by: 1) wherein R 7 is an unsubstituted or substituted phenyl group which may be substituted with one ore more groups which are the same or different and are halogen atoms, hydroxy groups, amino groups, lower alkyl groups, Ci-CG lower alkoxy groups, cyano groups, nitro groups, trifluoromethyl groups, C,-C, alkoxycarbonyl groups, C-C, alkanoyl groups, C,-C 6 alkylsulfonyl groups, s ifluoromethylsulfonyl groups, unsubstituted phenylsulfonyl groups or 133 substituted with a hydroxy group, 1-pyrrolylsulfonyl groups, CI-C, hydroxyalkylsulfonyl groups, alkanoylamino groups, or a group represented by .the formula: -CONReR' in which R' and are the same or different from each other, and are hydrogen atoms or CI-C 6 lower alkyl groups; A' is a group represented by the formula: -(CH or a group represented by formula: -(CHz)p-G-(CH),q in which G represents G' or G wherein G' represents -S02-, -CONH-, -NHCO-, -NHCONH-, or -NH-SO 2 and G' is (C=NH)NH-SO,-, -CO-NH-NH-CO-, -CO-NH-NH-CO-NR'"-, -CO-NH-CH 2 -CO-NH-NH-SO,- or -CO-N(CH-CO-OCHI)-NH-CO-, R 1 0 is a hydrogen atom or a phenyl group; m is an integer of 0-3; p is an integer of 1-3; and q represents 0 or 1; 2) -A-R" wherein A' is -CO- or R" is: a) and unsubstituted or substituted phenyl group wherein the substituents are one or more groups which are the same or different and are halogen atoms, lower alkyl groups, CI-C, lower alkoxy groups, groups represented by formula -CH 2 -NRI 2 or groups represented by the formula: 0 o b) an unsubstituted or substituted aromatic monocyclic heterocyclic group having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, nitrogen atoms or combinations thereof, wherein the substituents are one or more groups which are the same or different and are halogen atoms, lower alkyl groups, CI-C 6 lower alkoxy groups, or c) a group of the formula: -CH,-NR"R"6, where RL 2 R 3 R" and R 15 are the same or different groups, and are hydrogen atoms or C,-CE lower alkyl groups and R' 6 is an unsubstituted or substituted phenyl group or a phenylalkyl group, wherein the substituents are one or more of the samenor different groups and are halogen atoms, C,-C 6 lower alkyl group, or CI-C, lower alkoxy group; 3) wherein R' 7 is a group which may be substituted at any possible sites by one or more of the same or different groups such as halogen atoms, hydroxy groups, Ci-C 6 lower alkyl groups, or C 1 -Cs lower alkoxy groups j or R 17 eesenting 134 WO 97/44329 PCT/US97/08577 135 a hydrogen atom, cyano group, C 2 -C 7 alkoxycarbonyl group, Ci-C 6 hydroxyalkyl group, Ci-C 6 lower alkynyl group, C 3 -CI cycloalkyl group, C 3 -C 7 alkenoyl group, a group represented by the formula: -(CHOH)CH 2 OR' 1 a group represented by the formula: -CO-NH-NH-CO-OR' 9 a group represented by the formula: a group represented by the formula: H <YNH 0 a group represented by the formula: N 0 N' a group represented by the formula: 0 0 a group represented by the formula H CH ON-Y^ CH3 a group represented by the formula: H a group rep-resented by the f ormula: OH 3 H 3 C j\ -CH3 0 0 a group represented by the formula: 0 -N a a a. a a group represented by the formula: 0 -(GHOH) -CH a group, represented by the formula: 0 11 S or a group represented by the formula: 136 HO in which n is an integer of 1-4; R" is a lower alkyl group, C 2 -C 4 lower alkenyl group, or Cz-C, lower alkynyl group and R 1 is a lower alkyl group; 4) -(CHz) wherein r represents an integer of 0-3; A' represents a single bond, CO-NH-NH-CO-, -CO-NH-NH-CO-NH-, -CO-NH-CH,-CO-, -CO-NH-NH-SOZ-, -(CHOH)-CHz-, or -(CHOH)-CH,OCH,- R 20 represents an aromatic heterocyclic group containing 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, nitrogen atoms or combinations thereof in which the aromatic heterocyclic group may be substituted by one or more groups which are the same or different and are halogen atoms, Ct-C lower alkyl groups, C,-C lower alkoxy groups, or pyrrolyl groups or is condensed with a benzene ring to form a condensed ring; or wherein R2 is a hydrogen atom or a Ct-c, lower alkyl group; R" 2 represents a S hydrogen atom, Ct-C, lower alkyl group, or a group represented by the formula: R24 -CH -CHOH (CH)s 23 o ;*o a group represented by the formula: S-CH -C -R 26 (CH 2)t-R 2 or R n and taken together with the nitrogen to which they are attached form a 4 to 7 -membered saturated heterocycle, which may contain an oxygen atom, sulfur atom, or another nitrogen atom; where s represents 0 or 1; t represents an integer of 0-2; R 23 represents a hydrogen atom, hydroxy group, phenyl group, C.-CG lower alkyl group, or Ct-C, lower alkoxy group; R 2 represents a hydrogen atom or phenyl group which may be substituted by hydroxy group; R2 R presents a hydrogen atom, phenyl group which may be substituted by a hydroxy 137 group, C 2 alkoxycarbonyl group, C,-C 6 lower alkyl group, Ci-C, alkylthio group, or 3-indolyl group; and represents a hydroxy group, amino group, C,- C, lower alkoxy group, or phenylalkyloxy group; With the proviso that when R 3 is a hydrogen atom, then j is not 0, the substituent for R 7 is not hydroxy, CI-C 6 lower alkyl or Ci-C 6 lower alkoxy; G' is not or its substituents, if R 11 is a phenyl group, are not CI-C 6 lower alkyl group; R 17 is not a hydrogen atom, C 2 -C 7 alkoxycarbonyl group, or C1-C 6 hydroxyalkyl group; r is not O and A 3 is not a single bond or -CO-; With the further provisb that when R' is a hydrogen atom and k represents 2, R' is not unsubstituted; m is not 0 and R" is not a substituted or unsubstituted phenyl group; and, when R j is a cyano group, R' is not unsubstituted, and the substituent groups for R' are not a halogen atom, CI-C lower alkyl group or CI-C6 lower alkoxy group.
2. A compound as set forth in Claim 1, wherein k is 3 in formula
3. A compound as forth in Claim 1 wherein j is 2 in formula [II.
4. A compound as set forth in Claim 1, wherein R' is a hydrogen atom in formula A compound as set forth in Claim 1, in which R 3 is a hydroxy group in formula a
6. A compound as set forth in Claim 1, wherein R' and R 2 are the same or different from each other and are substituted or unsubstituted phenyl groups in formula 4*
7. A compound as set forth in Claim 1, wherein R' in formula [II is a group represented by the formula: wherein R 7 is as defined for R' in formula
8. A compound as set forth in Claim 1, wherein R' is -CH,-CO-NH-NH-CO-R 7 -CH:-CO-N-NNH-CO-CH 2 -R -CHz-CO-NH-NH-CO-NH-R' -CHz-CO-NH-CH 2 -CO-R 7 -CHz-CO- NH-NH-CO-R', -CH,-CO-NH-NH-CO-NH-R"O, or -CH,-CO-NH-CH,-CO-R" 0 where R' and RO 2 are as defined in formula
9. A method of inhibiting the binding of chemokines to the receptor of a target cell and/or its action on a target cell using a pharmaceutical 138 WO 97/44329 PCT/US97/08577 139 preparation containing as an effective ingredient, a cyclic diamine, or its pharmacologically acceptable acid addition salt, represented by the formula [II] below: (CH )j-N N-R 4 [I] R 2/ (CH [k wherein R' and R 2 are the same or different from each other and are a phenyl group or an aromatic heterocyclic group having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, nitrogen atoms or combinations thereof, in which the phenyl or aromatic heterocyclic group may be substituted by one or more halogen atoms, hydroxy groups, CI-C, lower alkyl groups, Ci-C 6 lower alkoxy groups, phenyl groups, benzyl groups, phenoxy groups, methylenedioxy groups, C 1 -C 6 hydroxyalkyl groups, carboxy groups, C 2 -C7 alkoxycarbonyl groups, C 2 -C alkanoylamino groups, dioxolanyl groups, or by group represented by the formula: -NR'R 6 or is condensed with a benzene ring to form a condensed ring, wherein the substituents for the phenyl or aromatic heterocyclic group and the condensed ring condensed with a benzene ring are optionally substituted by one or more substituents independently selected from halogen atoms, hydroxy groups, or CI-C 6 lower alkoxy groups, and R 5 and R 6 are the same or different from each other and are hydrogen atoms, C,-C 6 lower alkyl groups, or. C-C 6 lower alkenyl groups; R 3 is a hydrogen atom, hydroxy group, cyano group, C 1 -C 6 lower alkoxy group or C 2 -C 7 lower alkanoyloxy group; j represents an integer of 0-3; k represents 2 or 3; R' is a group represented by: 1) -A 1 -R 7 wherein R 7 is an unsubstituted or substituted phenyl group which may be substituted by one or more groups which are the same or different and are halogen atoms, hydroxy groups, amino groups, Ci-C 6 lower alkyl groups, C,-C 6 lower alkoxy groups, cyano groups, nitro groups, trifluoromethyl groups, C 2 -C 7 alkoxycarbonyl groups, C 2 alkanoyl groups, Ci-C 6 alkylsulfonyl groups, trifluoromethylsulfonyl groups, unsubstituted phenylsulfonyl groups or substituted with a hydroxy group, 1-pyrrolylsulfonyl groups, C,-C 6 hydroxyalkylsulfonyl groups, Cz-C 6 alkanoylamino groups, or a group of the formula: -CONR 8 R 9 in which R and R 9 are the same or different from each other, WO 97/44329 PCT/US97/08577 140 and are hydrogen atoms or CI-C 6 lower alkyl groups; A' is a group of the formula: -(CH 2 or a group represented by formula: -(CH 2 )p-G-(CH 2 in which G is G I or G 2 wherein G' represents -SO2-, -CONH-, -NHCO-, -NHCONH-, or -NH-SO 2 and G 2 represents -(C=NH)NH-SO z -CO-NH-NH-CO-, -CO-NH- NH-CO-NR 0 -CO-NH-CH 2 -CO-NH-NH-SO 2 or -CO-N(CH 2 -CO-OCH 3 -NH-CO-; R" is a hydrogen atom or a phenyl group; m is an integer of 0-3; p is an integer of 1-3; q represents 0 or 1; 2) -A2-R" wherein A 2 is -CO- or -SO 2 R 1 is; a) an unsubstituted or substituted phenyl group which is substituted by one or more groups which are the same or different and are halogen atoms, C 1 C 6 lower alkyl groups, CI-C 6 lower alkoxy groups, groups represented by formula -CH 2 -NR1 2 R" or groups represented by the formula: 0 N-R14 b) an aromatic monocyclic heterocyclic group having 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, nitrogen atoms or combinations thereof, which may be substituted with one or more of the same or different groups which are halogen atoms, Cl-C 6 lower alkyl groups, or Ci-C 6 lower alkoxy groups, or c) A group represented by the formula: -CH 2 -NRSR' 6 where R 12 R" and R 5 are the same or different groups, and are hydrogen atoms or C-C 6 lower alkyl groups and R' 6 is a phenyl group or a phenylalkyl group, which may be substituted by one or more of the same or different groups which are halogen atoms, Ci-Cs lower alkyl group, or CI-C 6 lower alkoxy group; 3) -(CH2)n-R 17 wherein R 17 is a group which may be substituted at any possible sites by one or more of the same or different groups which are halogen atoms, hydroxy groups, CI-C 6 lower alkyl groups, or Ci-C 6 lower alkoxy groups, representing a hydrogen atom, cyano group, C 2 -C 7 alkoxycarbonyl group, Cj-C 6 hydroxyalkyl group, Ci-C 6 lower alkynyl group, C 3 -C 6 cycloalkyl group, C 3 alkenoyl group, a group represented by the formula: -(CHOH)CH 2 0R 1 6 a group represented by the formula: -CO-NH-NH-CO-OR 19 a group represented by the formula: WO 97/44329 141 00 a group represented by the formula: H NOY K.NH 0 a group represented by the formula: 0 N a group represented by the formula: 0 a group represented by the formula O 9H3 CH3 a group represented by the formula: 0 H PCT/US97/08577 a group represented by the formula: CH 3 0 0 a group represented by the formula: 0 -N Q 0 a group represented by the formula: 8 0000 *0 S S 0 0 S 0 0 0 S *09 0 0 -(CHOH) -CH 2 N. a group represented by the formula: O 0 a group represented by the formula: 0 N H in which n ia an integer of 1-4; R l is a C I -c 6 lower alkyl group, C2-C lower alkenyl group or C lC-C lower alkyl group, C-C, loer alkenyl group r -C lower alkynyl group and R" 9 represents a CI-C, lower alkyl group; 142 WO 97/44329 PCT/US97/08577 143 4) -(CH 2 2 wherein r represents an integer of 0-3; A 3 represents a single bond, CO-NH-NH-CO-, -CO-NH-NH-CO-NH-, -CO-NH-CH 2 -CO-NH-NH-SO-, -(CHOH)-CH 2 or -(CHOH)-CH 2 OCH 2 R 20 represents an aromatic heterocyclic group containing 1-3 heteroatoms, selected from oxygen atoms, sulfur atoms, nitrogen atoms or combinations thereof in which the aromatic heterocyclic group may be substituted by one or more of the same or different groups which are halogen atoms, Ci-C 6 lower alkyl groups, CI-C lower alkoxy groups, or pyrrolyl groups) or is condensed with a benzene ring to form a condensed ring); -CH 2 -CO-NRZR 2 2 wherein R 21 is a hydrogen atom or C 1 -C 6 lower alkyl group; R 22 represents a hydrogen atom, Ci-C 6 lower alkyl group, or a group represented by the formula: 24 -CH,-CHOH I (CH 2 )-R 23 or a group represented by the formula: 0 -CH -C.-R 26 (CH2)t-R 2 or R' 2 and R 22 taken together with the nitrogen to which they are attached form a 4 to 7-membered saturated heterocycle, which may contain an oxygen atom, sulfur atom, or another nitrogen atom; where s represents 0 or 1; t represents an integer of 0-2; R 2 represents a hydrogen atom, hydroxy group, phenyl group, Ci-C 6 lower alkyl group, or Ci-CG lower alkoxy group; R" represents a hydrogen atom or phenyl group which nlay be substituted by a hydroxy group; R 25 represents a hydrogen atom, phenyl group which may be substituted a by hydroxy group, C 2 -C 7 alkoxycarbonyl group, Ci-C 6 lower alkyl group, Ci-C 6 alkylthio group, or 3-indolyl group; and R 26 represents a hydroxy group, amino group, Ci-C6 lower alkoxy group, or phenylalkyloxy group; 6) a hydrogen atom, Ci-C 6 alkanoyl group, or C 2 -C 7 alkoxycarbonyl group. A method according Claim 9, in which k is 3 in the above formula [II] or its pharmacologically acceptable acid addition salt.
11. A method according to Claim 9, where j is 2 in the above formula [II] or its pharmacologically acceptable acid addition salt. 4. WO 97/44329 PCTIUS97/08577 144
12. A method according to Claim 9, in which R 3 is a hydrogen atom in the above formula [II] or its pharmacologically acceptable acid addition salt.
13. A method according to Claim 9, in which R 3 is a hydroxy group in the above formula [II] or its pharmacologically acceptable acid addition salt.
14. A method according to Claim 9, in which R' and R 2 are the same or different from each other and are substituted or unsubstituted phenyl groups in the above formula [II] or its pharmacologically acceptable acid addition salt. A method according to Claim 9, in which R' is a group represented by the formula: -CH 2 -R 7 where R 7 is as defined in R 7 in the above formula or its pharmacologically acceptable acid addition salt.
16. A method according to Claim 9, where R' is a group represented by the formula: -CH 2 -R 2 F wherein R 20 is as defined in the above formula [II] or its pharmacologically acceptable acid addition salt.
17. A method according to Claim 9, wherein R 4 in the above formula [II] is -CH 2 CO-NH-NH-CO-R 7 -CH 2 -CO-NH-NH-CO-CHz-R 7 -CH 2 -CO-NH-NH-CO-NH-R', -CH 2 -CO-NH- CH 2 -CO-R 7 -CH 2 -CO-NH-NH-CO-R 20 -CH 2 -CO-NH-NH-CO-NH-R 2 or -CH 2 -CO-NH-CH 2 -CO- R 20 wherein in the formulas, R 7 and R 20 are the same as defined in the above formula [II] or its pharmacologically acceptable acid addition salt.
18. A method according to Claim 9, wherein the chemokine is MIP-la.
19. A method according to Claim 9, wherein the chemokine is MCP-1. A method according to Claim 9 wherein the chemokine is IL-8.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8-147846 | 1996-05-20 | ||
| JP8147846A JPH09309877A (en) | 1996-05-20 | 1996-05-20 | Cyclic diamine derivative and its production and use |
| PCT/US1997/008577 WO1997044329A1 (en) | 1996-05-20 | 1997-05-20 | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3135497A AU3135497A (en) | 1997-12-09 |
| AU731187B2 true AU731187B2 (en) | 2001-03-29 |
Family
ID=15439585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU31354/97A Ceased AU731187B2 (en) | 1996-05-20 | 1997-05-20 | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPH09309877A (en) |
| AU (1) | AU731187B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4120713B2 (en) * | 1997-09-04 | 2008-07-16 | 大塚製薬株式会社 | Treatment for multiple sclerosis |
| US6552188B2 (en) * | 2001-06-29 | 2003-04-22 | Kowa Co., Ltd. | Unsymmetrical cyclic diamine compound |
| US6509329B1 (en) * | 2001-06-29 | 2003-01-21 | Kowa Co., Ltd. | Cyclic diamine compound with 6-membered ring groups |
| CN117304076B (en) * | 2023-11-28 | 2024-02-20 | 苏州大学 | A kind of preparation method of N-sulfonylamidine compound |
-
1996
- 1996-05-20 JP JP8147846A patent/JPH09309877A/en active Pending
-
1997
- 1997-05-20 AU AU31354/97A patent/AU731187B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU3135497A (en) | 1997-12-09 |
| JPH09309877A (en) | 1997-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6686353B1 (en) | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists | |
| WO1997044329A9 (en) | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists | |
| Rowley et al. | 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT2A receptor antagonists | |
| SK5532000A3 (en) | Cyclic amine derivatives and their use as drugs | |
| KR101164258B1 (en) | Pyrazole derivatives as protein kinase modulators | |
| RU2232156C2 (en) | Compounds of n,n-substituted cyclic amine | |
| JP5754040B2 (en) | Modulator of TNFα signaling | |
| JP3421323B2 (en) | Piperidine CCR-3 receptor antagonist | |
| HUP0104364A2 (en) | Pyrrolidine derivatives-ccr-3 receptor antagonists | |
| WO2000069815A1 (en) | Ureido-substituted cyclic amine derivatives and their use as drug | |
| WO2000069432A1 (en) | Remedies or preventives for diseases in association with chemokines | |
| CN1414953A (en) | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and 5-hydroxytryptamine | |
| AU778173B2 (en) | Cycloamine CCR5 receptor antagonists | |
| JP2001525399A (en) | Selective β3 adrenergic agonist | |
| KR100785675B1 (en) | Calcium receptor antagonist | |
| AU731187B2 (en) | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists | |
| JP2007186422A (en) | Aryl sulfide derivatives | |
| KR100487692B1 (en) | Diarylalkylcyclic Diamine Derivatives as Chemokine Receptor Antagonists and Pharmaceutical Compositions Containing them | |
| CN1922148B (en) | Pyrazole derivatives as protein kinase modulators | |
| MXPA00004851A (en) | Cyclic amine derivatives and their use as drugs | |
| JP2005139106A (en) | Benzofuran derivatives | |
| MXPA01005232A (en) | Benzofuran derivatives, their preparation and use | |
| JPWO2000069432A1 (en) | Therapeutic or preventive drugs for diseases involving chemokines | |
| MXPA01005034A (en) | Pyrrolidine derivatives-ccr-3 receptor antagonists | |
| JPWO2001042208A1 (en) | Cyclic amine CCR5 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS BY DELETING US 08/858238 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: TEIJIN LIMITED, DUPONT PHARMACEUTICALS RESEARCH LA Free format text: FORMER OWNER WAS: TEIJIN LIMITED |